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inTRoducTion
congenital heart disease
The prevalence of Congenital Heart Disease (CHD) has been described to be 8,2 per 1000 live 
births in European countries.(1) Congenital heart disease is a collective term for a large num-
ber of different diagnoses with different anatomical substrate, complexity and prognosis. The 
most common subtypes that we encounter are: ventricular septal defect (VSD 2.6 per 1000 
live births), atrial septal defect (ASD 1.6 per 1000 live births), persistent arterial duct (PDA 0.9 
per 1000 live births), pulmonary stenosis (PS 0.5 per 1000 live births), tetralogy of Fallot (TOF 
0.3 per 1000 live births), coarctation of the aorta (0.3 per 1000 live births), transposition of the 
great arteries (TGA 0.3 per 1000 live births) and aortic stenosis (0.2 per 1000 live births).(1)
Until the 1950’s survival was very poor, with half of the patients that needed treatment, dying 
in the first decade of live. First cardio-thoracic surgery consisted of shunts from the aorta 
to the pulmonary artery to improve oxygenation and thereby survival of patients. The first 
successful corrective surgery of a patient with tetralogy of Fallot was done in 1954 in Minne-
sota.(2) Further advance of surgery was dependent of the development of cardiopulmonary 
bypass machines in the same time period. The first successful open heart procedure utilizing 
the heart lung machine was performed by John Gibbon on May 6, 1953 in Philadelphia.(3)
Figure 1. Birth Prevalence of CHD SubtypesReported birth prevalence of the 8 most common CHD 
subtypes per continent. Distribution of subtypes within total CHD is mentioned as percentages above 
bars. AoS = aortic stenosis; ASD = atrial septal defect; Coarc = coarctation; PDA = patent ductus arteriosus; 
PS = pulmonary stenosis; TGA = transposition of the great arteries; TOF = tetralogy of Fallot; VSD = 
ventricular septal defect. 
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Since then survival rate has dramatically improved and nowadays 95% of all congenital heart 
disease patients reach adulthood.(4) Corrective surgery can be performed even in the very 
complex diagnoses, such as a univentricular heart. Besides improvements in cardiothoracic 
surgery there have also been major advances in anaesthesia, intensive care and specialist 
(paediatric) cardiologic care. Consequently, even more patients with CHD reach adulthood, 
creating a completely new and steadily growing patient population: patients with grown-up 
congenital heart disease (GUCH).(5)
First results of corrective surgery were very promising, with high survival rates and low 
complication rates in the fi rst decade of life. Surgeons and cardiologists felt early optimism, 
but late complications became apparent in the second and third decade of life. Late compli-
cations include ventricular dysfunction, need for re-intervention, arrhythmias, heart failure 
and sudden death.(4) Surgical approaches have therefore been modifi ed over the years to 
try and decrease these late complications. For instance in patients with transposition of the 
great arteries fi rst an atrial switch operation was performed (Mustard or Senning procedure), 
which was later changed to an arterial switch procedure.(6) In the fi rst cohorts of patients 
operations were performed at a later age, for instance patients with tetralogy of Fallot were 
originally operated at the age of 4-10 years. Nowadays operations are performed at the age 
of 4 month and even some centres have tried and operated them earlier.(7)
Patients care in adult congenital heart disease
The type of care needed changes with patients growing up. Parents of the patients started to 
have questions related to participation in school and physical exercise, on work and sports. 
Determining safe levels of physical activity for children and adolescents with congenital 
heart disease is challenging. In the beginning both parents and doctors were very careful 
and restrictive. Evidence for making recommendations was limited and based on expert 
opinion and estimated risks of sudden cardiac death with activity. Nowadays, most jobs are 
Figure 2. A Mustard operation B Arterial switch operation
A B
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considered to be safe for most patients. Participation in sports and regular physical exercise 
have well documented beneficial effects on fitness, psychological well-being, confidence and 
social interaction as well as on the later risk of acquired cardiac disease. Counselling patients 
with question concerning sports include an appreciation of the type of energy expenditure 
involved in different sports and teaching of a method to enable the patient to limit his or her 
activities. The European guidelines advice to perform social exercise to a level of comfort, but 
not to attempt competitive sports in most situations.(8) Yet, still considerations are made per 
patient individually.(9)
The way patients evaluate their health can be a major determining feature for their well 
being. Previously, poor as well as good subjective states of health have been reported in 
adults with congenital cardiac malformations. In a large cohort study of congenital heart 
disease patients were compared to healthy peers. This study showed that congenital heart 
disease patients felt more impaired in physical functioning. But these patients reported less 
problems with work or social activities as a result of emotional problems.(10)
Pregnancy in congenital heart patients
Like women without heart disease, also women with heart disease have a desire to become 
pregnant. Originally, many women with cardiac disease were advised not to become preg-
nant, since it was considered to be a too large hemodynamic burden. Some of these women 
became pregnant nonetheless. Hereby providing evidence and experience that it was pos-
sible and a whole new field of cardiology arose.(11,12,13)
Pregnancy is known to impose a major hemodynamic burden and the risk of developing 
complications is clearly increased as compared with the normal population.(14) In addition 
to the hemodynamic impact, pregnancy is also a hypercoagulable state with a higher throm-
botic risk.(15) The combination of hormonal and hemodynamic changes during pregnancy 
will also affect the vascular wall with a higher risk of arterial/aortic dissection. Furthermore, 
it is not clear whether pregnancy causes an irreversible deterioration in cardiac function.(16) 
Finally, maternal cardiac disease will also influence fetal outcome (17).
Although the prevalence of heart disease is relatively low in pregnant women, it is the most 
important cause of maternal mortality. Acquired conditions like aortic dissection, peripartum 
cardiomyopathy and acute coronary syndrome cause the highest maternal mortality rates. 
Some of these conditions may not be diagnosed before pregnancy.(18) Most patients with 
congenital heart disease are already diagnosed and treated for cardiac disease at a young 
age offering ample opportunity for timely counselling. It is very important to counsel women 
at a young age, preferably before they become sexually active, to avoid women with a high 
risk becoming pregnant before being counselled.(19)
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Nowadays, also patients with complex heart disease, such as univentriculair heart disease, 
are now consulting cardiologists for advice about pregnancy. During counselling the follow-
ing subjects are discussed: the use of cardiac medication, maternal risk for complications, 
fetal risk for adverse event and recurrence risk for congenital heart disease. In addition to 
the risks for mother and fetus, also life expectancy of the mother should be discussed with 
both future parents in case of complex congenital heart disease with a history of heart fail-
ure, severely diminished systemic ventricular function or other complications. To aid in this 
decision process some risk scores have been developed defining independent predictors of 
maternal cardiovascular complications. Siu was the first to publish a predictor model in 2001. 
In his landmark study New York Heart Association class, previous cardio-vascular event, left 
ventricular outflow obstruction and impaired systemic ventricular function were predictors 
for cardiovascular events.(20) Khairy showed that smoking, pulmonary valve regurgitation 
and impairment of the pulmonary ventricular function can be additional predicators.(17) The 
ZAHARA investigators showed that also a mechanical valve is a strong predictor for adverse 
events.(21) Recently, the adapted World Health Organisation (WHO) risk classification was 
developed in which the type and severity of the underlying heart disease are the main de-
terminants.(22)
Heart failure has important implications for pregnancy, causing maternal morbidity and even 
mortality. It may also have negative impact on fetal outcome, increasing the incidence of fe-
Figure 3. Hemodynamic changes: Hemodynamic changes in pregnancy. CO Cardiac output, SV stroke 
volume, HR heart rate, Hb blood levels haemoglobin, TPVR total peripheral vascular resistance.
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tal mortality, premature birth and low birth weight.(17) In congenital heart disease patients, 
data on HF during pregnancy are lacking. Labour and delivery are considered a particularly 
risky period due to the additional fluid overload in this period (23).
The pre-pregnancy plan should detail which medication must be discontinued, lowered 
in dose or continued during pregnancy. Most experience with medication use is gained in 
patients with either pregnancy induced hypertension or pre-eclampsia.(24) Many drugs 
have been proven to be fetotoxic, others showed teratogenic effects.(25) Some drugs are 
considered save and are commonly used in pregnancy, for other drugs there is a clear lack of 
information.(26)
Fetal outcome
The outcome of the child is dependant of the complexity of maternal heart disease. The most 
frequent complications include premature delivery, children small for gestational age and 
increased perinatal mortality.(17,21)
Figure 4. The modified risk score for cardiac complications during completed (>20 weeks of gestation) 
pregnancies in women with congenital heart disease (expressed as % of the total number of completed 
pregnancies). AV, atrioventricular; AVA, aortic valve area; LHO, left heart obstruction; NYHA, New York 
Heart Association; PG, peak gradient; Pulm, pulmonary; Syst, systemic.
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Recurrence risk for an offspring to have a congenital heart defect varies among the specific 
cardiac defects but the overall recurrence risk for non-mendelian inherited congenital heart 
defects lies between 3-15%.(27) For autosomal dominant defects, such as Marfan syndrome, 
the recurrence risk is 50%.(28)
The CARPREG study, the ZAHARA 1 study and the study by Khairy et al defined several risk 
factors for fetal complications, including NYHA class>II, left heart obstruction, cyanosis, 
and mechanical valve prosthesis.(17,20,21) Smoking and twin pregnancies have a negative 
impact on birth weight. In addition, medication use during pregnancy may have a direct 
adverse effect on the baby.
There have been studies on growth in preterm and small children. These studies showed 
that most children show catch-up growth within the first year.(29,30) Children who do not 
show catch-up growth are at risk for short stature and neurodevelopment disorders.(31) So 
far there is no study on growth of children from mothers with heart disease.
Research in congenital heart disease
There is still a lack of knowledge in adult cardiology with regards to long-term outcome after 
surgical correction of congenital heart disease and a lack of standards for the management 
of these special patients. Despite the lack of randomized trials in this field, there is growing 
experience and observational data. Even an expert consensus based on large clinical experi-
ence, nonrandomized studies, retrospective data and registries should be helpful to support 
cardiologists taking care of adult congenital heart disease and should raise the quality of 
patient care.
Aims and objectives of this thesis
In this thesis we wanted to investigate the outcome of congenital heart disease patients 
operated at young age and compare the results of the first group operated in the first sur-
gical decade with the patients operated in the second decade of cardiac surgery. Surgical 
techniques, post operative care and psychological guidance of both children and parents 
have improved over time. By comparing two cohorts of patients operated upon in different 
time periods, we expected to find an improvement in cardiac and psychological outcome. 
We were hoping to find differences in survival, re-intervention rate, ventricular and valvular 
function and exercise capacity. In addition we studied quality of life and behaviour function-
ing. Information on the differences of the surgical cohorts could help us improve patient 
management. In case we would have found a reduction of adverse outcome the frequency of 
out patients clinic visit might have been reduced. If different long-term complications would 
have been present it would have help us to focus on these problems during patient contact 
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in the future. In addition, surgical techniques might benefit from these long-term outcome 
data.
Most studies in the field of pregnancy and heart disease described small series or retro-
spective cohorts. Only a few prospective studies were available and indeed randomised 
controlled trials are absent. There still is a demand for randomised trials on the use of 
medication. In addition there were few studies focussing on the neonatal outcome and child 
development. In the Registry On Pregnancy And Cardiac disease (ROPAC) we have started 
to collect patient data from all over the world to get insight in patient care in pregnancy 
and heart disease. The objectives of this large registry were to learn more about the optimal 
mode of delivery, the impact of medication use and to gain insight in the most prevalent 
complications during pregnancy and in the first six months thereafter. This information was 
largely missing in literature on pregnancy and heart disease. Most of our manuscripts could 
be seen as hypothesis forming, which might form the base for a randomised controlled trial 
in the future. Furthermore we collected data on the growth of the children of the patients 
from the ZAHARA study, known as the KIMAHA (Kinderen van Moeders met een Aangeboren 
HartAfwijking/children of mothers with a congenital heart disease) study. With this study we 
want to study growth in children of mothers with congenital heart disease. This was the first 
study focussing on the children. A healthy child is one of the main goals of treatment during 
pregnancy. With this study we studied a new approach to the long terms effects of heart 
disease in pregnancy.
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BPart I Adult congenital heart disease

Chapter 2
Long-term outcome and quality of life after arterial 
switch operation. A prospective study with a 
historical comparison.
T.P.E. Ruys, A.E. van der Bosch, J. A. A. E. 
Cuypers, M. Witsenburg, W.A. Helbing, 
A.J.J.C. Bogers, R. van Domburg, J.S. 
McGhie, M.L. Geleijnse, J.Henrichs, 
E. Utens, H.B. Van der Zwaan, J.J.M. 
Takkenberg, J.W. Roos-Hesselink
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Aim
To describe the long-term cardiological and psychological results of our first surgical cohort 
of arterial switch operation (ASO) patients and compare the results with our earlier series of 
Mustard patients.
methods
Twenty-four survivors of ASO operated in our centre (1985-1990) were evaluated by ECG, 
echocardiography, MRI, exercise-testing, 24-hour Holter-monitoring and health-related qual-
ity of life questionnaire. The result were compared with 58 adult Mustard patients who were 
evaluated in 2001 using the same study-protocol.
Results
ASO was performed at a median age of 13 days and Mustard operation at 2 years. Median 
follow-up was 22 (range 20-25) and 25 years (22-29), respectively. After ASO survival was 
better (p=0.04). The event-free survival after 22 years was 77% after ASO versus 44% after 
Mustard (p=0.03). Good systemic ventricular function was present in 93% after ASO versus 
6% after Mustard (p<0.01). Exercise capacity in ASO was 85% of predicted, compared to 72% 
in Mustard patients (p=0.01). Aortic regurgitation was found in 21% of in ASO versus 16% 
in Mustard patients. Arterial switch patients versus Mustard patients reported significantly 
better quality of life and less somatic complaints.
conclusion
The progression made in surgical treatment for transposition of the great arteries from Mus-
tard to ASO has had a positive impact on survival, cardiac function, exercise capacity, and 
also self-reported quality of life and somatic complaints. Longer follow-up is warranted to 
monitor aortic regurgitation.
Keywords
Arterial switch, Mustard operation, long-term outcome, survival, quality of life
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inTRoducTion
Complete transposition of the great arteries (TGA) is one of the most common cyanotic 
congenital heart diseases.(1) Until three decades ago, atrial repair (Mustard or Senning) was 
the only surgical option. Long-term follow-up showed considerable ongoing mortality and 
morbidity mainly caused by progressive right systemic ventricular failure.(2)
Nowadays, the arterial switch operation (ASO),has become the established surgical cor-
rection.(3) Operative survival after arterial switch in the current era is good, with a operative 
mortality rate of 5% to 6%.(4-5) Mid- and long-term follow-up studies are also encouraging, 
however the oldest survivors of ASO at most centres are young adults.(6-10) The aim of this 
study was to describe the long-term cardiac outcome and quality of life in our first surgical 
cohort of arterial switch patients and compare the results with the outcome data of our series 
of Mustard patients.
mEThods
study protocol
Simple TGA was defined as TGA without concomitant abnormalities or minor concomitant 
abnormalities (atrial septal defect, ventricular septal defect not requiring surgical patch 
closure or a persisting arterial duct); others were defined as complex TGA. Major events were 
defined as death, cardiac transplantation, re-intervention (surgery or catheter intervention), 
pacemaker implantation or hospital admission for arrhythmia, endocarditis or heart failure.
The protocol included physical examination, 12-lead electrocardiography (ECG), 24-hour 
Holter monitoring, echocardiography, cardiac Magnetic Resonance Imaging (MRI), bicycle 
exercise test, N-terminal pro-Brain Natriuretic Peptide measurements (NT pro BNP) and qual-
ity of life assessment (short form 36). The results of the ASO group were compared with 
patients after Mustard procedure operated between 1973 and 1980, who were studied in 
2001 after a comparable follow-up at a comparable age, using the same protocol except for 
MRI and NT pro BNP measurements.(2,11)
Echocardiography: Transthoracic two-dimensional echocardiography studies were per-
formed using the iE33 ultrasound system (Philips Medical Systems, Best, the Netherlands). 
Systemic ventricular systolic function was visually graded as normal, moderate or poor. Left 
ventricular end-systolic dimension and left ventricular end-diastolic dimension were mea-
sured using the standard parasternal long axis. Diastolic function was obtained by measure-
ments of transmitral inflow pattern. Valvular stenosis and regurgitation severity were graded 
according to current guidelines.(12-13) Body surface area (BSA) was derived with the DuBois 
formula and aortic diameter was corrected for BSA.(14) Aortic root dilatation at the sinuses of 
Valsalva was defined as an aortic root diameter ratio above the upper limit of 1,3 of predicted.
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mRi: MRI was performed using a Signa 1.5 Tesla MR imaging system (General Electric, 
Milwaukee, WI, USA). The CMR studies were analyzed on a Advanced Windows workstation 
(General Electric Medical Systems, Milwaukee, WI, USA), equipped with Q-mass (version 5.2, 
Medis Medical Imaging Systems, Leiden, the Netherlands). The ventricular volumetric data 
set was quantitatively analyzed using manual outlining of endocardial and epicardial borders 
in end-systole and end-diastole.(15)
Exercise capacity: Maximal exercise capacity was obtained using bicycle ergometry. The 
exercise capacity measured was indexed for age, sex and body height, standardized for the 
Dutch population.
nT-pro Brain natriuretic Peptide: Peripheral venous blood was collected from each patient 
and analysed using the electrochemiluminescence immunoassay kit (Elecsys 2010, Roche 
Diagnostics GmbH, Mannheim, Germany). NT-proBNP <15 pmol/L was defined as normal.
short form 36 (sF 36) Health-related quality of life was assessed using the Dutch SF 36.(16) 
Higher scores indicate a better quality of life. Effect sizes were expressed in terms of Cohen’s 
d, (small effects: d<0.3., medium effects: 0.3<d<0.8, large effects:d>0.08). The scores of the 
arterial switch patients were compared to the Mustard patients and also to an age- and 
gender-specific Dutch population sample.(17)
Behavioural/Emotional Problems were assessed using a screening list for psychopathology: 
the Adult Self-Report (ASR) (Achenbach & Rescorla, 2003) and its previous version (Young 
Adult Self-Report (YASR) (Achenbach, 1997), respectively. Age-equivalent Dutch population 
data on the ASR (n=938) was derived from Vanheusden et al.(18) For historical comparisons, 
88 common items of the ASR and YASR were used.
Patients
Between 1985 and 1990, 75 consecutive patients underwent successfully ASO in our institute. 
Forty-five patients were referred from other countries in Europe and could not be traced for 
adequate follow-up. Baseline characteristics and survival data of all other 30 patients were 
obtained by chart review and by contacting the civil registry. Twenty-nine (Dutch) survivors 
were invited to participate in this follow-up study in 2009. Institutional board review was ob-
tained (NL26121.078.08) and participating patients provided informed consent. Five patients 
refused to participate, thus this cohort comprised 24 patients.
Control groups
In 2001 an extensive study of Mustard patients was performed with survival data available 
in all 91 patients and 58 patients participated in the in-hospital protocol. These 58 patients 
serve as the Mustard control group. The results of these Mustard patients were described 
previously in detail and are presented in the tables.(2)
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The scores of the SF 36 and the Adult Self-Report were compared to the Mustard patients 
and also to Dutch population sample. Additionally, for comparison of echocardiographic 
measurements we studied 23 gender- and age matched healthy controls.
statistical methods
Continuous data are presented as mean with standard deviation and were compared with 
the Student-T or Mann-Whitney test. Discrete variables are presented in absolute numbers 
and percentages and were analysed using the chi-square or Fischer’s exact test and Mann-
Whitney test for ranked discrete data. Cumulative survival rates were calculated with the 
Kaplan-Meier method and the Tarone-Ware test was used to compare the ASO and Mustard 
patients. The level of significance was p < 0.05 (2-sided). The data were analyzed with the 
SPSS version 16.0 software (SPSS Inc, Somers, NY).
REsuLTs
Baseline characteristics of the 30 patients after ASO are shown in table 1. Thirteen patients 
had complex TGA (43%), of which 2 patients with hypoplastic right ventricle (1 with hypoplas-
tic aorta). Lecompte’s manoeuvre was applied in 70% of cases; the main reason not to apply 
the Lecompte’s manoeuvre was side to side position of the aorta and pulmonary artery. The 
coronary pattern was left anterior descending artery and circumflex from the left coronary 
sinus and right coronary artery from the right coronary sinus in 50% of the patients; all other 
had various other coronary patterns.
Table 1. Baseline characteristics of arterial switch population and Mustard population.
All data are number of patients (%) IVS intact ventricular septum VSD ventricular septal defect DORV 
double outlet right ventricle.
ASO
30
Mustard
58
p value
Male 17 (57) 40 (69) 0.26
Age at operation 13 days 2 years <0.01
Rashkind septostomy 12 (40) 41 (71) <0.01
Simple TGA
 With IVS
 With VSD without patch
Complex TGA
 TGA with VSD with patch
 TGA with DORV and/or aortic pathology
17 (57)
16 (53)
1 (4)
13 (43)
7 (23)
6 (20)
22 (38)
36 (62)
0.1
C
ha
pt
er
 2
28
survival
One patient with hypoplastic right ventricle and hypoplastic aorta died at 18 months of age, 
no specific cause could be identified by autopsy. Overall cumulative survival rate of the arte-
rial switch patients was 97% at 25 years after operation while in Mustard patients this was 
77% (Figure 1).
Re-interventions
Twelve re-interventions were performed in 6 arterial switch patients, mainly for pulmonary 
artery stenosis: reoperation (n=7), balloon dilatation (n=3) and 1 reoperation for residual 
ASD and VSD. One patient with complex TGA suffered from ventricular tachycardia (VT) at 
age 19, treated by ablation and Implantable Cardioverter Defibrillator (ICD) implantation. No 
interventions for neo-aortic regurgitation or coronary obstruction or hospital admission for 
heart failure were necessary. At 22 years follow-up the overall event-free survival was 77% in 
arterial switch patients versus 44% in Mustard patients p=0.03.(Figure 2) Event-free survival 
was 88% for simple TGA and 62% for complex TGA for patients who underwent ASO (p=0.15). 
In complex TGA patients there were 0.036 events per patient year, this was 0.006 events per 
patient year in simple TGA patients.
Figure 1. Cumulative survival after transposition of the great arteries. ASO: patients with Arterial Switch 
Operation studied in 2009, Mustard: Patients after Mustard operation, studied in 2001.
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Follow-up study
Twenty-four arterial switch patients participated in our in-hospital prospective follow-up 
study with a median age at follow-up of 22 years (IQR 20-24), of which 63% was male.
(24 hours) Ecg monitoring
All 24 patients were in sinus rhythm at follow-up. One patient needed anti-arrhythmic medi-
cation and received an ICD. Voltage criteria for left ventricular hypertrophy or dilatation were 
found in 47%. Nineteen patients had Holter-monitoring. In 3 patients, non-sustained VT’s 
were documented, of which 2 had VTs shorter than 10 beats. None of the arterial switch 
patients had supraventricular arrhythmias.
Echocardiographic findings
Echocardiography was performed in 23 of the 24 arterial switch patients. Mild or moderate 
neo-aortic regurgitation was present in 17% and 4%, respectively while no severe neo-aortic 
regurgitation was found. Mild neo-aortic stenosis was observed in one patient. Increased 
peak flow velocity (>2.0 m/s) was found across the pulmonary artery in 43% of the patients, 
the highest velocity found was 3,8 m/s. By detailed inspection of the images, it was concluded 
that anatomical deformities were responsible for 50% of obstructions; while surgery related 
obstruction (suture line or Lecompte’s manoeuvre) was responsible for the other 50%. Mild 
pulmonary regurgitation was found in 42%, severe pulmonary regurgitation in 4%.
Systemic ventricular function was judged to be normal in 93% and no diastolic dysfunc-
tion was found. Mean fractional shorting was 37%, which was comparable with the healthy 
controls (Table 2).
Figure 2. Event free survival after transposition of the great arteries. Events were defined as re-
intervention, heart failure or arrhythmias. 
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Physical capacity
Results are presented in table 3. Two patients needed medication; the patient with the ICD 
received beta-blockers, another patient was treated with ACE-inhibitors because of moder-
ate LV dysfunction.
Twenty patients underwent exercise testing. No arrhythmias occurred. One patient had a 
rate depended right bundle branch block during exercise and 3 patients (20%) showed ST 
alterations (downslope ST depression > 2 mm), but with additional testing no coronary artery 
obstruction was found (2 MIBI scans and CT angiogram).
Table 2. Echocardiography findings in arterial switch patients.
Echocardiography: All data are mean ± standard deviation. ASO patients with Arterial Switch Operation, 
LVESD Left ventricular end-systolic dimension, LVEDD left ventricle end-diastolic dimension, FS fractional 
shortening, IVSED end-diastolic thickness of the interventricular septum, LVPWED end-diastolic thickness 
of the posterior wall, E early component of the transmitral inflow pattern, A late component of the 
transmitral inflow pattern, DET deceleration time of E.
Echocardiogram ASO
23
Controls
23
p-value
LVEDD mm 52 ± 6 49 ± 4 0.09
LVESD mm 32 ± 5 29 ± 3 0.06
FS % 37 ± 7 38 ± 5 0.35
IVS ED mm 9 ± 1 9 ± 1 0.93
PW ED mm 8 ± 1 8 ± 1 0.48
Aortic sinus mm 33 ± 6 26 ± 3 < 0.01
Aortic sinus ratio 1.1 ± 0.15 0.9 ± 0.08 < 0.01
E m/s 0.9 ± 0.3 0.8 ± 0.2 0.06
A m/s 0.4 ± 0.1 0.4 ± 0.1 0.21
E/A ratio 2.3 ± 0.9 2.2 ± 0.5 0.65
DET msec 193 ± 51 202 ± 30 0.47
Table 3. Overview outcome after surgery for transposition of the great arteries. 
ASO = arterial switch operation, Mustard = Mustard correction.
ASO (2009) Mustard (2001) p- value
NYHA class I 100% 24% < 0.01
Sinus rhythm 100% 63% < 0.01
Sinus node disease 0% 43% < 0.01
Normal systemic ventricular function 93% 4% < 0.01
Maximum heart rate reached during exercise testing 89% 84% 0.12
Exercise tolerance % of expected 88% 72% 0.03
Exercise capacity below 85 % of predicted value 53% 76% 0.05
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mRi
Magnetic resonance imaging was performed in 13 arterial switch patients (54%). Reasons for 
not participating in the MRI were: claustrophobia(5), refused(5) and ICD(1). The mean ejec-
tion fraction measured with MRI was 66% for the left ventricle and 62% for the right ventricle. 
One patient had a left ventricle ejection fraction of 41%. The neo-aortic root had a mean 
diameter of 39 mm (range 30 to 49 mm), 44% of the patients had a neo-aortic root diameter 
of more than 40 mm.
nT-proBnP
NT-proBNP was measured in 18 arterial switch patients. Mean NT-proBNP was 10,1 pmol/L 
± 12,2. Three patients had an elevated NT-proBNP level, of which 2 patients (21.4 and 23.3 
pmol/L) had normal LV function. Their exercise capacity was 82 and 84% of predicted. The 
patient with the ICD had a moderate LV dysfunction and a NT-proBNP level of 52, 2 pmol/L.
Quality of life
Eighteen patients completed the quality of life questionnaires. Outcomes are presented in 
figure 3. Arterial switch patients scored better than the normal Dutch population on the 
scales physical functioning, vitality and role limitations due to emotional problems (p <0.01). 
Compared to Mustard patients, arterial switch patients scored better in the sub domains 
physical functioning (p<0.01), general health perceptions (p=0.04) and vitality (p=0.04). All 
differences showed medium effect size.
Figure 3. Quality of life: SF 36
PF Physical Functioning, RP role limitations due to physical health problems, BP bodily pain, SF social 
functioning, MH general mental health, RE role limitations due to emotional problems, VT vitality, GH 
general health perceptions, ASO: patients with Arterial Switch Operation, Mustard: Patients after Mustard 
operation, Norm: normal Dutch population matched for sex and age (20) * significant difference between 
ASO versus Mustard and versus Norm † significant difference between ASO versus Norm ‡ significant 
difference between ASO versus Mustard.
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Behavioural/Emotional Problems
Data was available on 17 arterial switch patients and is presented in table 4. Overall, be-
havioural/emotional functioning was good. There was no significant difference between the 
arterial switch patients and the normative data from the Dutch general population on any 
of the ASR scales (data not shown). Arterial switch patients had significantly less somatic 
complaints than the Mustard patients (p=0.04).
discussion
This study describes the outcome of a small cohort of arterial switch patients. However, this 
group represent a good sample of the whole surgical cohort and was studied extensively, 
including MRI and psychological outcome. This study offers the possibility of a historical 
comparison with outcome after Mustard operation, because a large cohort of Mustard pa-
tients was studied with the same follow-up protocol after a comparable period of time in our 
institution before.
Twenty-two years after arterial switch operation excellent survival, low morbidity and 
favourable quality of life was found and outcomes are significantly better than after Mustard 
correction. Lessons from the past taught us that one should be careful with early optimism: 
where first results of the Mustard operation were reported to be good, major problems be-
came apparent in adult life, of which most significant the failing capacity of the right ventricle 
Table 4. Differences in mean behavioural/emotional problems scale scores between ASO patients and 
Mustard patients. 
a Data on behavioural/emotional problems was available in 17 arterial switch patients and 55 Mustard 
patients
ASR = Adult Self-Report
Problems Scores
ASR scales
Switch
(n=17)a
M (SD)
Mustard
(n=55)a
M (SD) p-value
Anxious/Depressed 4.1 (4.3) 5.9 (5.2) 0.19
Withdrawn 1.9 (2.0) 3.1 (2.6) 0.90
Somatic Complaints 2.3 (3.3) 3.6 (3.1) 0.04
Thought Problems 1.8 (2.4) 2.0 (2.1) 0.45
Attention Problems 3.4 (2.1) 3.5 (2.4) 0.98
Aggressive Behavior 1.9 (1.8) 2.8 (2.3) 0.15
Rule-Breaking Behavior 2.4 (1.8) 2.8 (2.3) 0.95
Intrusive 2.0 (2.2) 2.3 (2.0) 0.48
Internalizing Problems 8.4 (8.8) 12.6 (9.1) 0.05
Externalizing Problems 6.4 (4.0) 7.8 (5.3) 0.47
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to sustain the systemic circulation.(2,19) Until now few studies have been published on the 
outcome after ASO in adulthood. Until now results are favourable.(5-8) Therefore, optimism 
about the outcome after arterial switch operations seems justified.
Our results show that both survival and event-free survival of TGA patients has dramati-
cally improved with the introduction of ASO, as was expected and hoped for. In this study 
we compared the outcome of the two surgical techniques used in patients with TGA, as 
both cohorts are based on the planned follow-up of consecutive operated patients and 
not random patients seen at an outpatient clinic. Furthermore, both groups are studied in 
a similar designed long-term follow-up study using the same instruments for a medical and 
psychological assessment.
In our cohort of arterial switch patients there was a relatively high percentage of complex 
TGA. Survival was clearly better than after the Mustard and comparable with other studies af-
ter ASO with a lower percentage of complex TGA.(4, 5, 6) However, in complex arterial switch 
patients the event rate per patient year was considerably higher than in the simple patients. 
Especially pulmonary artery stenosis was common in these patients.
clinical condition and ventricular function
Arterial switch patients were in good clinical condition 22 years after surgery, whereas only 
24% of the Mustard patients were in NYHA class I. The inferior condition of the Mustard 
patients may be caused by the impaired systemic (right) ventricular function.
At long-term follow-up 93% of arterial switch patients in our study had normal systemic 
(left) ventricular function. The feared deterioration of the ventricular function late after arte-
rial switch operation, related to coronary artery abnormalities, was not observed. However, 
in one patient a diminished left ventricular function was found (ejection fraction 41% using 
MRI) without a good explanation. Also diastolic function parameters were found to be normal 
in this small sample of patients.
Surprisingly, we found a reduced exercise capacity in arterial switch patients compared 
to the normal Dutch population (although better than Mustard patients).(19) This reduced 
exercise capacity was not exclusively found in patients with diminished left ventricular func-
tion or significant right ventricular outflow tract obstruction. The reduced levels of physical 
activity may be caused by overprotection of parents during childhood. In addition lack of 
training or self esteem have been described in literature, as cause for this diminished exercise 
capacity.(20) Ischemia was also suggested and in our study; three patients showed ST seg-
ment changes, however additional evaluation excluded coronary pathology. Giardini et al 
described reduced exercise capacity in young patients after ASO, but none showed ischemic 
electrocardiographic during exercise.(21) Finally, chronotrope incompetence may play a role.
(22)
The development of arrhythmias was rare and sinus rhythm with normal conduction is 
maintained long-term after ASO, while after Mustard procedure there is a high incidence of 
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supraventricular arrhythmias and sinus node dysfunction. Only one arterial switch patient 
with complex TGA and moderate LV function underwent ICD implantation for ventricular 
tachycardia, he also had a mildly elevated NT-pro BNP. This was also seen in two other pa-
tients, who did not have a diminished LV function. More data on biomarkers as a predictor of 
adverse outcome is warranted.(23)
Valvular abnormalities
From other studies we know that neo-aortic regurgitation may become a problem later in 
life.(24) Our results confirm the presence of mild to moderate neo-aortic regurgitation in 
21% of the patients, none of them has yet required re-intervention and non showed severe 
regurgitation.
Some degree of neo-aortic root dilatation is almost universal and several studies have 
shown serial increases in neo-aortic root diameter.(24) We found in 44% of the ASO patients 
a neo-aortic root of more than 40 mm. Early data suggest that neo-aortic dilatation may 
stabilize in adulthood, but follow-up is too short to be certain.
The main indication for re-intervention in ASO patients was pulmonary artery stenosis, as 
was the case in the study by Oda et al.(7) In our study nearly half of the arterial switch patients 
had a residual gradient across the pulmonary artery or pulmonary valve and some may need 
additional re-interventions in the future, warranting further close monitoring.
health-related quality of life and behavioural/emotional problems
Self-reported physical functioning and vitality was better in arterial switch patients compared 
to normative data.(17) This is remarkable, since exercise capacity was reduced. Overestima-
tion of physical functioning compared to actual exercise test results, has also been found 
by Gratz et al. (25). Noteworthy, behavioural/emotional functioning was as good as in the 
normal population.(18)
Compared to the Mustard group (26), arterial switch patients scored more favourable on 
physical functioning, general health and vitality, which confirms results of Muller et al.(8) In 
addition they had less self-reported somatic complaints.(27) These findings are of utmost 
importance since subjective wellbeing influences costs of medical and also other care.
study limitations
As with many studies on congenital heart disease patient numbers are small in this study. 
Furthermore, we realize that a direct comparison between the results of Mustard and arte-
rial switch patients in the same era would be the best possible study design. However, this 
is not feasible as nowadays all our TGA patients undergo an arterial switch operation. The 
study design, using the same tests after a comparable follow-up period and at the same age, 
seems the second best option. The two groups differ in several aspects: not only have surgical 
treatment feasibilities and age at repair changed, but anaesthetic techniques and neonatal 
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care have improved. Both groups were the first cohort of patients using that specific surgery, 
therefore results of more recent patients may be slightly different. Although patients were 
lost of follow-up due to foreign citizenship, the cohort described represents all arterial switch 
patients still under regular follow-up.
concLusion
Long-term follow-up after arterial switch operation shows excellent survival, low morbidity 
and favourable quality of life and is clearly better when compared to the outcome after Mus-
tard operation. Good cardiac function is the norm after ASO. However, results indicated lower 
than expected exercise capacity, the ongoing risk of developing important neo-aortic root 
dilatation with neo-aortic regurgitation. Re-interventions for pulmonary artery problems did 
occur. Careful systematic clinical follow-up is warranted to monitor these patients further.
AcKnowLEdgEmEnTs
We would like to thank Denise van der Linde en Petra Opic for their help with statistical 
analyses and Professor Hall for his support in the English grammar.
C
ha
pt
er
 2
36
REFEREncEs
 1. van der Linde D, Konings EE, Slager MA, et al. Birth prevalence of congenital heart disease world-
wide: a systematic review and meta-analysis. JACC 2011; 58: 2241-7.
 2. Roos-Hesselink JW, Meijboom FJ, Spitaels SE, et al. Decline in ventricular function and clinical 
condition after Mustard repair for transposition of the great arteries (a prospective study of 22-29 
years). Eur heart J 2004; 25: 1264-70.
 3. Jatene AD, Fontes VF, Paulista PP, et al. Anatomic correction of transposition of the great vessels. 
J Thorac Cardiovasc Surg 1976; 72: 364-70.
 4. Losay J, Touchot A, Serraf A, et al. Late outcome after arterial switch operation for transposition of 
the great arteries. Circulation 2001; 104: I121-6.
 5. Lalezari S, Bruggemans EF, Blom NA, et al. Thirty-year experience with the arterial switch opera-
tion. Ann Thorac Surg 2011; 92: 973-9.
 6. Tobler D, Williams WG, Jegatheeswaran A, et al. Cardiac outcomes in young adult survivors of the 
arterial switch operation for transposition of the great arteries. JACC 2010; 56: 58-64.
 7. Oda S, Nakano T, Sugiura J, et al. Twenty-eight years’ experience of arterial switch operation for 
transposition of the great arteries in a single institution. Eur J Cardiothorac Surg 2012.
 8. (8) Muller J, Hess J, Horer J, et al. Persistent superior exercise performance and quality of life 
long-term after arterial switch operation compared to that after atrial redirection. Int J Cardiol 
2011. Published online First: 18 November 2011. doi.org/10.1016/j.ijcard.2011.10.116
 9. Y Yamazaki A, Yamamoto N, Sakamoto T, et al. Long-term outcomes and social independence 
level after arterial switch operation. Eur J Cardiothorac Surg 2008; 33: 239-43.
 10. Vandekerckhove KD, Blom NA, Lalezari S, et al. Long-term follow-up of arterial switch operation 
with an emphasis on function and dimensions of left ventricle and aorta. Eur J Cardiothorac Surg 
2009; 35: 582-7.
 11. Meijboom F, Szatmari A, Deckers JW, et al. Long-term follow-up (10 to 17 years) after Mustard 
repair for transposition of the great arteries. J Thorac Cardiovasc Surg 1996; 111: 1158-68.
 12. Vahanian A, Baumgartner H, Bax J, et al. Guidelines on the management of valvular heart disease: 
The Task Force on the Management of Valvular Heart Disease of the European Society of Cardiol-
ogy. Eur heart J 2007; 28: 230-68.
 13. Zoghbi WA, Enriquez-Sarano M, Foster E, et al. Recommendations for evaluation of the severity 
of native valvular regurgitation with two-dimensional and Doppler echocardiography. J Am Soc 
Echocardiogr 2003; 16: 777-802.
 14. Roman MJ, Devereux RB, Kramer-Fox R, et al. Two-dimensional echocardiographic aortic root 
dimensions in normal children and adults. The Am J Cardiol 1989; 64: 507-12.
 15. Luijnenburg SE, Robbers-Visser D, Moelker A, et al. Intra-observer and interobserver variability of 
biventricular function, volumes and mass in patients with congenital heart disease measured by 
CMR imaging. Int J Cardiovasc Imaging 2010; 26: 57-64.
 16. Ware JE, Jr., Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual 
framework and item selection. Med Care 1992; 30: 473-83.
 17. Aaronson NK, Muller M, Cohen PD, et al. Translation, validation, and norming of the Dutch lan-
guage version of the SF-36 Health Survey in community and chronic disease populations. J Clin 
Epidemiol 1998; 51: 1055-68.
 18. Vanheusden K, van der Ende J, Mulder CL, et al. Beliefs about mental health problems and help-
seeking behavior in Dutch young adults. Soc Psychiatry Psychiatr Epidemiol 2009; 44: 239-46.
Long term outcome of arterial switch operation 37
 19. Budts W, Scheurwegs C, Stevens A, et al. The future of adult patients after Mustard or Senning 
repair for transposition of the great arteries. Int J Cardiol 2006; 113: 209-14.
 20. Massin MM, Hovels-Gurich HH, Gerard P, et al. Physical activity patterns of children after neonatal 
arterial switch operation. Ann Thorac Surg 2006; 81: 665-70.
 21. Giardini A, Khambadkone S, Rizzo N, et al. Determinants of exercise capacity after arterial switch 
operation for transposition of the great arteries. Am J Cardiol 2009; 104: 1007-12.
 22. de Koning WB, van Osch-Gevers M, Ten Harkel AD, et al. Follow-up outcomes 10 years after arte-
rial switch operation for transposition of the great arteries: comparison of cardiological health 
status and health-related quality of life to those of the a normal reference population. European 
journal of pediatrics 2008; 167: 995-1004.
 23. Eindhoven JA , van den Bosch AE, Jansen PR, Boersma E, Roos-Hesselink JW, The usefulness of 
Brain Natriuretic Peptide in Complex Congenital Heart Disease, JACC 2012 in press.
 24. Schwartz ML, Gauvreau K, del Nido P, et al. Long-term predictors of aortic root dilation and aortic 
regurgitation after arterial switch operation. Circulation 2004; 110: II128-32.
 25. van Rijen EH, Utens EM, Roos-Hesselink JW, et al. Current subjective state of health, and longi-
tudinal psychological well-being over a period of 10 years, in a cohort of adults with congenital 
cardiac disease. Cardiol Young 2005; 15: 168-75.
 26. van Rijen EH, Utens EM, Roos-Hesselink JW, et al. Longitudinal development of psychopathology 
in an adult congenital heart disease cohort. Int J Cardiol 2005; 99: 315-23.

Chapter 3
Long-term outcome of surgery for tetralogy of 
Fallot: comparison between two historical cohorts.
T.P.E. Ruys, E. Utens, A.E. van den Bosch, 
J.A. A. E. Cuypers, M. Witsenburg, 
W.A. Helbing, A.J.J.C. Bogers, R. van 
Domburg, P. Opić, J.S. McGhie, J.J.M. 
Takkenberg, J. W. Roos-Hesselink
C
ha
pt
er
 3
40
ABsTRAcT
Aim
To describe differences in cardiological and psychological outcome after surgical correction 
of Tetralogy of Fallot (ToF) over time.
methods
Survivors of ToF surgery performed in our centre: between 1980-1990 (ToF80) and between 
1969-1980 (ToF70) were followed and evaluated 20-30 years after the initial correction in hos-
pital. The study included ECG, echocardiography, exercise-testing, 24-hour Holter-monitoring 
and health-related quality of life questionnaire.
Results
Survival at 25 years after successful surgery was 93% for ToF70 and 98% for ToF80 (p=0.22). 
Pulmonary valve replacement for pulmonary regurgitation was performed more often in 
the ToF80 patients (p=0.030). Right ventricular dysfunction was found in 7.2% ToF70 and 
in 15.6% ToF80 (p=0.11),and left ventricular end-diastolic diameters were 49 mm and 45 
mm (p = 0.008) respectively. Mean aortic sinus diameter was 37mm in ToF70 and 33mm in 
ToF80 (p=0.001). Aortic regurgitation was present in 21.1% and 7.5%, respectively (p<0.001). 
There was no difference in exercise capacity and quality of life between the ToF70 and ToF80 
patients. ToF patients of both cohorts scored lower compared to healthy controls with re-
spect to general health, but higher on social functioning and experienced less behavioural 
problems such as anxiety and aggression.
conclusion
Compared to patients operated on in the 70’s, patients from the 80’s showed less aortic root 
dilatation, aortic regurgitation and a smaller end diastolic left ventriclular diameter, indicat-
ing an improvement of the left side of the heart. However, surprisingly pulmonary valve 
replacement was needed more often in patients who were operated in the 80’s.
Keywords
Tetralogy of Fallot, survival, long-term outcome, quality of life, left and right ventricular 
dysfunction.
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Tetralogy of Fallot (ToF)
inTRoducTion
Tetralogy of Fallot (ToF) is the most common cyanotic congenital heart disease. (1) Late 
outcomes after ToF repair are reported good with regard to survival. However, a considerable 
proportion of patients develop late complications or have residual lesions.(2,3,4) The surgical 
technique for right ventricular outflow tract (RVOT) reconstruction frequently distorts the 
pulmonary valve causing pulmonary regurgitation (PR) or residual stenosis. Late pulmonary 
valve replacement is often needed.(2,4,5) In addition concern exists regarding the fate of the 
left ventricle dysfunction, aortic valve regurgitation, aortic dilatation and arrhythmias.(6,7)
A detailed description of the time-related instantaneous hazard or risk of death, re-oper-
ation and pulmonary valve replacement (PVR), is required to assess the long-term outcome 
into adulthood for children operated for ToF. These late hazards are probably multifactorial. 
There has been consistent progress in treatment strategy, both with regard to patient selec-
tion and surgical techniques. In the 1970’s patients often first had a palliative shunt, followed 
by corrective surgery with a right ventricular (RV) incision at around 4 years of age. In the 
1980’s surgeons attempted to avoid RV incision and shunts, the latter by operating earlier. 
The use of the transannular patch became more common in the 80s. In the 90’s surgeons 
tried to avoid transannular patches, to decrease the reoperation rate for pulmonary valve 
dysfunction. (8) The impact of these developments on late outcome has not been studied.
Age at operation and new techniques may also influence psychological outcome. In a 
study by Knowles et al. patients with ToF reported lower functional health status then their 
healthy siblings, but quality of life and life satisfaction were comparable.( 9)
We analysed clinical and psychological outcome of patients who underwent surgical 
correction for ToF in our institute between 1980 and 1990, and compared the results with 
previously reported outcome of patients who underwent surgical correction for tetralogy 
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of Fallot in our institute between 1969 and 1980. Assessment was done in a similar manner, 
enabling comparison of the two decades.
mEThods
Patients
The study population includes patients with ToF without major concomittant abnormalities 
such as pulmonary atresia with aorto-pulmonary collaterals or absent pulmonary valve.
The long term outcome of our first cohort of patients operated for ToF between 1969-1980 
has been described extensively, previously.(2) Survival data were available in all of the 140 of 
the operated patients and in 2001 90 patients (64%) participated in the in-hospital protocol , 
as define below. Baseline characteristics of the patients who participated did not differ from 
the patients who did not participate. The data of these 90 patients studied and described in 
2001, will be referred to as the ToF70 group. (2)
Between 1980 and 1990, 105 consecutive patients underwent surgical correction for ToF 
in our institute. Survival status was obtained in all patients. All survivors (n=95) were invited 
to participate in our study in 2010 using the same study protocol as used in ToF70. In total 
82 patient (78%) participated. This group will be referred to as the ToF80 group. Institutional 
board approval was obtained (NL26121.078.08) and participating patients provided written 
informed consent.
Quality of life and behavioural problems assessment scores (the Short form 36 (SF 36) and 
the Adult Self-Report) of the ToF80 were not only compared with the ToF70 group, but also 
with the normal Dutch population adjusted for age and sex.(10)
study protocol
The study protocol in both ToF70 and ToF80 included physical examination, 12-lead electro-
cardiography (ECG), 24-hour Holter monitoring, echocardiography, bicycle exercise test, and 
quality of life assessment (SF 36 and Adult Self-report).
Events: Events were defined as any cardiac intervention (either surgical or catheter interven-
tion), arrhythmia requiring treatment or heart failure.
Echocardiography: Transthoracic two-dimensional echocardiography studies were per-
formed using the iE33 ultrasound system (Philips Medical Systems, Best, the Netherlands). 
Chamber quantification, valvular function, systolic and diastolic function were assessed 
according to the current recommendations. (11,12i) Left and right ventricular function were 
assessed by eyeballing as this method was used in 2001 by the same echo-technician as 
at that time. Body surface area was defined using the DuBois formula, aortic diameter was 
corrected for body surface area. Aortic root dilatation was defined as the diameter at the 
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sinuses of Valsalva ratio above 1.3 of the predicted diameter by the formula described by 
Roman. (13ROMAN)
Exercise capacity: Maximal exercise capacity was obtained using bicycle ergometry. The 
exercise capacity measured in Watts and was indexed for age, sex and body height, standard-
ized for the Dutch population.
Quality of life was assessed by the Dutch SF 36, for which good reliability and validity have 
been proven.(14) Higher scores indicate a better quality of life. Mean scale scores of patients 
were compared between the cohorts ToF70 and ToF80.
Behavioural/Emotional Problems were assessed using a screening questionnaire for 
psychopathology, using the Adult Self-Report (ASR) for the ToF80 patients and its previous, 
parallel version the Young Adult Self-Report (YASR) for the ToF70 patients (Achenbach, 1997, 
2003). Age-equivalent Dutch normative data on the ASR (n=1211) was derived from Van-
heusden et al.(15) For the historical comparison between the ToF80 and T0F70 patients, only 
the 88 identical and overlapping items of the ASR and YASR were used.
statistical methods
Continuous data were presented as mean with standard deviation and were compared with 
the Student-T or Mann-Whitney test. Discrete variables were presented in absolute numbers 
and percentages and were analysed using the chi-square or Fischer’s exact test. Cumulative 
survival rates were calculated with the Kaplan-Meier method and the Tarone-Ware test 
was used to compare the two cohorts of patients. In a Cox-regression model (multivariable 
stepwise upward method) we evaluated era of operation (ToF70 or ToF80), right ventricular 
incision, age at operation < 2 years, transannular patch and prior palliative shunt as potential 
predictors for pulmonary valve replacement for pulmonary regurgitation. The level of sig-
nificance was p < 0.05 (2-sided). The data were analyzed with the SPSS version 16.0 software 
(SPSS Inc, Somers, NY).
REsuLTs
Baseline characteristics
Baseline characteristics and surgical data are shown in Table 1. Age at operation was lower 
in ToF80 compared to ToF70 (p<0.001). Prior shunt and RV incision were more prevalent in 
ToF70 (p<0.001). A transannular patch was more often used in ToF80 (p= 0.001).
survival
In the ToF70 cohort the 30 days mortality was 14%. Late mortality in this group concerned 
6 patients (TOF70 mortality linearised occurrence rates (LOR) 0.0024%/patient year).(2) The 
early (30 days) mortality was 8% in the ToF80 cohort (p=0.098). At 6 months of age 1 patient 
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died due to ventricular tachycardia (recorded on Holter monitoring). In addition one patient 
died at the age of 22 due to endocarditis and liver failure after percutaneous pulmonary valve 
implantation for severe pulmonary regurgitation (mortality LOR 0.00098%/patient year). 
Late survival at 25 years after successful surgery (excluding early mortality) was 96% (95%CI 
92%-100%) for ToF70 and 98% (95%CI 95%-100%) for ToF80 (p=0.24). Overall late cumulative 
survival after successful surgery of both cohorts is shown in Figure 1.
Re-interventions
Event-free survival at 25 years after successful surgical correction was 63% (95%CI 53%-73%) 
for ToF70 and 52% (95%CI 41%-63%) for ToF80 (p=0.072) as shown in Figure 1. In the ToF70 
the most frequently found re-intervention was homograft replacement for pulmonary 
regurgitation (n=22; LOR 0.010%/patient year) followed by closure of a residual VSD (n= 9; 
Figure 1. (Event free) Survival after successful surgery
Table 1. Characteristics from surgical correction of Tetralogy of Fallot.
ToF70 ToF80 p value
Number of patients 140 106
Male (n (%)) 85 (61%) 64 (61%) 1.00
Prior palliative shunt (n (%)) 49 (35%) 13 (12.4%) <0.001
Blalock 20 (14%) 5 (4.8%) 0.015
Waterston 27 (19%) 8 (7.6) 0.010
Age at operation (median, IQR) 4.5 (0-6.5) 1.7(0-5.1) <0.001
Transannular patch (n (%)) 95 (68%) 85 (81%) 0.022
Right ventriculotomy (n (%)) 138 (98.6%) 87 (83%) <0.001
Follow up time (years, SD) 24.3 (4.7) 23.3 (2.6) 0.90
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LOR 0.0041%/patient year), relief of RVOT obstruction (n=8; LOR 0.0036%/patient year) and 
pacemaker implantation (n=5; LOR 0.0023%/patient year). Finally, one internal cardioverter-
defibrillator was implanted.(2) In the ToF80 cohort the most frequently found complication 
was also homograft replacement for pulmonary regurgitation (n=29; LOR 0.0178%/patient 
year) followed by closure of a residual VSD (n= 8; LOR 0.0049%/patient year), relief of RVOT 
obstruction (n=6; LOR 0.0037%/patient year), an aortic valve replacement (n=1; LOR 0.0006%/
patient year) and pacemaker implantation (n=1; LOR 0.0006%/patient year). In addition 2 
aortic valve implantations were performed for severe aortic regurgitation (LOR 0.0012%/
patient year). Two patients underwent a percutaneous pulmonary valve implantation in 
pulmonary position for severe homograft dysfunction. Pulmonary valve replacement free 
survival at 25 years after surgery is shown in Figure 2. In the Cox regression the use of a 
transannular patch was the only predictor for pulmonary valve replacement for pulmonary 
regurgitation (p=0.021), while era of operation (ToF70 or ToF80), right ventricular incision, 
age at operation < 2 years, or prior palliative shunt were not.
clinical function state
The mean follow up duration after corrective surgery of patients was 24.3 ±4.7 years in ToF70 
and 23.3 ±2.6 years in ToF80 (p=0.903). At last follow-up most patients were in NYHA class I in 
both groups; respectively 80% in ToF70 and 91% in ToF80 (p=0.104). More patients in ToF70 
reported having had shortness of breath at some time after surgery 52% versus 10% in ToF80 
(p<0,001).
(24 hours) Ecg monitoring
Electrocardiography was performed in 90 ToF70 patients and 82 ToF80 patients. Mean QRS 
duration was 136 msec ± 33 and 136 ± 30 (p=0.97), respectively. Duration of the QRS was 
longer than 180 msec in 9.4% of ToF70 and 7,2% of ToF80 (p= 0.61). At follow-up 92% of 
Figure 2a. Pulmonary valve replacement free survival for both pulmonary regurgitation and pulmonary 
stenosis
Figure 2b. Pulmonary valve replacement free survival for pulmonary regurgitation
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patients in ToF80 were in sinus rhythm versus 84% in ToF70 (p=0.14). Holter monitoring was 
performed in 70 ToF70 patients and 65 ToF80 patients. Supraventricular tachycardias were 
found in 2.7% of ToF70 and 14% of ToF80 (p=0.012). Non-sustained ventricular tachycardias 
were documented in 13% of ToF70 patients and 4.6% of ToF80 patients (p=0.12); only one of 
the ToF80 patients had a ventricular tachycardia longer than 10 beats.
Echocardiographic findings
Table 2 presents the echocardiographic data of the two groups. Left ventricular (LV) dysfunc-
tion was found in 10% in ToF70 and 4.9% in ToF80 (p=0.20), while RV dysfunction was found 
in 7% and 15.6% (p=0.12), respectively.
Table 2. Echocardiography. 
All data are mean (± standard deviation) unless indicated otherwise. LVESD Left ventricular end-systolic 
dimension, LVEDD left ventricle end-diastolic dimension, FS fractional shortening, IVS ED end-diastolic 
thickness of the interventricular septum, LVPW ED end-diastolic thickness of the posterior wall, LA 
left atrium dimension, E early component of the transmitral inflow pattern, A late component of the 
transmitral inflow pattern, DET deceleration time of E.
ToF70 (n=75) ToF80 (n=81) p value
Number of patients 75 81
LVEDD (mm(SD))) 49 (6.4) 45 (7.9) 0.008
LVESD (mm (SD)) 34 (5.3) 33 (6.7) 0.22
FS (%(SD)) 30 (6.8) 31 (8.2) 0.89
IVS ED (mm (IQR)) 10 (7-13) 8 (6-10) <0.001
PW ED (mm (IQR)) 10 (7-13) 9 (7-11) 0.071
LA (mm (SD)) 37 (7.4) 36 (7.2) 0.77
Aortic sinus (mm (SD)) 37 (6.3) 33 (6.0) 0.001
Aortic ratio 1.23 (0.20) 1.09 (0.19) <0.001
Aortic ratio > 1,3 34 10 0.001
E/A ratio (SD) 2.1 (0.8) 1.9 (0.7) 0.046
DET (msec (SD) 177 (39) 193 (60) 0.10
Tricuspide regurgitation (mild to moderate) % 62 78 0.037
Tricuspide regurgitation (severe) % 2.8 6.3 045
Pulmonary regurgitation (moderate) % 34 53 0.017
Pulmonary regurgitation (severe) % 53 32 0.007
Mitral regurgitation (moderate) % 39 13.8 <0.001
Aortic regurgitation (moderate) % 21.1 7.5 <0.001
Aortic stenosis % 5.4 3.8 0.71
Pulmonary stenosis % 49 52 0.70
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Exercise capacity
Exercise testing was performed in 73 ToF70 patients and 68 ToF80 patients. Mean exercise 
capacity was 82% of the expected value in ToF70 and 81% in ToF80 (p=0.55). Respectively 
56% and 60% patients performed below 85% of the predicted value (p=0.57).
Quality of life
Outcomes of the SF 36 are presented in Figure 3. No difference was found on any of the SF-36 
scales between the ToF70 and ToF80 patients.
Compared to normative data, ToF80 patients scored higher on mental health (p<0.001) and 
social functioning, (p<0.0001) but lower on general health (p<0.01) and vitality (p<0.0001).
Behavioural/Emotional Problems
Regarding behavioural and emotional problems no significant differences were found be-
tween the ToF70 and ToF80 patients.
Compared to the normative group, ToF80 patients scored better on the scales anxious/de-
pressed, attention problems, aggressive behaviour, internalizing and externalizing problems, 
as shown in Table 3.
Figure 3. Mean SF-36 scale scores for the ToF70, ToF80 and normative group.
* ToF70 and ToF 80 versus norm p<0.001, † ToF70 and ToF 80 versus norm p<0.0001 , ToF 80 versus norm 
p<0.01 
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discussion
This study provides a historical comparison of late outcome after surgical correction for ToF. 
Two large cohorts of ToF patients operated in the 70’s and in the 80’s were studied, using the 
same standardized follow-up protocol after a comparable period of time in the same institu-
tion. There was a trend towards a decrease of early mortality rate while the hazard of late 
death for adults with repaired ToF is low. The late mortality rate was not statistically different 
between both cohorts, although survival did show a positive trend.
morbidity
Pulmonary valve regurgitation is a frequent late complication after ToF correction.(4) The 
relationship between the type of corrective surgery and long-term effects of the resulting PR 
has received considerable interest. In particular the use of transannular patching as a possible 
cause of PR and long-term morbidity has been suggested.(16) There have been contradicting 
reports about the influence of a transannular patch on the need for PVR. De Ruiter et al de-
scribed an increase in right ventricular dilatation and need for PVR. On the other hand Hickey 
et al did not demonstrate more PR or ventricular dilatation after the use of a transannular 
patch.(5,17) With the shift towards earlier corrective surgery, more transannular patches were 
implanted in the ToF80 cohort of our study. In our study, the only factor associated with the 
increased need for re-operation for PR was the use of a transannular patch.
Table 3. Differences in mean behavioural/emotional problems scale scores between ToF70 patients, 
ToF80 patients and the norm group
  Problem scores    
ToF70 ToF80 norm
(n=72) (n=41) (n=1211)
ASR scales M (SD) M (SD) M (SD) p-valuea p-valueb
Anxious/Depressed 4.5 (4.5) 4.3 (4.7) 6.1 (6.1) 0.84 0.022
Withdrawn 2.3 (2.1) 2.3 (2.4) 2.9 (2.7) 0.95 0.19
Somatic Complaints 3.2 (3.1) 2.7 (3.0) 2.9 (3.2) 0.45 0.77
Thought Problems 1.7 (2.2) 1.6 (2.1) 1.8 (2.1) 0.78 0.56
Attention Problems 3.0 (2.2) 3.0 (2.3) 6.1 (4.7) 0.98 <0.001
Aggressive Behavior 2.2 (2.5) 2.2 (1.8) 4.2 (4.1) 0.95 <0.001
Rule-Breaking Behavior 2.1 (2.3) 2.3 (2.3) 2.8 (2.8) 0.63 0.21
Intrusive 1.8 (1.7) 1.8 (1.6) 1.9 (1.9) 0.88 0.54
Internalizing Problems 9.9 (8.5) 9.3 (7.5) 11.9 (10.5) 0.89 0.042
Externalizing Problems 6.1 (5.4) 6.2 (4.7) 9.0 (7.2) 0.71 0.001
ASR = Adult Self-Report
a p value ToF70 versus ToF80
b p value ToF80 versus norm
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Our centre follows a rather selective policy towards pulmonary homograft replacement.
(2,18,19) The indication for pulmonary homograft replacement nowadays consists of severe 
pulmonary valve regurgitation with a combination of symptoms, a reduction in exercise 
capacity over time, a decrease in right ventricular function or an indexed RV volume on MRI 
of > 150 ml/m2. Over time there have not been essential differences in policy or indication 
for PVR in our centre. However, there has been an increase in the use of magnetic resonance 
imaging, which has become a standard diagnostic tool in the follow-up of Fallot patients. The 
use of MRI may have influenced the decision making concerning PVR and this may explain 
some of the differences found between both cohorts. However, in our centre the decision 
making for PVR is never done on the basis of MRI measurements only.
An unexpected finding was the trend towards increased right ventricular dysfunction in 
the ToF80 cohort, which may also be related to the frequent use of transannular patches with 
longstanding pulmonary regurgitation. In the 90s there was a tendency to avoid transan-
nular patching and surgical correction was performed at an even earlier (neonatal) age.(8) 
Nowadays this very early intervention has been abandoned by most surgeons. It will be very 
interesting to study the additional impact of further changes in surgical technique on long-
term reoperations rate and right ventricular function.
LV dysfunction significantly influences late prognosis in ToF patients.(20) In contrast to the 
unexpected negative findings on the right side of the heart, improvements in relation to 
the left side were noted in the 80’s cohort. Positive effects on LV dimensions were observed, 
which may be explained by the corrective operation performed at younger age in the 80’s. In 
addition less aortic regurgitation and aortic dilatation were found in this cohort. The question 
remains whether the aortic dilatation is the cause or rather the result of aortic regurgitation. 
Grotenhuis et al. hypothesised that aortic dilatation and regurgitation could be the cause for 
LV dysfunction.(21) Tan et al. showed post-mortem histological changes of the aortic root 
(as in Marfan and bicuspid valve patients) which may contribute to the aortic root dilatation 
and thereby regurgitation. (Tan23, Kalra3) In addition to morphological changes of the aorta 
another explanation could be found in flow patterns. Niwa et al. speculated that the use of 
prior palliation, with high aortic flow, is responsible for the increased aortic dilation with 
secondary aortic regurgitation. (22)
clinical condition
Most patients were in NYHA class I and QRS duration was comparable in the two cohorts. 
QRS duration has been described to be a predictor of arrhythmias. (8,24) In the ToF80 more 
patients had supra ventricular tachycardias on holter monitoring, which may be associated 
with the RV dysfunction. (3) Short runs of ventricular tachycardia were found in both cohorts. 
In these patients thorough evaluation of the hemodynamic state and additional testing was 
done. Although most patients were able to exercise until an acceptable maximum heart rate, 
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both cohorts showed exercise capacity of around 80% of predicted. This is comparable with 
the exercise capacity mentioned in the literature between 77%-89%. (25,26)
health-related quality of life
As quality of life and behavioural/emotional functioning showed the same results in the 
ToF70 and ToF80 patients, no clear improvements over time could be observed. Compared 
to the normal population ToF patients scored lower on general health and vitality.(27) This 
could indicate patients are aware of the disease in daily life. On the other hand they scored 
higher on social sub domains, thereby indicating they did not feel to be emotionally with-
held because of this disease. This is in line with previous studies, for instance by Hickey et al. 
who showed SF-36 scores were significantly below normal for physical domains in 840 adults 
ToF patients(5) This appreciation of social functioning was confirmed by the results of the 
Adult Self-Report, in which we found less anxiety or internalizing problems and aggressive or 
externalizing problems.(18) The lower prevalence of behaviour problems may be due to the 
fact that these patients show a “response shift””. A respons shift is described in patients who 
have survived surgical correction and often had multiple hospital admissions. To cope with 
this major life event they have consequently developed a better coping mechanism. This may 
lead to a better subjective quality of life.(28)
study limitations
In 2001 MRI was not performed routinely and also the modern echocardiographic measure-
ments, such as speckle tracking and 3D, were not available yet. Since we could not compare 
these techniques, we did not include these techniques in this study. The echocardiographic 
left ventricular end systolic diameter may not be valid in all patients, considering the para-
doxal septal deviation, therefore LV end systolic diameter and fractional shortening should 
be seen in this light. Exercise testing was done without maximum VO2, which would have 
been optimal. This study is an observational non-randomised trial; therefore conclusions 
should be drawn with care.
concLusion
In 2001 we studied patients with ToF operated between 1968-1980, in the current study we 
repeated the protocol 10 years later in patients operated between 1980-1990. This study 
demonstrats that with an earlier stage surgery, there is a trend towards a diminished early 
mortality rate and late survival remained good. Although the left ventricle seems to be better 
protected by surgery at younger age. By avoiding the extensive use of a transannular patch, 
the need for reoperations may further decrease. Overall, quality of life was good with no 
significant differences between the two cohorts.
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Long-term psychosocial outcome of adults with 
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ABsTRAcT
objective
Making a historical comparison on the long-term psychosocial outcome of cardiothoracic 
surgery during childhood.
methods
Adult patients operated for Tetralogy of Fallot or Transposition of the Great Arteries between 
1980-1990 (recent sample) were compared with patients operated ten years earlier (historical 
sample). Also, atrial switch and arterial switch patients within the recent sample were com-
pared. Psychosocial functioning was measured using standardised, validated psychological 
questionnaires.
Results
Although the recent sample of patients overall shows a favorable quality of life, impairments 
were found in income, living conditions, relationships, offspring and occupational level. Com-
pared to the historical sample, the recent sample showed no significant improvements on 
psychosocial functioning, except for a better educational level. The amount of educational 
problems (such as learning difficulties) was still high compared to normative data. Recently 
operated patients with Transposition of the Great Arteries scored significantly better on the 
Short Form-36 vitality scale (p=0.02) compared to historical patients with Transposition of 
the Great Arteries.
conclusions
Despite improvements in medical treatment over the past decades, hardly any change was 
found in psychosocial outcome of the recent patient sample compared to the historical pa-
tient sample. Especially the percentage of patients needing special education and showing 
learning problems remained high, while income was low compared to normative data.
Keywords
Transposition of the great arteries, Tetralogy of Fallot, quality of life, historical comparison, 
congenital heart disease
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inTRoducTion
The dramatically improved long-term survival of children born with congenital heart disease 
has resulted in a new and growing population of adults with congenital heart disease.1,2 This 
has raised interest in the quality of life of adult congenital heart disease patients.
Adults with congenital heart disease differ from the general population by medical status 
and medical history, and have specific psychosocial needs and problems.3 It has been shown 
that young adults with congenital heart disease obtained a lower educational and occupa-
tional level compared to normative reference groups.4 Furthermore, as to subjective health 
status, patients experienced more limitations in physical functioning.5
Since 1980, many aspects of diagnostic, surgical and medical treatment of congenital heart 
disease have improved, supposedly resulting in less physiological stress on the patient. Our 
hypothesis is that improvements in cardiological outcome may also specifically result in more 
favorable long-term psychosocial outcome. To the best of our knowledge this study is the 
first to test this hypothesis using two cross-sectional samples of all adult congenital heart 
disease patients (matched for age and cardiac diagnosis), comparing results over a 10-year 
period.
The objective of this study was three-fold: 1) to investigate the psychosocial outcome of 
adults operated recently (between 1980 – 1990) for Tetralogy of Fallot or Transposition of 
the Great Arteries, 2) to compare those outcomes with a matched historical cohort (operated 
between 1968 – 1980), and 3) to make a comparison within the recent Transposition of the 
Great Arteries group between patients operated with the Mustard procedure versus the arte-
rial switch procedure.
mATERiALs And mEThods
study design
In this cross-sectional single center study psychosocial outcome of a recent versus a historical 
patient sample was compared using a comparable age-range (20-37) and comparable cardiac 
diagnostic groups: Transposition of the Great Arteries and Tetralogy of Fallot.
Assessment procedure
For both the recent and historical sample, the institutional ethical committee on human 
experimentation approved the research protocol. In both studies, patients were approached 
uniformly and signed informed consent before participating. All patients were medically 
examined by a cardiologist in our center. The semi-structured interview and psychological 
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questionnaires were completed in our hospital. In both samples data collection took place in 
the same standardized way.
Recent patient sample
Out of 185 selected patients, 19 patients died, 45 patients were lost to follow-up and 6 pa-
tients were living abroad. Of the remaining 115 elegible patients, 36 refused to participate 
resulting into 79 participating patients. Five patients were not able to complete all question-
naires. Thus the overall response rate was 69%.
The recent congenital heart disease sample (n=79) consisted of all consecutive surviving 
patients with either Transposition of the Great Arteries (n=31) or Tetralogy of Fallot (n=48), 
who underwent their first open heart surgery for congenital heart disease in our center 
between 1980 - 1990, and were younger than 15 years at the time of surgery. At follow-up 
(2010), all patients were between 20 and 35 years of age. Of the 31 patients with Transposition 
of the Great Arteries, 18 patients underwent arterial switch surgery (58%) and 13 patients 
underwent a Mustard or Senning procedure (42%). All patients with Tetralogy of Fallot had 
a complete correction and in 74% a right-ventricular outflow tract patch was inserted. The 
median follow-up time of this group was 24.2 years (22.7 – 26.5).
historical comparison
Historical patient selection
The 362 congenital heart disease patients that have been included in the historical patients 
sample has been described in detail previously.4 These patients were all operated for con-
genital heart disease between 1968 and 1980 in our center, and were evaluated medically 
and psychosocially in 2000/2001. Out of this population, we excluded 230 patients because 
of non-comparable diagnosis (ASD, VSD and PS). A total of 22 patients did not fill in the 
questionnaires we need for the historical comparison, and 3 patients were excluded because 
of mental retardation, resulting in 107 eligible patients.
Matching procedure
The mean age of the 107 eligible patients was significantly higher than the selection made 
in the recent sample. We therefore stratified by congenital diagnosis (ToF and TGA) and 
removed the oldest patients until age was not significantly different anymore (ToF p=0.09, 
TGA p=0.33). This resulted into 88 included patients (ToF N=53, TGA N=55). Both groups were 
comparable on gender (ToF p=0.7, TGA p=0.9).
instruments and normative data
The psychological examination consisted of the following instruments:
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Biographical characteristics, such as nationality, living conditions, marital status, offspring, 
educational- and occupational status were assessed by a semi-structured interview.6 Norma-
tive data were extracted from multiple tables, which were all derived from a variety of (very) 
large samples of the Dutch population, so that representativeness for the average Dutch situ-
ation was warranted (Netherlands Central Bureau of Statistics).7 For some tables sample sizes 
were not provided by the CBS. Also, the sample sizes of the reference groups vary between 
different tables. To prevent confusion, these sample sizes were not included in the tables. 
Where possible, normative data were stratified by sex and age. Data tables used were:
Subjective health status was assessed by the Short Form-36.8 Good reliability and validity 
for the Dutch Short Form-36 has been reported.9 Normative data were derived from a nation 
wide, population based Dutch health status survey.9
The Satisfaction with Life Scale was has been proven psychometrically sound to be used 
in patients with congenital heart disease.10 Normative data was derived from a large general 
population sample.10
The Linear Analogue Scale was used to assess self-perceived quality of life. This instrument 
has been proven valid, reliable and responsive for the congenital heart disease population.10 
Normative data was derived from a large general population sample.10
statistical analyses
In order to make the comparison between the historical and the recent sample, both datasets 
of the recent and historical congenital heart disease samples was categorized according to 
the age and gender categories of normative groups. For categorical characteristics, propor-
tions of patients are presented in percentages.
 P-values were calculated on the basis of 95% confidence intervals. Because of the skewed 
nature of the data, Mann-Whitney-U tests were used to assess difference in outcome (Short 
Form-36, Satisfaction With Life Scale and Linear Analogue Scale) between diagnostic groups 
within the recent congenital heart disease sample. Pearson Chi-square tests were used to 
test for differences in distributions of gender and cardiac diagnoses between both patient 
samples. If cell values were less than 5, the Fisher exact test was used. The statistical package 
IBM SPSS Statistics for Mac version 19.0 (Release 19.0.0) was used. Figures were made using 
GraphPad Prism version 6.0a for Mac, GraphPad Software (Released July 18, 2012), La Jolla 
California USA.
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REsuLTs
Recent sample versus normative data
Biographical characteristics (Table 1, Figure 1 and 2)
Patients with congenital heart disease were living less often independently (p<0.0001), and 
were less often married or had a stable relationship compared to normative data (p<0.01). 
Patients with congenital heart disease were less likely to have children compared to norma-
tive data, stratified by age and gender categories (p<0.0001) (Figure 1).
Figure 1: Biographical data
Figure 1 shows the comparison on three different biographical variables between the recently operated 
patients with congenital heart disease (shown in red) and a normative group (shown in green).
Living at parents = proportion of people still living at their parents; mother/father or both
Married = the proportion of people that are married
Children = the proportion of people that have one or more children.
p-values were calculated by chi-square tests
Figure 2: Comparison on income between the recently operated congenital heart disease group and the 
normative group
Figure 2 shows the comparison on income between the recently operated congenital heart disease group 
and a normative group (matched on age and gender). Shown in red is the proportion of the group that 
earns < €20 000, shown in green is the proportion of the group that earns ≥ €20 000 
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Patients with congenital heart disease obtained a similar educational level compared to 
normative data, except for females aged 25 to 35 years, who less often had higher educa-
tion (p<0.05, not listed in the Table). As to occupation, recent patients with congenital heart 
disease less often had an academic occupational level (p<0.01), and more often had a lower 
occupational level (p=0.02) compared to normative data.
Considering employment, remarkably, patients with congenital heart disease who had a 
paid job were less frequently working part-time (p<0.01) and more often working full-time 
compared to normative data. There was no effect of gender as to working part-time versus 
full-time. Congenital heart disease did not appear to be the reason for working part-time 
in the majority of patients (80%). Regarding income, patients with congenital heart disease 
earned significantly less compared to the general Dutch population (p<0.01) (Figure 2). 
Finally, patients with congenital heart disease showed a significant higher percentage of sick 
leave compared to the general Dutch population (7% vs. 4.4%). This effect was mainly found 
in arterial switch patients.
Quality of Life (Table 2)
Subjective health status: Compared to normative data, the recent congenital heart disease 
sample obtained less favorable results on bodily pain, vitality and general health scales. 
Patients with congenital heart disease more often experienced bodily pain (p=0.05) and as 
to vitality, reported to feel more worn out and tired (p<0.0001). Patients scored their gen-
eral health as significantly lower and believed it was likely to get worse over time (p<0.01). 
Also, the recent sample obtained more favorable scores (p<0.0001) on social functioning, 
indicating less interference from physical or emotional problems in attending social activi-
ties. Recent patients reported a better general mental health compared to normative data 
(p<0.0001).
Compared to normative data (Figure 3) the recent Tetralogy of Fallot group obtained more 
favorable scores on social functioning (p<0.0001) and mental health (p<0.001). Less favorable 
scores for the recent Tetralogy of Fallot group were obtained on the vitality scale (p<0.0001) 
and general health scale (p<0.01).
The recent Mustard group obtained more favorable scores compared to normative data, 
on social functioning (p<0.0001), mental health (p=0.02), role emotional (p<0.0001), and less 
favorable on physical functioning (p=0.01) and vitality (p=0.04) (Figure 4)
Within the recent sample, no differences were found between patients with Tetralogy 
of Fallot and patients with Transposition of the Great Arteries. When comparing Mustard 
and arterial switch patients within the recent sample, two differences were found: arterial 
switch patients reported better physical functioning compared to patients operated with 
the Mustard procedure (p<0.01). This indicates that arterial switch patients feel less limited 
in performing physical activities compared to patients operated with the Mustard procedure. 
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Table 1. Medical and biographical characteristics of the recent 
and historical sample compared to normative groups (in 
percentages).
Table legend: 
* Normative data was derived from the Netherlands Bureau 
of Statistics 2010. Normative data on daily activities was not 
available and is therefore not displayed in the table.
Fallot = patients with Tetralogy of Fallot; TGA = patients with 
transposition of the Great arteries; Switch = patients with 
arterial switch (subgroup of TGA); Mustard = patients with 
Mustard correction (subgroup of TGA); Part-time is working < 
36 hours a week; Fulltime is working ≥ 36 hours a week.
a significant difference Switch versus Mustard
b significant difference in ToF versus TGA
c all patients that do not live together with a partner
d persons living in institutions for mentally handicapped are 
excluded
e Only persons that have a paid job and are between 25 and 
35 years of age are included
f Sick-leave percentage was used instead of number of days on 
sick-leave, since the number of hours a person works a week 
(full-time/part-time) might vary considerably. P-values could 
not be calculated since data on standard deviations or ranges 
were missing for the normative groups. P-values for the 
historical comparison were calculated using Mann-Whitney U 
tests because of the skewed nature of the data.
 
Recent versus normative data Historical comparison
ToF
TGA
Total * Norm Total ConHD 
vs Norm 
p-value
Historical Recent Historical
  N=61 vs
Total Switch Mustard N=88   recent
N=48 N=31 N=18 N=13 N=79 N~     p-value
Age 28.5±3.5 26.1±2.7 24.0±1.2 26.7±1.6 27.5±3.4     26.8±4.0 26.4±3.1 0.5
Gender (male) 66.7 67.7 66.7 69.2 67.1     66.7 67.2 0.9
NYHA-class                    
  I     95.8 92 91.7 92.3 94.5     28.9 95.7 <0.001
  II     4.2 8 8.3 7.7 5.5     53.3 4.3 <0.001
  III                   17.8 - <0.001
                           
Daily activities                   0.4
  Attending education a 14.6 29 44.4 7.7 20.3 - - 9.3 13.1 0.4
  Paid job a,b 64.6 38.7 16.7 69.2 54.4 - - 67.3 65.6 0.8
  Combination above b 4.2 22.6 27.8 15.4 11.4 - - 3.7 6.6 0.4
  Looking for work 2.1 0 0 0 1.3 - - 4.7 1.6 0.3
  Long-term sick leave 4.2 0 0 0 2.5 - - 3.7 3.3 0.9
  Volunteer unpaid work 2.1 0 0 0 1.3 - - 0.9 1.6 0.7
  Mentally handicapped 8.3 9.7 11.1 7.7 8.9 - - 3.7 8.2 0.2
  Housewife/man 0 0 0 0 0 - - 1.9 0 0.3
  Other 0 0 0 0 0 - - 4.7 0 0.09
Living conditions                    
  Parents 34 54.8 66.7 38.5 42.3 23.7 <0.01 31.8 34.4 0.7
  Independently 57.4 45.2 33.3 61.5 52.6 75.6 <0.0001 65.4 59 0.4
  Institution 8.5 0 0 0 5.1 0.7 0.1 2.8 6.6 0.2
Marital status                    
  No stable relationship b,c 59.6 80.6 88.9 69.2 67.9 51.5 <0.01 47.7 60.7 0.1
  Cohabitants 27.7 9.7 11.1 7.7 20.5 25.5 0.3 24.3 24.6 1
  Married a 12.8 9.7 0 23.1 11.5 23.1 <0.01 26.2 14.8 0.09
  Divorced                  1.9 - 0.3
Offspring                    
  No children 87.2 96.8 100 92.3 91 55.5 <0.0001 79.4 88.5 0.13
  ≥1 children 12.8 3.2 0 7.7 9 44.5   20.6 11.5  
Educational attainment d                    
  Lower 16.7 14.3 25 10 15.9 17.9 0.7 48.1 24 0.004
  Average 53.3 57.1 75 50 54.5 43 0.1 33 52 0.02
  Higher 30 28.6 0 40 29.5 39.1 0.2 18.9 24 0.5
Educational problems                    
  Special education 25 16.7 16.7 16.7 21.8 3.5   34.6 23.3 0.1
  Doubled a class 45.8 43.3 50 33.3 44.9       43.3  
  Learning difficulties 43.8 30 22.2 41.7 38.5       43.3  
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Table 1. Medical and biographical characteristics of the recent 
and historical sample compared to normative groups (in 
percentages).
Table legend: 
* Normative data was derived from the Netherlands Bureau 
of Statistics 2010. Normative data on daily activities was not 
available and is therefore not displayed in the table.
Fallot = patients with Tetralogy of Fallot; TGA = patients with 
transposition of the Great arteries; Switch = patients with 
arterial switch (subgroup of TGA); Mustard = patients with 
Mustard correction (subgroup of TGA); Part-time is working < 
36 hours a week; Fulltime is working ≥ 36 hours a week.
a significant difference Switch versus Mustard
b significant difference in ToF versus TGA
c all patients that do not live together with a partner
d persons living in institutions for mentally handicapped are 
excluded
e Only persons that have a paid job and are between 25 and 
35 years of age are included
f Sick-leave percentage was used instead of number of days on 
sick-leave, since the number of hours a person works a week 
(full-time/part-time) might vary considerably. P-values could 
not be calculated since data on standard deviations or ranges 
were missing for the normative groups. P-values for the 
historical comparison were calculated using Mann-Whitney U 
tests because of the skewed nature of the data.
 
Recent versus normative data Historical comparison
ToF
TGA
Total * Norm Total ConHD 
vs Norm 
p-value
Historical Recent Historical
  N=61 vs
Total Switch Mustard N=88   recent
N=48 N=31 N=18 N=13 N=79 N~     p-value
Age 28.5±3.5 26.1±2.7 24.0±1.2 26.7±1.6 27.5±3.4     26.8±4.0 26.4±3.1 0.5
Gender (male) 66.7 67.7 66.7 69.2 67.1     66.7 67.2 0.9
NYHA-class                    
  I     95.8 92 91.7 92.3 94.5     28.9 95.7 <0.001
  II     4.2 8 8.3 7.7 5.5     53.3 4.3 <0.001
  III                   17.8 - <0.001
                           
Daily activities                   0.4
  Attending education a 14.6 29 44.4 7.7 20.3 - - 9.3 13.1 0.4
  Paid job a,b 64.6 38.7 16.7 69.2 54.4 - - 67.3 65.6 0.8
  Combination above b 4.2 22.6 27.8 15.4 11.4 - - 3.7 6.6 0.4
  Looking for work 2.1 0 0 0 1.3 - - 4.7 1.6 0.3
  Long-term sick leave 4.2 0 0 0 2.5 - - 3.7 3.3 0.9
  Volunteer unpaid work 2.1 0 0 0 1.3 - - 0.9 1.6 0.7
  Mentally handicapped 8.3 9.7 11.1 7.7 8.9 - - 3.7 8.2 0.2
  Housewife/man 0 0 0 0 0 - - 1.9 0 0.3
  Other 0 0 0 0 0 - - 4.7 0 0.09
Living conditions                    
  Parents 34 54.8 66.7 38.5 42.3 23.7 <0.01 31.8 34.4 0.7
  Independently 57.4 45.2 33.3 61.5 52.6 75.6 <0.0001 65.4 59 0.4
  Institution 8.5 0 0 0 5.1 0.7 0.1 2.8 6.6 0.2
Marital status                    
  No stable relationship b,c 59.6 80.6 88.9 69.2 67.9 51.5 <0.01 47.7 60.7 0.1
  Cohabitants 27.7 9.7 11.1 7.7 20.5 25.5 0.3 24.3 24.6 1
  Married a 12.8 9.7 0 23.1 11.5 23.1 <0.01 26.2 14.8 0.09
  Divorced                  1.9 - 0.3
Offspring                    
  No children 87.2 96.8 100 92.3 91 55.5 <0.0001 79.4 88.5 0.13
  ≥1 children 12.8 3.2 0 7.7 9 44.5   20.6 11.5  
Educational attainment d                    
  Lower 16.7 14.3 25 10 15.9 17.9 0.7 48.1 24 0.004
  Average 53.3 57.1 75 50 54.5 43 0.1 33 52 0.02
  Higher 30 28.6 0 40 29.5 39.1 0.2 18.9 24 0.5
Educational problems                    
  Special education 25 16.7 16.7 16.7 21.8 3.5   34.6 23.3 0.1
  Doubled a class 45.8 43.3 50 33.3 44.9       43.3  
  Learning difficulties 43.8 30 22.2 41.7 38.5       43.3  
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Table 1. Medical and biographical characteristics of the recent 
and historical sample compared to normative groups (in 
percentages). (Continued)
 
Recent versus normative data Historical comparison
ToF
TGA
Total * Norm Total ConHD 
vs Norm 
p-value
Historical Recent Historical
  N=61 vs
Total Switch Mustard N=88   recent
N=48 N=31 N=18 N=13 N=79 N~     p-value
Occupational level d                    
  Elementary 3.6 0 0 0 2.5 5.6 0.2 5.4 2.3 0.4
  Lower 35.7 41.7 50 40 37.5 19.5 0.02 40.5 39.5 0.9
  Average b 50 16.7 50 10 40 40 1 32.4 37.2 0.6
  Higher b 7.1 41.7 0 50 17.5 24.1 0.3 16.2 16.3 1
  Academic 3.6 0 0 0 2.5 10.7 <0.01 5.4 4.7 0.9
Duration of employment e                    
  Part-time 16.7 18.2 50 11.1 17.1 33.8 <0.01 24 15.9 0.3
  Full-time 83.3 81.8 50 88.9 82.9 66.2   76 84.1  
                         
  Male                    
    Part-time a 9.1 11.1 50 0 9.7 12.8 0.6 10.2 6.3 0.5
    Full-time a 90.9 88.9 50 100 90.3 87.2   89.8 93.8  
  Female                    
    Part-time 37.5 50 0 50 40 56.9 0.3 50 41.7 0.6
    Full-time 62.5 50 0 50 60 43.1   50 58.3  
                         
  Reason part-time work                    
    Heart sole reason 12.5 0 0 0 6.7 - - 27.8 14.3 0.5
    Heart a reason 25 0 0 0 13.3 - - 5.6 28.6 0.1
    Heart no reason 62.5 100 100 100 80 - - 66.7 57.1 0.7
Income                    
  < €20000 63.6 66.7 80 60 64.6 41.3 <0.01 44.6 61.9 0.1
  ≥ €20000 36.4 33.3 20 40 35.4 58.7   55.4 38.6  
                     
Sick-leave f 7 7.1 13.4 3.6 7 4.4   12.1 5.1 0.1
                           
Sick-leave compared to collegues                    
  More   7.9 28.6 30 27.3 15.3 - - 13.9 11.6 0.7
  Equal   34.2 47.6 50 45.5 39 - - 33.3 34.9 0.9
  Less   57.9 23.8 20 27.3 45.8 - - 52.8 53.5 0.9
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Table 1. Medical and biographical characteristics of the recent 
and historical sample compared to normative groups (in 
percentages). (Continued)
 
Recent versus normative data Historical comparison
ToF
TGA
Total * Norm Total ConHD 
vs Norm 
p-value
Historical Recent Historical
  N=61 vs
Total Switch Mustard N=88   recent
N=48 N=31 N=18 N=13 N=79 N~     p-value
Occupational level d                    
  Elementary 3.6 0 0 0 2.5 5.6 0.2 5.4 2.3 0.4
  Lower 35.7 41.7 50 40 37.5 19.5 0.02 40.5 39.5 0.9
  Average b 50 16.7 50 10 40 40 1 32.4 37.2 0.6
  Higher b 7.1 41.7 0 50 17.5 24.1 0.3 16.2 16.3 1
  Academic 3.6 0 0 0 2.5 10.7 <0.01 5.4 4.7 0.9
Duration of employment e                    
  Part-time 16.7 18.2 50 11.1 17.1 33.8 <0.01 24 15.9 0.3
  Full-time 83.3 81.8 50 88.9 82.9 66.2   76 84.1  
                         
  Male                    
    Part-time a 9.1 11.1 50 0 9.7 12.8 0.6 10.2 6.3 0.5
    Full-time a 90.9 88.9 50 100 90.3 87.2   89.8 93.8  
  Female                    
    Part-time 37.5 50 0 50 40 56.9 0.3 50 41.7 0.6
    Full-time 62.5 50 0 50 60 43.1   50 58.3  
                         
  Reason part-time work                    
    Heart sole reason 12.5 0 0 0 6.7 - - 27.8 14.3 0.5
    Heart a reason 25 0 0 0 13.3 - - 5.6 28.6 0.1
    Heart no reason 62.5 100 100 100 80 - - 66.7 57.1 0.7
Income                    
  < €20000 63.6 66.7 80 60 64.6 41.3 <0.01 44.6 61.9 0.1
  ≥ €20000 36.4 33.3 20 40 35.4 58.7   55.4 38.6  
                     
Sick-leave f 7 7.1 13.4 3.6 7 4.4   12.1 5.1 0.1
                           
Sick-leave compared to collegues                    
  More   7.9 28.6 30 27.3 15.3 - - 13.9 11.6 0.7
  Equal   34.2 47.6 50 45.5 39 - - 33.3 34.9 0.9
  Less   57.9 23.8 20 27.3 45.8 - - 52.8 53.5 0.9
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Arterial switch patients reported better general health compared to patients operated with 
the Mustard procedure (p=0.05).
On the Satisfaction with Life Scale, the recent patients with congenital heart disease 
showed more favorable scores compared to normative data (p<0.01). No difference was 
found for patients with Tetralogy of Fallot versus patients with Transposition of the Great 
Arteries or arterial switch versus patients operated with the Mustard procedure.
On the Linear Analogue Scale, the recent congenital heart disease sample rated their qual-
ity of life significantly higher compared to normative data (p=0.02). No difference was found 
for patients with Tetralogy of Fallot versus patients with Transposition of the Great Arteries or 
arterial switch versus patients operated with the Mustard procedure.
Recent sample versus historical sample
Medical background. The age at first treatment differed between the recent and historical 
sample (Recent: median = 0.8(0.5–1.8) years. Historical: median = 1.5(0.6–4.2) years, p=0.02). 
Table 2. Mean scale scores of the recent sample and normative data on instruments.
Table legend: 
ConHD = all ConHD patients (ToF & TGA combined). Norm = normative data for the general Dutch 
population corrected for age and sex where possible.
 ToF = patients with Tetralogy of Fallot; TGA = patients with Transposition of the Great Arteries, including 
arterial switch patients and patients operated with the Mustard procedure. 
Switch = patients with arterial switch operation; Mustard = patients operated with the Mustard procedure. 
The SF-36 scales range from 0 to 100. Lower scores indicate poorer subjective health status, higher scores 
indicate a more favorable subjective health status
Norm vs ConHD ToF vs TGA TGA
ConHD Norm ToF TGA Switch Mustard
n=74 n=1742 n=44 n=30 n=17 n=13
x sd x sd p x sd x sd p x sd x sd p
SF-36
 
Physical 
functioning 92.8 11.3 94.1 13.2 0.3 92.6 13.5 93.0 7.1 0.3 96.5 5.2 88.5 6.9 <0.01
 
Role function 
phyisical 93.2 16.2 92.2 22.3 0.6 94.9 12.7 90.8 20.2 0.6 86.8 23.6 96.2 13.9 0.2
  Bodily pain 86.7 18.7 91.1 15.1 0.05 87.5 17.2 85.5 20.9 0.8 85.8 21.0 85.2 21.5 1.0
  Social functioning 92.7 12.2 80.8 14.5 0.000 92.6 11.8 92.9 13.0 0.8 90.4 15.6 96.2 7.9 0.4
  Mental health 82.6 13.5 75.1 15.6 0.000 82.0 12.6 83.5 14.8 0.5 82.6 16.4 84.6 13.0 0.8
 
Role function 
emotion 95.0 17.2 91.5 15 0.08 92.4 21.4 98.9 6.1 0.1 98.0 8.1 100.0 0.0 0.4
  Vitality 76.9 16.2 90.3 24.6 0.000 74.7 18.2 80.2 12.3 0.4 79.1 11.2 81.5 13.9 0.4
  General health 74.9 17.5 80.6 14.7 <0.01 72.0 17.0 79.1 17.7 0.1 84.1 15.9 72.7 18.5 0.05
SWLS 27.6 4.8 25.8 4.6 <0.01 27.5 5.1 28.3 3.7 0.7 29.1 3.1 27.4 4.2 0.5
LAS 80.2 9.0 77.1 8.9 0.02 80.1 9.7 80.3 8.0 0.9 82.2 6.5 77.9 9.3 0.1
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Table 3. Differences in mean behavioural/emotional problems scale scores between ToF70 patients, 
ToF80 patients and the norm group.
ASR = Adult Self-Report
a p value ToF70 versus ToF80
b p value ToF80 versus norm
  Problem scores    
ToF70 ToF80 norm
(n=72) (n=41) (n=1211)
ASR scales M (SD) M (SD) M (SD) p-valuea p-valueb
Anxious/Depressed 4.5 (4.5) 4.3 (4.7) 6.1 (6.1) 0.84 0.022
Withdrawn 2.3 (2.1) 2.3 (2.4) 2.9 (2.7) 0.95 0.19
Somatic Complaints 3.2 (3.1) 2.7 (3.0) 2.9 (3.2) 0.45 0.77
Thought Problems 1.7 (2.2) 1.6 (2.1) 1.8 (2.1) 0.78 0.56
Attention Problems 3.0 (2.2) 3.0 (2.3) 6.1 (4.7) 0.98 <0.001
Aggressive Behavior 2.2 (2.5) 2.2 (1.8) 4.2 (4.1) 0.95 <0.001
Rule-Breaking Behavior 2.1 (2.3) 2.3 (2.3) 2.8 (2.8) 0.63 0.21
Intrusive 1.8 (1.7) 1.8 (1.6) 1.9 (1.9) 0.88 0.54
Internalizing Problems 9.9 (8.5) 9.3 (7.5) 11.9 (10.5) 0.89 0.042
Externalizing Problems 6.1 (5.4) 6.2 (4.7) 9.0 (7.2) 0.71 0.001
Figure 3: Comparison between normative data, recently operated Tetralogy of Fallot patients and 
historically operated Tetralogy of Fallot patients.
Figure 3 shows the comparison on the Short Form-36 scale for the recent patients with Tetralogy of Fallot 
(shown in red) versus the historical patients with Tetralogy of Fallot (shown in orange) and a normative 
group (shown in green). The Short Form-36 scales range from 0 to 100. Lower scores indicate poorer 
subjective health status, higher scores indicate a more favorable subjective health status. 
a = Significant difference between the normative group and the recently operated congenital heart 
disease group
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The difference in age at treatment was also observed in recent patients with Tetralogy of Fal-
lot versus historical patients with Tetralogy of Fallot patients (median = 1.2(0.5–2.4), respec-
tively 2.8(1.2-4.8) p=0.07), and recent patients operated with the Mustard procedure versus 
historical patients operated with the Mustard procedure (median = 0.5(0.2-0.7) respectively 
0.7(0.4-2.3) p=0.002). No significant difference was found on the number of surgeries using 
a right-ventricular outflow tract patch between the recent sample (74%) versus the historical 
sample (77%) (p=0.7).
Biographical characteristics (Table 1). A trend was observed showing that the recent pa-
tients with congenital heart disease less often had a relationship (p=0.1), and were married 
less often (p=0.09) compared to the historical sample. Recent patients with congenital heart 
disease obtained a significantly higher educational level compared to the historical sample. 
Both recent and historical sample showed a comparable high amount of special education , 
35% for the historical group and 23% for the recent group (p=0.1).
Figure 4: Comparison between normative data, recently operated patients operated with the Mustard 
procedure and patients historically operated with the Mustard procedure.
Figure 4 shows the comparison on the Short Form-36 scale for the recent patients operated with the 
Mustard procedure (shown in red) versus the historical patients operated with the Mustard procedure 
(shown in orange) and a normative group (shown in green). The Short Form-36 scales range from 0 to 100. 
Lower scores indicate poorer subjective health status, higher scores indicate a more favorable subjective 
health status.
a = Significant difference between the normative group and the recently operated congenital heart 
disease group
b = Significant difference between the recently operated congenital heart disease group and the 
historically operated congenital heart disease group.
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Quality of life (Figure 3 and 4)
Diagnostic groups. Figure 3 shows no differences between recent versus historical patients 
with Tetralogy of Fallot on any of the Short Form-36 scales. Figure 4 shows that recent patients 
operated with the Mustard procedure obtained more favorable scores on the vitality scale 
of the Short Form-36 compared to historical patients operated with the Mustard procedure 
(p=0.02). The other non-significant differences, except for general health, all pointed in the 
same direction of a better outcome for recently operated patients with Transposition of the 
Great Arteries.
discussion
Although the recent sample of patients with congenital heart disease overall shows a favor-
able quality of life, impairments were found on living conditions, relationships, offspring, 
occupational level, and also the income of patients with congenital heart disease is still lower 
than expected. Compared to the historical sample, the recent sample showed no significant 
improvements on psychosocial outcome, except for a better educational level.
To our knowledge, this is the first published psychosocial study making a historical 
comparison on long-term psychosocial outcome between a recent and historical sample of 
adult patients with congenital heart disease. To ensure that both samples were comparable, 
patients with the same diagnoses and same age-range were selected. Clinically relevant 
areas of psychosocial functioning were investigated, using internationally standardized as-
sessment instruments.
Recent sample versus normative data
Biographical outcome
Although a few older studies showed similar patterns on living less independently and lower 
offspring rates, our recent findings still show an impressive impact on living conditions in 
our complex ConHD population.11-16 The relatively young age of this patient sample cannot 
be the sole reason for these findings, since the same categories for age and sex were used 
in comparing our patient data with normative data. The low amount of offspring might be 
explained by the high amount of patients working fulltime, but it can also be the other way 
around, that patients less often have children and thus keep on working fulltime. The recent 
sample obtained a lower occupational level and was earning a significantly lower income 
compared to the general Dutch population. Our present findings on living conditions, marital 
status and occupational level all point in the same direction of being less independent and 
having a lower socio-economic status for patients with congenital heart disease. A delayed 
process of gaining autonomy and striving for independence might explain the differences in 
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biographical outcome and occupational level. Our findings support previous research from 
Kovacs, Kokkonen and Paavilainen, Utens and Simko et al.3,11,17,18 Furthermore, overprotec-
tiveness from parents may play a role in the delayed process of gaining autonomy.19 The way 
in which the physician informs the parents may play a role in overprotectiveness as well.
The recent patients with congenital heart disease reported a higher amount of sick leave 
compared to the general Dutch population. Surprisingly, when asked about sick leave, the 
majority of patients with congenital heart disease reported to be less often sick compared 
to their colleagues. This findings points towards a gap between objective and subjective sick 
leave. Van Rijen explained a similar phenomenon by “denial”, social desirability or overcom-
pensation by the patients with congenital heart disease.4
Recent patients with congenital heart disease still experience more educational related 
problems compared to normative groups. The percentage of patients requiring special edu-
cation in the recent congenital heart disease sample was 24%, which is almost seven times 
as high as compared to normative data (3.5%). Also, 45% of our patients reported having re-
peated a class and 39% experienced learning difficulties. Although normative data on these 
two categories was not available, we assume that this is higher than in the general popula-
tion.20,21 Possible explanations for these findings are the underlying cardiac diagnoses with 
frequent periods of cyanosis, cardiac surgery and school absences due to hospitalizations. 
These unfavorable findings may be explained neuropsychological impairments in patients 
with surgical corrected congenital heart disease, which have been reported in reviews.20,21 
Besides pre-operative factors (genetics, structured brain injury, severity of disease), preop-
erative- (e.g. deep hypothermic circulatory arrest, pH-management during cooling, hemodu-
lation) and postoperative factors (e.g. number of operations, clinical and EEG seizures), also 
school absenteeism may contribute to learning problems. Also genetic patterns such as the 
22q11 deletion can play a role.20,21
Quality of life
Our recent sample reported a quality of life which was comparable or even better than that of 
normative groups on three different instruments (Short Form-36, Satisfaction With Life Scale, 
Linear Analogue Scale). Our results are in line with previous studies, in which a good quality 
of life for patients with Tetralogy of Fallot and patients operated with the Mustard procedure 
has been reported.10,14,22-24
On the Short Form-36 social functioning scale, recent patients with congenital heart dis-
ease obtained a more favorable outcome compared to normative data. Previous studies have 
shown that a favorable social functioning has a protective role against a low quality of life.25,26 
The favorable self-reported social functioning on the Short Form-36 scale could therefore be 
protecting our patients from a low quality of life.
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Recent sample versus historical sample
Biographical outcome
The educational level of the recent sample was significantly better than that of the historical 
sample. This might be explained by improved social acceptance of congenital heart disease 
over time, stimulating patients to get the same educational levels compared to normative 
data. Despite this improvement, the need for special education was comparable in both 
samples and high compared to the general population.
The historical sample showed a higher amount of sick leave compared to normative data. 
This finding was also seen in the recent sample.
Quality of life
Recent patients with Tetralogy of Fallot obtained comparable scores on all Short Form-36 
scales compared to historical patients with Tetralogy of Fallot.
The only significant difference found between the recent and historical patients operated 
with the Mustard procedure was the improved Short Form-36 vitality score for current pa-
tients. Although not significant, improvements were found on role limitations due to physical 
and emotional health, bodily pain, social functioning and mental health. These findings all 
pointed towards a better psychological functioning for patients operated with the Mustard 
procedure over time.
Role of mustard versus arterial switch surgical procedures
Our data showed comparable psychosocial functioning for patients operated with the 
Mustard procedure versus the arterial switch patients. Within the present sample, arterial 
switch patients scored more favorable results on two Short Form-36 scales, namely physical 
functioning and general health. These findings are in line with Görler et al., who found no 
significant difference between Mustard and switch patients, but did describe a tendency 
towards a better result of the arterial repair group in general health perceptions and role 
limitations due to emotional problems.27 Loup et al. found that patients operated with the 
Mustard/Senning procedure patients showed significantly lower scores on vitality and the 
psychological functioning Short Form-36 scales.28 These findings indicate that arterial switch 
patients feel less limited in performing physical activities and evaluate their personal health 
as being better compared to patients operated with the Mustard procedure. Despite these 
improvements, the overall quality of life was not affected as reported on the Satisfaction With 
Life Scale and the Linear Analogue Scale.
clinical implications
The more dependent life-style and high amount of special education are prominent in pa-
tients with congenital heart disease. Patients still score less favorable on vitality and general 
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health compared to normative data. These findings provide a solid argument for offering 
routinely applied comprehensive and multidisciplinary psychosocial care.
When looking at the historical picture, some improvements over time can be seen, espe-
cially for patients operated with the Mustard procedure on the quality of life instruments.
Limitations
The patients included in this study either had Tetralogy of Fallot or Transposition of the 
Great Arteries and all these patients were followed in a tertiary academic medical center. The 
obtained results therefore, may not be representative for all patients with congenital heart 
disease.
Future research
Future research should aim to investigate the relationship between a lower occupational 
level and a lower income in patients with congenital heart disease, and what interventions 
can be implemented to decrease these impairments in socio-economic status. Also the low 
offspring rate and low independence should be studied further. In addition, the relation be-
tween psychological characteristics and quality of life should be investigated in more depth. 
A large cohort is advisable to avoid underpowered conclusions.
concLusion
This article presents a comparison between psychosocial problems encountered in patients 
with congenital heart disease, operated between 1980 and 1990, to those of patients with 
congenital heart disease operated between 1968 and 1980.
Despite evident improvements in treatment, hardly any changes were found in psychoso-
cial outcome. The recent patients with congenital heart disease sample showed a favorable 
quality of life, despite several psychosocial impairments as to relationships, offspring, lower 
occupational level and lower income. When comparing psychosocial outcome of the recent 
congenital heart disease sample with the historical congenital heart disease sample, no 
significant better outcome for the recent congenital heart disease sample were observed.
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CPart II Pregnancy in women with heart 
disease

Chapter 5
Pregnancy and delivery in cardiac disease
TPE Ruys, J Cornette, 
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ABsTRAcT
Although its prevalence is relatively low in pregnant women, heart disease is the most impor-
tant cause of maternal mortality. Problems may arise due to hemodynamic burden and the 
hypercoagulable state of pregnancy. Heart disease may be congenital or acquired. In devel-
oped countries, the former composes the biggest part of women with heart disease. Patients 
with unrepaired lesions, cyanotic lesions, diminished systemic ventricular function, complex 
congenital heart disease, left ventricular outflow tract obstruction, pulmonary hypertension, 
or mechanical valves are at highest risk of developing complications during pregnancy. 
All patients with known cardiac disease should preferably be counseled before conception. 
Pre-pregnancy evaluation should include risk assessment for the mother and fetus, including 
medication use and information on heredity of the cardiac lesion. Management of pregnancy 
and delivery should be planned accordingly on individual bases. The types of complications 
are related to the cardiac diagnosis, with arrhythmias and heart failure being most common. 
Treatment options should be discussed with the future parents, as they may affect both 
mother and child. In general, the preferred route of delivery is vaginal. The optimal care 
for pregnant women with heart disease requires multidisciplinary involvement and is best 
concentrated in tertiary centers. 
KEywoRds
Pregnancy; Heart disease; Counseling; Delivery; Fetal outcome
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inTRoducTion
Epidemiology
In the developed world many women with congenital heart disease are reaching childbear-
ing age and wish to become pregnant.
While congenital heart disease is more often encountered than acquired disease in 
pregnant women, it seems associated with a lower risk. Acquired conditions such as aortic 
dissection, peri-partum cardiomyopathy, and acute coronary syndrome (ACS) cause the 
highest maternal mortality rates) (1,2). Pregnancy increases the risk of having an ACS three- 
to four-fold (3). The overall incidence of pregnancy related ACS is reported to be between 
2.7 and 6.2 per 100,000 deliveries and this figure is increasing, probably due to changes in 
lifestyle, higher prevalence of obesity, and older age at pregnancy (3,4). In the developing 
world, rheumatic heart disease remains the most common pathology (5).
Physiological changes in normal pregnancy
Major hemodynamic changes take place during pregnancy. Total peripheral vascular 
resistance (TPVR) is reduced and blood volume and cardiac output are increased around 
50% (6). During labor and delivery, cardiac output is further increased as a result of uterine 
contractions and maternal effort (6). After delivery, most changes are rapidly reversed in the 
first 2 weeks with further normalization toward preconception values after 3-12 months. 
Figure 1 shows the hemodynamic changes. However, some structural changes might never 
completely be reversed. 
Figure 1. Hemodynamic changes in pregnancy. CO, cardiac output; SV, stroke volume; HR, heart rate; Hb, 
hemoglobin; TPVR, total peripheral vascular resistance.
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In order to reduce blood loss around delivery, the production of tissue plasminogen activa-
tor (tPA), protein C and S is decreased and tPA inhibitor and factors V, VII, VIII, IX, X, XII and von 
Willebrand factor are increased, leading to a hypercoagulable state (7,8,9). 
mAnAgEmEnT oF PREgnAncy in womEn wiTh hEART disEAsE
Pre-pregnancy counseling 
Counseling after thorough evaluation should be offered to all women of reproductive age 
with known cardiac disease. This should preferably be done before conception or alterna-
tively in early pregnancy (5). Risk for persistent deterioration of heart function may influ-
ence the choice whether to become pregnant. Pre-pregnancy evaluation should focus on 
identifying and quantifying risks for both mother and offspring. An exercise test (with VO2 
max measurements) and echocardiogram provide essential information on pre-pregnancy 
cardiac status and reserve. 
Life expectancy and ethical aspects of parenthood should also be discussed during the 
pre-pregnancy consultation. Genetics and inheritance will be of special interest in some pa-
tient groups (congenital heart disease, Marfan syndrome, and hypertrophic cardiomyopathy) 
(5). The advantages and disadvantages of medication should be discussed including terato-
genicity. If necessary, drug schedules should be adapted. More information on medication in 
pregnancy can be found in Table 1.
Several risk stratification models have been described over the years. Siu et al. published 
the CARPREG risk score in 2001 mainly based on women with congenital and valvular heart 
disease. Significant predictors for adverse maternal and neonatal outcome were prior car-
diac events (heart failure, transient ischemic attack, stroke before pregnancy or arrhythmia), 
baseline New York Heart Association (NYHA) functional class >II or cyanosis, left heart ob-
struction (mitral valve area <2 cm2, aortic valve area <1.5 cm2, peak left ventricular outflow 
tract gradient >30 mmHg by echocardiography) and reduced systemic ventricular systolic 
function (ejection fraction <40%) (10). Khairy et al. found additional predictors for adverse 
outcome namely a history of smoking and severe pulmonary regurgitation (11). The ZAHARA 
investigators showed in a large retrospective cohort of women with congenital heart disease 
that a history of arrhythmic events or mechanical valve implantation are independent pre-
dictors for maternal and neonatal complications (12). The World Health Organization (WHO) 
developed a risk score based on cardiac pathology and co-morbidity. WHO class 1 indicates 
low risk, WHO class 2 indicates an intermediate risk, WHO class 3 indicates high risk, and WHO 
class 4 indicates a contraindication for pregnancy (Table 2) (13).
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Table 1. Medication during pregnancy. Food and drug administration (FDA) classification: Category A: 
Adequate and well-controlled studies have failed to demonstrate a risk to the fetus in the first trimester of 
pregnancy (and there is no evidence of risk in later trimesters). Category B: Animal reproduction studies 
have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in 
pregnant women. Category C: Animal reproduction studies have shown an adverse effect on the fetus 
and there are no adequate and well-controlled studies in humans, but potential benefits may warrant 
use of the drug in pregnant women despite potential risks. Category D: There is positive evidence of 
human fetal risk based on adverse reaction data from investigational or marketing experience or studies 
in humans, but potential benefits may warrant use of the drug in pregnant women despite potential 
risks. Category X: Studies in animals or humans have demonstrated fetal abnormalities and/or there is 
positive evidence of human fetal risk based on adverse reaction data from investigational or marketing 
experience, and the risks involved in use of the drug in pregnant women clearly outweigh potential 
benefits.
Medication FDA Information
Atenolol D Intrauterine growth restriction and premature birth
Other beta-blockers C Low birth weight, hypoglycemia, and bradycardia in the fetus
Angiotensin-converting enzyme 
inhibitors 
D High incidence fetal death and fetotoxic effect: renal failure, renal dysplasia
Amiodarone D Thyroid insufficiency
Angiotensin receptor blockers D High incidence fetal death and fetal renal failure
Aspirin B Low-dose aspirin is safe (large database)
Calcium channel antagonists C Diltiazem: an increase in major birth defects has been reported
Clopidogrel B The benefits of using clopidogrel in some high-risk pregnancies may outweigh 
the potential fetal risks
Digoxin C No reports of congenital defects, monitor serum levels
Loop diuretics C Hypovolemia can lead to reduced uterine perfusion
Low molecular weight heparin and 
unfractionated heparin
C Factor Xa should by measured weekly, levels may fluctuate during pregnancy
Nitrates B Careful titration is advised to avoid maternal hypotension
Spironolactone D Potential anti-androgenic effects on the developing male fetus
Statins X Animal studies demonstrated increased skeletal abnormalities, fetal and 
neonatal mortality.
Thiazide diuretics B Hypovolemia can lead to reduced uterine perfusion
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Table 2. Different diagnoses with corresponding risks categories and most encountered problems.
Type of heart disease WHO categories
Most often encountered 
complications
Other important information
Congenital heart disease (corrected)
Atrial septal defect 1 Arrhythmias (1%)
In uncorrected atrial septal defect higher 
risk of pre-eclampsia
Ventricular septal defect 1 Premature delivery (12%)
In uncorrected ventricular septal defect 
higher risk of pre-eclampsia
Atrio-ventricular septum 
defect
2 or 3
Arrhythmias (10%) / deterioration of 
atrio-ventricular valve regurgitation 
(17%)
Recurrence of congenital heart disease in 
up to 10%
Tetralogy of Fallot 2 Arrhythmias (6%)
Patients with severe pulmonary 
regurgitation are at risk for progressive right 
ventricular dilation
Coarctation of the aorta 2 or 3 Hypertensive disorders (11%) Increased risk of aortic dissection 
Transposition of the great 
arteries (Mustard/Senning)
3
Arrhythmias (22%) / Heart failure 
(11%) 
Irreversible ventricular dysfunction in 10%
Fontan operation 3
Arrhythmias (16%) / Heart failure 
(4%)
In case of cyanosis risk for miscarriage
Eisenmengers syndrome 4
Heart failure (21%) / Maternal 
mortality up to 50% 
Mainly in post-partum period (first 3 days)
Valvular heart disease
Mitral stenosis 2 or 3
Heart failure (31%)/ Arrhythmias 
(11%)
Mainly in patients with mitral valve <1.5 cm2
Aortic stenosis 2 or 3
Heart failure (3- 44%)/ Arrhythmias 
(6-25%)
Mainly in patients with an aortic valve 
<1.5 cm2
Pulmonary stenosis 1 Right sided heart failure (9%)
Mainly in patients with moderate to severe 
pulmonary stenosis 
Regurgitation lesions 1 or 2
Heart failure (7%) / Supra ventricular 
tachycardia (9%)
Mainly in patients with decreased cardiac 
function at baseline
Mechanical valves 3
Valvular thrombosis up to 10% 
maternal mortality up to 4%
Outcome depends on anticoagulation 
regimen used
Cardiomyopathy
Peri-partum 
cardiomyopathy in current 
pregnancy
2 or 3
Severe heart failure at the end of 
pregnancy 100%, maternal mortality 
in 15%
Half of the patients have complete recovery 
of ventricular function
Peri-partum 
cardiomyopathy in 
previous pregnancy 
without abnormal 
ventricular function
2 or 3 Recurrence of heart failure (21%) 
Ventricular function further decreases in 
some patients
Peri-partum 
cardiomyopathy in 
previous pregnancy with 
abnormal ventricular 
function
4
Recurrence of heart failure (44%) 
maternal mortality (20%)
Ventricular function further decreases in 
most patients
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complications during pregnancy 
The type of complication depends on the specific cardiac pathology (Table 1). Arrhythmias 
and heart failure are the most common complications encountered (14).
heart failure: All patients with heart failure during pregnancy should be admitted for bed 
rest. Medical treatment includes salt and fluid restriction, diuretics to limit the volume load, 
and antihypertensive therapy for afterload reduction. Angiotensin-converting enzyme (ACE) 
inhibitors can induce fetal anuria, pulmonary hypoplasia, and skull deformities especially 
when used in the second and third trimester. They are, therefore, contraindicated during 
pregnancy. However, in some specific situations the maternal benefits can outweigh the fetal 
risks and ACE inhibitors may be used for a short time (5,15). 
Table 2. Different diagnoses with corresponding risks categories and most encountered problems. 
(Continued)
Type of heart disease WHO categories
Most often encountered 
complications
Other important information
Dilated cardiomyopathy 2 or 3
Heart failure (25%) arrhythmia’s 
(19%)
Mainly in patients with abnormal ventricular 
function (left ventricular ejection fraction 
<45%) at baseline
Hypertrophic obstructive 
cardiomyopathy
2 or 3 Heart failure (28%) 
Mainly in symptomatic patients at baseline, 
beta-blockers should be considered 
Hypertrophic 
non obstructive 
cardiomyopathy
2 or 3 Low risk of heart failure Mainly in symptomatic patients at baseline
Ischemic heart disease
Before pregnancy 2 or 3
Recurrence risk unknown, heart 
failure in patient with reduce 
ventricular function
Increasing prevalence in recent decades
During pregnancy Not applicable Maternal mortality (9%)
Electrocardiographic changes and troponin 
are essential diagnostic tools
Peri-partum Not applicable
High risk of coronary dissection 
(34%) Maternal mortality (18%)
Coronary dissection partly due to hormonal 
changes during the last trimester and 
hemodynamic burden
Aortic disease
Marfan 2 or 3 Aortic dissection (1-10%) 
High risk in patients with aortic diameter 
> 45 mm
Bicuspid aortic valve 
disease
2 or 3 Aortic dissection (<1%)
High risk in patients with aortic diameter 
> 50 mm
Turner’s syndrome 3
Hypertensive disorders (67%) / 
Aortic dissection (5%)
Women with Turner’s syndrome are often 
not fertile
Ehlers-Danlos 3 or 4 Maternal mortality (11,5%)
An increased risk of spontaneous uterine 
rupture
Pulmonary arterial 
hypertension
4 Maternal mortality (17-33%) Mainly in post-partum period (first 3 days)
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Arrhythmias: The incidence of arrhythmias may be increased during pregnancy in women 
with heart disease. When drug therapy is deemed necessary, beta-blockers or digoxin are the 
preferred choice. The latter can be used in women with atrial fibrillation. Due to the increase 
in blood volume during pregnancy, higher doses are necessary to reach adequate blood 
levels. Electrical cardioversion is the treatment of choice for all drug-refractory maternal ar-
rhythmias. It can be performed safely during pregnancy (16). 
Bradyarrhythmias are uncommon and usually well tolerated. Pacemaker implantation may 
be necessary in selected patients whereby radiation should be kept to a minimum (17). 
Ectopic beats are often benign and also present in one-third of healthy pregnant women. 
Management mainly consists of reassurance. Supraventricular tachyarrhythmias are rare 
(17). Nakagawa et al. studied 11 patients with new-onset ventricular arrhythmia during 
pregnancy, 73% of these originated from the right ventricular outflow tract, post-pregnancy 
the arrhythmia disappeared completely in all patients (18). 
diagnosis in pregnancy
Identifying deterioration of an existing cardiac condition can be a diagnostic challenge as 
cardiopulmonary signs and symptoms reported during normal pregnancy closely mimic 
heart disease. In addition, acquired heart diseases often present acutely and catastrophically 
in women with no known pre-existing disease. Recognition of the acute presentation, im-
mediate diagnostic examination, and appropriate management will improve their chances 
of survival (15).
Physical examination: In a healthy pregnant woman, normal findings include a mild increase 
in resting heart rate, a widened pulse pressure, peripheral edema, and a slight elevation of 
venous pressure. During the later stages of pregnancy there is a physiological fixed splitting 
of the second heart sound (S2). Systolic murmurs are common, secondary to the increased 
cardiac output. However, diastolic murmurs are unusual and therefore call for further evalu-
ation (16). 
Electrocardiogram: The electrocardiogram changes as a result of the upward shift of the 
diaphragm caused by the growing uterus. There is left axis deviation and in the third trimes-
ter Q waves in lead III and aVF and inverted T waves in leads III, V1, and V2 are seen (17). 
Echocardiography: Trans-thoracic (and trans-esophageal) echocardiography is a safe, rapid, 
and useful diagnostic tool. In a normal pregnancy a significant increase in cardiac output, 
cardiac index, left ventricular end-diastolic volume, and left ventricular wall thickness is 
observed (17). Cardiac ultrasound is indicated in women with symptoms of cardiac disease 
as well as in women with established heart disease in order to monitor cardiac condition and 
valvular function (5). In patients with aortic dilatation, echocardiography should be done at 
6-8 weeks intervals throughout the pregnancy until 6 months postpartum (15). 
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Imaging: Chest X-ray should be performed on indication (19). Magnetic resonance imaging 
(MRI) may be useful in complex heart disease and aortic pathology. MRI is considered to be 
safe from 12 weeks’ gestation. Gadolinium contrast is best avoided (20).
Laboratory: For the diagnosis of ACS both creatinine kinase (CK) MB and troponin are used. 
During labor elevated CK and CK MB can be found due to uterine contractions. These levels 
normalize during the second day after labor (21). Troponin I is not elevated in normal preg-
nancy, as a result troponin I is the recommended laboratory test in pregnancy (22). However, 
troponin I serum levels can be elevated in patients with pre-eclampsia or a hypertensive 
crisis. It is not clear whether this is a sign of cardiac ischemia in these patients. Increased 
B-type natriuretic peptide levels are found during pregnancy in many pregnant women with 
heart disease. In the study by Tanous et al. B-type natriuretic peptide levels lower than 100 
picograms per milliliter had a negative predictive value of 100% for identifying events dur-
ing pregnancy. Therefore during pregnancy serial B-type natriuretic peptide levels could be 
helpful, specifically in excluding suspected adverse cardiac events (23).
Treatment during pregnancy 
Medication: Table 2 shows the safety profile of commonly used cardiovascular drugs during 
pregnancy.
Interventional treatment: Indications for intervention may arise when cardiac function dete-
riorate during pregnancy or when a cardiac condition is either unknown or underestimated 
before pregnancy (24). In emergency situations, interventional procedures are justified. 
Ultrasound-guidance and abdominal shielding can help to limit fetal radiation exposure to 
acceptable doses. The uterus receives radiation scattered from the irradiated area, which is 
more important than the direct exposure (only 2%). The actual risk depends on the dose and 
stage of development of the fetus. Radiation doses to the fetus higher than 50 to 100 mGy 
place the child at risk for growth retardation, malformation, or miscarriage. For low doses to 
the fetus, the principal risk is radiation-induced cancer (stochastic effects) (19). 
Cardiac surgery: Cardiac surgery during pregnancy should only be done if all other treatment 
modalities (medication and percutaneous intervention) have failed. Intraoperative hypoten-
sion and hypothermia, embolic complications, and placental hypoperfusion and preterm 
labor cause fetal mortality in 14% to 33% or severe morbidity in another 20% where maternal 
mortality is not much encountered. Severe maternal illness, total operative time, emergency 
surgery, necessity of revision, advanced maternal age, and gestational age are all associated 
with poorer outcome (25).
Fetal heart rate monitoring eventually combined with intermittent uterine and umbilical 
artery Dopplers reflect placental perfusion and should be used to guide bypass pump flow. 
However, one should take into account that fetal heart rate variability and movements will 
probably be depressed as a result of the central anesthetics and hypothermia. External to-
colysis and clinical examination might reveal uterine contractions. Due to an increased risk of 
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malformations, surgery is best avoided in the first trimester. In the third trimester, the risks of 
prematurity should be balanced against the risks of surgery. Therefore European guidelines 
advise considering delivery before surgery after 28 weeks of gestation (26). 
dELiVERy
delivery team
Timing and mode of delivery should be discussed in advance in a multidisciplinary team 
consisting of at least an obstetrician, an anesthesiologist, and a cardiologist. The patient’s 
preference should to be taken into account and she should be thoroughly counseled about 
the delivery plan and potential complications. A written record should be available at all 
times for all involved caregivers and should include plans to manage foreseeable complica-
tions.
Timing 
In asymptomatic women in good condition, spontaneous delivery can be awaited. In women 
with complex lesions, severe cardiac dysfunction, heart failure, aortic dilatation, Eisenmenger 
syndrome, or mechanical valve switched to heparin, a planned delivery might be more ap-
propriate. Maternal or fetal condition might warrant a planned delivery before 37 weeks.
mode of delivery 
The mode of delivery mainly depends on obstetric indication and the maternal hemodynamic 
condition. Vaginal delivery is preferred in women with adequate cardiac output. According to 
the European guidelines, primary Cesarean section should be considered for the patient on 
oral anticoagulants (OAC) in pre-term labor, in women with severe heart failure, aortic root 
diameter >45 mm, and patients with acute or chronic aortic dissection (5,27).
Vaginal delivery: Vaginal delivery is uncomplicated in most women with heart disease. 
Decreased blood loss, more rapid recovery, absence of abdominal surgery, and decreased 
thrombogenic risks are the most important benefit over Cesarean section. Adequate pain 
relief with epidural analgesia can help to attenuate the hemodynamic changes that ac-
company labor and delivery. It also allows controlled fetal descent to the pelvic floor by 
suppressing bearing down reflex. As such the need for bearing down effort with accompany-
ing Valsava manoeuver is often reduced. Epidural catheters are contraindicated in women 
using anticoagulants. Alternatives like intravenous analgesia can be considered. Adequate 
measures to prevent a sudden fall in peripheral vascular resistance associated with epidural 
anesthesia should be taken in women with left ventricular outflow tract obstruction (28). 
Assisted vaginal delivery (by vacuum or forceps extraction) is recommended when excessive 
maternal efforts and prolonged labor are contraindicated. Cervical ripening using either 
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prostaglandins or mechanical methods and induction of labor with oxytocine are relatively 
safe in most women with cardiac disease (29). 
cesarean section: Cesarean delivery annihilates the hemodynamic changes associated 
with labor. It also often permits more appropriate invasive and non-invasive hemodynamic 
monitoring and management. However it increases the risk of venous thrombo-embolism, 
infection, and post-partum hemorrhage. Controlled loco-regional anesthesia is often pos-
sible and preferred. However some cases may warrant general anesthesia (30,31).
Post-partum period 
Care should be given with intravenous bolus of oxytocine in the third stage of labor, as it 
might cause a sudden fall in cardiac output. Controlled intravenous infusion might be more 
appropriate. Also certain intravenous prostaglandins, used to prevent or treat post-partum 
hemorrhage can cause coronary vasospasms (such as sulprostone).
The volume shifts caused by auto-transfusion the first days after delivery have deleterious 
effects on patients with diminished left ventricular function. Several days of close monitor-
ing for signs of heart failure is recommended in high-risk women (5). Prophylactic diuretics 
and ACE inhibitors may be indicated in high-risk patients with severe systemic ventricular 
dysfunction. A routine echocardiographic examination post-delivery in high-risk women is 
advisable, paying careful attention to the aortic root in women with Marfan syndrome or 
aortic valve disease. The risk of thrombo-embolic complications is further increased post-
partum and anticoagulation should be adjusted accordingly (9). 
In patients with low risk for heart failure and with normal ventricular function, a short 
observation period of several hours up to 48 hours post-partum might be sufficient. While 
lactation is possible in most women with heart disease, it might be contraindicated due to 
medication use, severely decreased effort tolerance, or risk of mastitis and bacteremia in 
some women. The use of diuretics can complicate the initiation of milk production.
Fetal outcome 
Predictors Neonatal outcome is strongly correlated with maternal outcome. Similar to 
maternal risk factors, several predictors for neonatal outcome have been described such 
as baseline NYHA class >II or cyanosis, left heart obstruction, smoking during pregnancy, 
the use of oral anticoagulants during pregnancy, mechanical valve prosthesis, and multiple 
gestation. Cardiac surgery causes high fetal mortality during pregnancy (up to 30%) (23).
Monitoring Genetic counseling and invasive prenatal diagnosis should be offered women 
carriers of known genetic anomalies (e.g. Marfan syndrome, 22q11 deletions, familial cardio-
myopathies, and arrhythmias). A second trimester ultrasound screening for fetal abnormali-
ties with special focus on potential congenital heart defects is indicated in all women with 
congenital heart disease as the risk for congenital heart disease in the offspring is around 
3-5% (5, 32). From 24 weeks’ gestation, assessment of fetal growth and well-being should be 
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performed at regular intervals using clinical examination, ultrasound biometry and biophysi-
cal profile, uteroplacental and fetal Dopplers, and fetal heart rate monitoring as appropriate 
(33)
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ABsTRAcT
Background
Many women with structural heart disease reach reproductive age and contemplate mother-
hood. Pregnancy induces and requires major hemodynamic changes. Pregnant women with 
structural heart disease may have a reduced cardiac reserve. There are no longitudinal data 
on cardiovascular adaptation throughout pregnancy in women with structural heart disease. 
methods
Thirty-five women with structural heart disease were included in a prospective observational 
trial. Maternal hemodynamics were assessed before conception, during pregnancy and 
6 months postpartum by transthoracic echocardiography. Uteroplacental perfusion was 
analyzed by obstetric Dopplers. Longitudinal evolution over time was analyzed as well as the 
long term influence of pregnancy on cardiac function.
Results
Cardiac output (CO), stroke volume (SV), left ventricular mass (LV mass) and E/E’ ratio signifi-
cantly increased and ejection fraction (EF) and fractional shortening (FS) decreased during 
pregnancy. There was a statistically significant difference in EF, FS and E/E’ ratio before and 
after pregnancy.
conclusions
The characteristic pattern of hemodynamic adaptation to pregnancy is attenuated in women 
with structural heart disease. The pregnancy related volume load induces progression of 
diastolic dysfunction. Our data suggest a persistent reduction in systolic and diastolic cardiac 
functions after pregnancy in women with structural heart disease. 
Keywords
Congenital, Heart, Pregnancy, Hemodynamic
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inTRoducTion
Normal pregnancy induces and requires a major cardiac adaptation. An initial arterial vaso-
dilatation, early in pregnancy, triggers a rapid increase in blood volume, cardiac output and 
ventricular mass(1, 2). Most of these changes are reversed 6 months after pregnancy(3).
Advances in medical and surgical care of patients with structural heart disease have led 
to improved survival and outcome, especially in women with congenital and valvular heart 
disease. Many of these women reach reproductive age and experience their quality of life 
to be sufficient to consider pregnancy and motherhood. However, they are at increased risk 
for cardiac and obstetric complications(4-6). The hemodynamic changes can put a strain 
on their circulatory system and may induce cardiac complications such as heart failure or 
arrhythmia. Alternatively, their reduced cardiac reserve could prevent adequate adaptation, 
possibly leading to hypertensive disorders of pregnancy, fetal growth restriction or adverse 
fetal outcome.
Timely counseling and specialized follow up by a dedicated team of cardiologists, obstetri-
cians and anesthesiologists, with knowledge of the implications of structural heart defects as 
well as adaptive requirements of pregnancy, are therefore advised(7, 8).
While cardiac (mal)adaptation to pregnancy has mostly been studied in healthy women, 
women with hypertensive disorders or with growth restricted fetuses, there is hardly any lon-
gitudinal data on women with structural heart disease(9). As such most information comes 
from extrapolation of other patient groups(10-17).
Also, little is known on the degree of reversibility of hemodynamic adaptation and its ef-
fects on cardiac function after pregnancy(18, 19).
We therefore aimed to prospectively study longitudinal hemodynamic adaptation to 
pregnancy in women with structural heart disease and asses the influence of this cardiac 
adaptation on postpartum cardiac function.
mEThods
The prospective single center observational study was conducted from 2007 until 2010 in 
a joint collaboration by the departments of Cardiology and Obstetrics at the Erasmus MC. 
Women with inherited or acquired structural heart disease visiting the outpatient clinic of 
cardiology and/or obstetrics for preconceptional counseling or pregnancy during the study 
period were invited to participate. Women received an individualized, standard management 
by a multidisciplinary team consisting of dedicated cardiologists, obstetricians and anesthe-
siologists according to international guidelines.
Maternal and uteroplacental hemodynamics were assessed by transthoracic echocardiog-
raphy and obstetric Dopplers. Maternal and pregnancy outcomes were assessed. Cardiac 
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measurements were performed before pregnancy, in each trimester of pregnancy and six 
months postpartum. Obstetric Doppler measurements of the uterine and umbilical artery 
were performed in the second and third trimesters. Preconceptional hemodynamics were in-
vestigated at inclusion or retrieved from a recent previous echocardiographic exam. Pre and 
post pregnancy measurements were performed irrespective of the menstrual cycle, method 
of anticonception and breast feeding status. The study was approved by the medical ethical 
committee of the Erasmus MC University Medical Centre of Rotterdam and all participants 
gave written informed consent. The authors of this manuscript have certified that they com-
ply with the Principles of Ethical Publishing in the International Journal of Cardiology(20).
general outcomes 
Demographics, cardiac diagnoses, obstetric outcomes and both maternal and obstetric com-
plications were prospectively recorded. Post-partum hemorrhage (PPH) was defined as blood 
loss above 500 ml after vaginal delivery and 1000 ml after cesarean section(21). 
Birthweight centiles, corrected for gestational age, maternal race, parity and fetal sex 
were derived from the Dutch national reference curves(22). A birthweight less than the 10th 
percentile, was considered as small for gestational age (SGA). 
Hypertension (HT) during pregnancy was classified as either pre-existent (occurring before 
20 weeks of gestation), gestational hypertension (de novo hypertension without proteinuria 
occurring after 20 weeks of gestation) or pre-eclampsia (hypertension in combination with 
proteinuria)(23).
Preterm delivery was defined as a delivery occurring before 37 weeks of gestation. Preg-
nancy loss was defined as a miscarriage before and intrauterine death from 20 weeks of 
gestation. 
Echography:
Transthoracic echocardiography was performed using commercially available devices with 
sector transducers (SONOS 7500, Philips Medical Systems, Best, The Netherlands or iE33, 
Philips Medical Systems, Best, The Netherlands), according to the guidelines of the American 
Society of Echocardiography and, when necessary, adapted to the structural abnormality(24).
Diastolic and systolic volumes were computed from the left ventricular end systolic and 
end diastolic diameters (LVESD,LVEDD) using the Teicholz formula and fractional shortening 
(FS) and ejection fraction (EF) were calculated accordingly(25). Left ventricular mass (LVmass) 
was calculated using the Devereux formula(26). Left ventricular outflow tract diameter was 
obtained from the parasternal long access view and left ventricular outflow tract velocity 
time integral from the apical five chamber view. Stroke volume (SV) was calculated by multi-
plying left ventricular outflow area with left ventricular velocity time integral, cardiac output 
(CO) by multiplying stroke volume with heart rate. Diastolic function was assessed by pulsed 
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wave Doppler of the mitral inflow (E/A ratio) and tissue Doppler of the septal mitral annulus 
(E/E’ ratio).
Obstetric Dopplers were obtained with commercially available ultrasound devices with 
curved array transducers (iU22, Philips Ultrasound Bothell, WA, USA and Voluson 730 Expert 
G.E, Medical systems, Zimpf, Austria). Pulsatility index of the umbilical artery (Umb PI) and 
mean pulsatility index of both uterine arteries (Uter PI) were obtained by color directed 
pulsed wave Doppler.
statistical analysis
Continuous variables are displayed as means with a standard deviation (SD) and range, 
discrete variables are displayed as counts and proportions.
To investigate the longitudinal evolution over time of the individual cardiac and obstetric 
Doppler parameters and to account for the correlation in the measurements taken from 
the same patients, a repeated measurement analysis using linear mixed effect models’ was 
performed (27). As the evolution of each parameter during pregnancy may not be linear, we 
used in our model specification second degree polynomials for both the fixed and random 
effects parts. The models’ assumptions were validated using residual plots. The analysis was 
performed in the R statistical software (version 2.14.0, 2011-10-31) using package nlme (ver-
sion 3.1-102). The significance level was set at 5% and no multiple testing corrections were 
applied. 
Differences between pre-and post-pregnancy values were analyzed with an F-test. To as-
sess whether the evolution during pregnancy predicted this pre-post pregnancy difference, 
the area under the longitudinal trajectory during pregnancy using a linear mixed effect 
models was computed and subsequently the association between this area and pre-post 
pregnancy difference was tested. 
To investigate the association between fetal growth and cardiac adaptation, these areas 
were also correlated with adjusted birthweight centiles and evolution in uterine artery flow. 
To assess the influence of the severity of cardiac condition and the occurrence of preg-
nancy complications on the longitudinal evolution of the parameters, the population was 
divided in two groups. For the severity of cardiac condition, the division was based on the 
WHO cardiac function classification (WHO classes 1-2 versus WHO classes 3-4)(28). For the 
occurrence of pregnancy complications, only those associated with maladaptation to hemo-
dynamic changes were taken into account. As such the population was divided based on the 
occurrence of hypertension and/or small for gestational age fetuses (HT/SGA).
The same types of analysis as for the whole population were performed, allowing for 
differences in the average longitudinal evolutions per risk group. Likelihood ratio tests for 
differences in average longitudinal evolutions between both groups were calculated as well 
as differences between the pre-post pregnancy values. The effect of the severity of cardiac 
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condition on adjusted birthweight centiles and occurrence of complications was analyzed 
with a Wilcoxon test and Fisher’s exact test respectively. 
REsuLTs
Thirty-five women with structural heart disease were invited to participate into the study. 
Thirty-two of them became pregnant and 29 reached a gestational age beyond the limits of 
viability (24 weeks). One woman had a spontaneous first trimester miscarriage, one woman 
miscarried after a septic episode following a first trimester reduction of a spontaneous triplet 
to a singleton pregnancy and one woman had an intrauterine death with signs of severe 
placental insufficiency at 20 weeks gestation.
Figure 1 represents an organogram of the study population. Table 1 offers details on diag-
nosis, previous cardiac interventions, the cardiac condition before pregnancy as well as the 
Figure 1. Organogram of the study population with details on cardiac diagnosis.
* Five women with mechanical aortic and/or mitral valve.
** One woman after previous chemotherapy and one woman with a dilated cardiomyopathy.
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Table 1. Detailed information on type of structural heart disease, previous interventions, preconceptional 
cardiac condition and WHO group of the study population. 
Abbreviations in order of appearance: WHO: WHO group, RHD: rheumatic heart disease, AVR: aortic valve 
replacement, MVR: mitral valve replacement, //: subsequent intervention, TV: tricuspid valve, AF: atrial 
fibrillation, AS: aortic valve stenosis, bicus AV: bicuspid aortic valve, MS: mitral valve stenosis, LV: left 
ventricle, MV: mitral valve, ACS: acute coronary syndrome, Ao asc: aorta ascendens, PS: pulmonary valve 
stenosis, MI: mitral valve insufficiency, LA: left atrium, DM: diabetes mellitus, RF: renal failure, Coarct: aortic 
coarctation, HT: hypertension, APVD: anomalous pulmonary venous drainage, ASD I: atrium septum 
defect type 1, Le-Ri shunt: left to right shunt, RV: right ventricle, TI: tricuspid valve insufficiency, VSD: 
ventricular septum defect, PODB: persistent open ductus of Botalli, PA: pulmonary artery, PV: pulmonary 
valve, TOF: tetralogy of Fallot, RA: right atrium, RV: right ventricle, PI: pulmonary valve insufficiency, 
AI: aortic valve insufficiency, ASD II: atrium septum defect type 2, DCM: dilated cardiomyopathy, CM: 
cardiomyopathy, TGA: transposition of the great arteries: pAVSD: partial atrioventricular septum defect, 
AMI: acute myocardial infarction, PTCA: percutaneous transluminal coronary angioplasty, RCA: right 
coronary artery, LAD: left anterior descendens coronary artery, RCX: ramus circumflexus.
Diagnosis Interventions prior to pregnancy Condition prior to pregnancy WHO 
RHD St Judes AVR (2x), St Judes MVR // TV plasty (2x) AF 3
RHD St Judes MVR // St Judes AVR AF 3
AS (bicus AV) St Judes AVR Aortic root dilatation 48 mm 3
MS (congenital) St-Judes MVR Good LV and MV function after previous 
valve thrombosis with ACS
3
AS (bicus AV) Homograft Ao asc 43 mm 2
PS balloon dilatation Mild PS 1
MI No Severe MI , dilated LA with DM and RF 1
Coarct, bicus AV Patch // valvulotomy // Ross //stent recoarctation // 
Bentall
No rest coarct, no HT 3
Coarct , bicus AV End to end anastomosis Mild AS, no rest coarct, Ao asc 40 mm, 
no HT 
2
Coarct, APVD Subclavian flap Mild rest coarct , no HT 2
Coarct, ASD I End to end anastomosis // balloon dilatation Mild rest coarct, HT, Le-Ri shunt over ASD 
and elevated RV filling pressures
3
Coarct, bicus AV, 
cervical arch
End to end anastomosis Mild rest coarct, no HT, Ao asc 44mm 3
Coarct End to end anastomosis No rest coarct, no HT, moderate MI and TI 2
Coarct End to end anastomosis Mild rest coarct, HT 2
Coarct, bicus AV End to end anastomosis // balloon dilatation Mild rest coarct, HT, Ao asc 37 mm 2
Coarct, VSD, PODB Subclavian flap, PA banding, closure PODB // 
PA debanding, PV plasty (2x), balloon dilatation 
recoarctation
Mild rest coarct, mild PS, no HT 2
VSD, subvalvular 
aortic membrane
Closure VSD (2x), resection subvalvular aortic 
membrane
Ao asc 41 mm 2
TOF Closure VSD, transannular patch Dilated RA and RV, mild PS and severe PI 3
TOF, atresia left PA Closure VSD and PODB , transannular patch Mild PS 2
TOF Closure VSD, transannular patch // homograft for 
severe PI
Moderate PI 2
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WHO risk group classification for each women individually. Of the 32 included women, 85% 
had a congenital structural heart defect and 82% had a prior cardiac intervention. Fifty-six 
percent of women were nulliparous at inclusion. Mean age at delivery was 32 years (SD: 4.3 
years, Range: 24 to 41 years) and mean BMI was 25 (SD: 3.9, Range: 18 to 34). 
Major maternal (both cardiac and non-cardiac) and/or obstetric (miscarriage, fetal death, 
gestational hypertension, pre-eclampsia, SGA, PPH and major congenital abnormality) com-
plications occurred in 62.5% of pregnancies. There was no significant difference in complica-
tion rate between the low risk (WHO 1-2) and high risk (WHO 3-4) groups.
Three women had pre-existent atrial fibrillation and 3 other women reported transient epi-
sodes of palpitations. There were no new arrhythmic complications during the study period. 
One woman developed a thrombosis of her prosthetic aortic valve (St-Judes) at 32 weeks, 
leading to heart failure and requiring postpartum valve replacement. Details of maternal and 
obstetric complications as well as obstetric outcomes are represented in Table 2.
The longitudinal profiles over time of the echocardiographic and uteroplacental param-
eters, starting before pregnancy until six months postpartum, are presented in Figure 2 and 
Table 1. Detailed information on type of structural heart disease, previous interventions, 
preconceptional cardiac condition and WHO group of the study population. (Continued)
Diagnosis Interventions prior to pregnancy Condition prior to pregnancy WHO 
TOF, atresia PA Waterston // Rastelli // plasty for PS, closure VSD Severe AI and moderate PI 3
TOF Closure VSD, transannular patch // homograft Mild PI 2
TOF Blalock-Taussig //closure VSD, infundibulectomy 2x // 
balloon dilatation PV
Moderate PI 2
VSD No Mild Le-Ri shunt 2
VSD, ASD II No Mild Le-Ri shunt 2
VSD, double orifice 
MV
PA banding // PA debanding, closure VSD // MV plasty Mild MI and PS 2
DCM (familial) No Mild LV impairment 2
CM 
(chemotherapy)
No Dilated LV, mild LV impairment, mild MI 2
TGA Senning Mild RV impairment 3
TGA Mustard Mild RV impairment 3
pAVSD Closure ASD, VSD, MV plasty Moderate MI 2
pAVSD Closure ASD (2x), VSD (2x), MV plasty (2x) and TV 
plasty
Moderate MI, dilated LA 2
AMI 
(inferioposterior)
PTCA RCA, stent LAD and RCX // PTCA LAD for 
restenosis 
Mild LV impairment 3
Marfan syndrome No Aorta 39 mm 2
Ebstein anomaly RV and TV plasty (Chauvaud), partial cavopulmonary 
shunt
AF, severe TI, RV impairment 3
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Table 2.
Details of maternal and obstetric complications and outcomes. 
* Excluding the intrauterine death at 21 weeks
Complications N % WHO 1-2
(n)
WHO 3-4
(n)
remarks
cardiac
21 11
Valve thrombosis 1 3% - 1 Aortic valve thrombosis leading to heart 
failure
Heart failure 1 3% - 1
non-cardiac
Kidney transplant 1 3% 1 - Kidney failure during pregnancy in 
diabetic women with pre-existent kidney 
dysfunction necessitating postpartum 
dialysis and transplant
Sepsis 1 3% 1 After early reduction of a triplet pregnancy
Suicide attempt 1 3% - 1
Post partum depression 2 6% 1 1
Pyelonefritis 1 3% 1
obstetric
Pre-existent hypertension 3 9% 2 1
Gestational hypertension 3 9% 3 -
Pre-eclampsia 1 3% 1 -
Preterm delivery 3 9% 1 2 343/7,351/7,356/7 weeks
Postpartum hemorrhage 8 25% 5 3
Caesarean section 7 22% 6 1
early miscarriage 2 6% 1 1
Fetal-neonatal
Intrauterine death 1 3% - 1 At 21 weeks
Major congenital abnormality 1 3% 1 - Trisomy 21 with duodenal atresia
NICU admission 3 9% 1 2
SGA 6 18% 2 4
Pregnancy outcomes
Mean SD WHO 1-2
(mean)
WHO 3-4
(mean)
Median Min Max
Gestational age (weeks) 39 2 39,175 38,011 39 34 3/7 41 6/7
Birth weight (gram) 3156 587 3319 2792 3255 1810 4100
Apgar 5 minute 9 1 9,40 9,56 10 8* 10
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estimated regression coefficients in Table 3. A statistically significant linear evolution was 
observed towards a larger LVESD (P=0.001) and smaller FS (P=0.001) and EF (P≤0.001). E/E’ 
ratio (P=0.008), SV (P=0.045), CO (P=0.028), LVmass (P=0.005) as well as uterine and umbilical 
artery PI (P≤0.001, P≤0.001 respectively) showed a statistically significant parabolic evolution 
(quadratic effect) with increase during pregnancy for the cardiac parameters and decrease 
for the obstetric Doppler indices.
There was a statistically significant increase in LVESD (P=0.001) and E/E’ ratio (P=0.006) and 
decrease in FS (P=0.001) and EF (P=0.001) after pregnancy as compared to before pregnancy, 
however evolution during pregnancy was not predictive for this difference. Neither was it 
related to evolution in uterine artery flow nor with adjusted birthweight.
The influence of severity of cardiac structural defect based on WHO class on longitudinal 
evolution of the parameters is illustrated in Figure 3. There were no significant differences 
in average evolution over time between groups except for heart rate (LRT 9.78, P=0.021). 
Severity of structural heart defects only influenced heart rate on pre-post pregnancy differ-
ence. Adjusted birthweight centiles were significantly higher in the low risk group (WHO1-2) 
(median = 38: IQR 35,6) as compared to the high risk group (WHO3-4) (median = 14: IQR 24) 
(P = 0.04). 
Thirteen women presented with pregnancy complications associated with hemodynamic 
maladaptation (HT/SGA). There were no significant differences in average longitudinal evolu-
tion of the parameters between patients with and without HT/SGA . The corresponding fitted 
average longitudinal evolutions are illustrated in Figure 4. There was a significant pre-post 
Figure 2.
Fitted longitudinal profiles of each parameters for the whole population. The dashed lines denote 95% 
point-wise confidence intervals. The symbol `&’ denotes parameters for which there was a significant time 
effect, and the symbol `*’ parameters for which there was a significant difference between pre- and post 
pregnancy measurements.
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pregnancy difference for the LVEDD (mean diff= -2.97 mm, P=0.031) between patients with 
and without HT/SGA.
Table 3. 
Estimated regression coefficients per parameter for the for the whole population.
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Figure 3.
Fitted longitudinal profiles for each parameter divided according to the severity of the cardiac condition.
The dark gray area surrounding the dashed red line and lighter gray area surrounding the full blue line 
denote the 95% pointwise confidence intervals for the WHO1-2 group and WHO3-4 group respectively. 
The symbol ‘&’ denotes parameters for which there was a significant difference in the average evolutions 
in time, and the symbol ‘*’ parameters for which there was a significant difference between pre and post 
pregnancy measurements between groups.
Figure 4.
Fitted longitudinal profiles for each parameter divided according to the occurrence of hypertension and/
or small for gestational age fetus. 
The dark gray area surrounding the dashed red line and lighter gray area surrounding the full blue line 
denote the 95% pointwise confidence intervals for the group with and the group without hypertension 
and/or small for gestational age fetus respectively. The symbol `*’ parameters for which there was a 
significant difference between pre and post pregnancy measurements.
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discussion
Our results offer an insight on both hemodynamic adaptation to pregnancy and long term 
influence of pregnancy on cardiac function in a population of women with structural heart 
disease. They show an attenuated cardiovascular adaptation with reduction in systolic func-
tion and progression of diastolic dysfunction during pregnancy, which persist 6 months after 
pregnancy.
We observed the characteristic significant increase in SV and CO, with steep rise in the first 
half and a more gradual plateau-like phase in the second half of pregnancy.
However, the magnitude of increase seems lower than in previously described normal 
pregnant populations and more comparable to the pattern observed in pregnancies compli-
cated by growth restriction and pregnancies at high altitude(10, 11, 13-15, 29).
The pre-pregnancy LVmass was already elevated in our population, comparable to third tri-
mester levels for normal healthy women(17). While somewhat attenuated, we still observed 
a statistically significant increase in LVmass during pregnancy. 
Our data also showed a gradual decline in FS and EF due to an increase in LVESD, similar 
to normal pregnancy (17). While the absolute values persisted within normal ranges, the 
decline continued until six months postpartum leading to a statistically significant difference 
between pre- and post-pregnancy measurements.
 These findings suggest a negative influence of pregnancy on systolic function in women 
with structural cardiac disease. Our data are in contrast to Uebing’s findings who could not 
observe a deleterious effect pregnancy on left ventricular function(19). One could question 
the accuracy of EF and FS derived from the Teicholz formula in reflecting systolic function 
in pregnant women with structural heart disease. As most other echocardiographic volume 
estimations equally have intrinsic limitations, we believe that MRI analysis of systolic function 
is necessary to confirm our findings.
Normally the E/A ratio decreases with gestational age, as the importance of atrial contri-
bution to ventricular filling increases along with HR towards the end of pregnancy (13, 17, 
30). We observed a relatively constant E/A ratio and HR within normal ranges throughout 
pregnancy in our population. However, E/E’ ratio, which was already elevated before preg-
nancy in our population, showed a further significant increase with gestational age. While 
the pattern is similar to normal pregnancy the absolute values were far above both normal 
and pre-eclamptic pregnancy values, clearly in the pathological range(11-13). Our findings 
suggest a progressive diastolic dysfunction in women with structural heart disease with ad-
vancing gestational age. In normal pregnancy, increased load is compensated by myocardial 
hypertrophy. Due to elevated baseline levels, the capacity for further expansion in LVmass 
seems reduced in our population. Increments in load therefore lead to elevation of filling 
pressures, as reflected by the E/E’ ratio. The significant difference in pre-post-pregnancy E/E’ 
ratio, indicates a persistent negative influence of pregnancy on diastolic function in women 
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with structural heart disease 6 months postpartum. Future studies should consider a longer 
postpartum follow-up to evaluate the transient or permanent nature of these changes.
To our knowledge this is the first study assessing diastolic function during and after preg-
nancy in women with structural heart disease. Our observations also highlight the importance 
of tissue Doppler in the longitudinal assessment of diastolic dysfunction during pregnancy. 
As important volume- and loading shifts occur along with gestational age, changes are best 
evaluated by a combined assessment of the pulsed wave mitral inflow Doppler and load 
independent tissue Doppler of the mitral annulus.
Not surprisingly, all these findings suggest a mildly reduced cardiac potential for adaptation 
to the normal requisites of pregnancy in women with structural heart disease. The maladapta-
tion is partly comparable to that observed in women with growth restriction and gestational 
hypertension, however diastolic dysfunction is more severe(11, 31).
When assessing the influence of severity of cardiac disease on cardiac adaptation we ob-
served a similar pattern betweenWHO1-2 and WHO3-4 groups. While the trend seems visu-
ally more pronounced for the severe group (WHO 3-4) in Figure 3, it failed to show statistical 
significance except for heart rate. Considering the known association between fetal growth 
restriction and hemodynamic maladaptation, the difference in adjusted birthweight centiles 
nevertheless emphasizes the impression of a reduced cardiac adapative potential in high risk 
groups (Figure 3) and thus requires further investigation in a larger population.
A similar effect is observed for the influence of HT/SGA in Figure 4. This suggests that the 
reduced cardiac reserve is probably intrinsic to the structural heart disease rather than caused 
by the relatively high prevalence of hypertensive complications and SGA in our population 
(40%). 
While the incidence of cardiac complications was relatively low in our population, the overall 
complication rate was high (62.5%). Previous research has demonstrated that women with 
heart disease are also at increased risk for non-cardiac and obstetric pathology(4-6). Most 
hypertensive complications occurred in women with known risk factors such as aortic steno-
sis and coarctation(4). As expected, SGA infants occurred mostly in women with atrial repair 
of transposition of the great arteries and pulmonary stenosis spectra(32, 33). Of note is the 
occurrence of post-partum depression in 2 women and a suicide attempt during pregnancy 
in a third woman. One could imagine that the burden of cardiac disease adds to the normal 
psychological challenge which accompanies pregnancy and early motherhood.
A higher incidence of depression or psychiatric disturbances has not been described 
in women with structural heart disease. It merits attention in further prospective trials as 
both cardiac disease and suicide are the main causes of maternal mortality in the western 
world(34). 
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Data on hemodynamic adaptation in pregnancy in women with structural heart disease 
are scarce and have not been described in a longitudinal matter. Therefore comparison with 
other studies is very difficult. Lesniak et al. analyzed the evolution of echocardiographic 
parameters of various valvular conditions during pregnancy, describing slightly different 
patterns according to the specific valvular pathology(9). 
The strength of our study lies in its prospective nature and longitudinal assessment of 
hemodynamic adaptation during pregnancy as well as in the observation of the influence of 
pregnancy on long term cardiac outcome.
The main weaknesses of our study are the relatively limited number of patients, the hetero-
geneity of structural heart diseases and the absence of a control group. Future prospective 
research should be multicentric in order to allow pathology specific pattern analysis. Where 
evolutions during pregnancy were compared with previously published populations of preg-
nant women, a matched control group would certainly be preferable, ideally with inclusion 
of preconceptional measurements. 
 In conclusion our results show an attenuated cardiovascular adaptation to pregnancy in 
women with structural heart disease. Our data indicate a reduction in systolic function and 
progression diastolic dysfunction during pregnancy, which persist 6 months after pregnancy. 
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Chapter 7
Pregnancy in congenital heart disease: prospective 
validation and assessment of cardiovascular and 
offspring risk
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ABsTRAcT
Background 
Adequacy of prepregnancy prediction of cardiovascular and offspring risk associated with 
pregnancy in women with congenital heart disease (CHD) determines for a large part the 
efficacy of counseling prior to and management during pregnancy. The accuracy of the dif-
ferent risk assessment tools needs prospective validation and comparison.
methods 
In this prospective study, we included 183 women with CHD and determined the outcomes 
of 191 pregnancies. The ZAHARA I and CARPREG cardiovascular risk scores were calculated 
for each pregnancy, as was the total number of cardiovascular (TPc) or offspring risk predic-
tors (TPo) from these and other studies combined. Pregnancies were also classified according 
to the modified World Health Organization (WHO) classification of maternal cardiovascular 
risk and according to disease complexity (DC).
Results 
Maternal cardiovascular events occurred during 19 (9.9%) pregnancies. Offspring events oc-
curred during 63 pregnancies (33.0%). Both cardiovascular and offspring event rate increased 
with higher risk scores, higher TPc or TPo, higher WHO class and greater DC. The highest area 
under the curve (AUC) for cardiovascular risk was achieved by the WHO class (AUC: 0.79). 
CARPREG and ZAHARA I offspring risk scores and TPo performed comparably in estimating 
offspring risk (AUC: 0.67, 0,66 and 0.68 respectively). A combination of different risk estima-
tion systems resulted in a slightly higher AUC for both maternal and offspring risk. 
conclusion 
The WHO classification is the best available individual risk assessment model for estimating 
cardiovascular risk in pregnant women with CHD. For the estimation of offspring risk, the 
total number of offspring risk predictors, the CARPREG risk model and the ZAHARA I risk 
model are equally predictive.
Keywords
Pregnancy, outcome, risk predictors, heart disease
Risk validation in pregnancy and heart disease 115
inTRoducTion
Pregnancy in women with structural congenital heart disease (CHD) is associated with 
increased maternal cardiac and offspring risk. Maternal cardiac risk consists mainly of ar-
rhythmias and episodes of heart failure, whereas the offspring is mainly at risk of premature 
birth, small for gestational age and mortality.1-8 The magnitude of cardiac and offspring risk 
depends on the underlying CHD and is attributable to the complexity of the heart disease 
and (residual) lesions such as valvular and ventricular dysfunction.1,2,7 For the attending 
cardiologist, adequate risk assessment is essential to optimize prepregnancy counseling and 
pregnancy management. 
Several classifications and risk scores are available to estimate the cardiac and offspring risk 
associated with pregnancy in women with CHD.2,5,7,9,10 Risk assessment models developed by 
the CARPREG investigators and by our own ZAHARA research group provide quantification of 
maternal cardiovascular and offspring risk of pregnancy. Both identified independent predic-
tors of maternal cardiovascular and offspring events, as described elsewhere in detail.2,7 Both 
models attribute points to each predictor of maternal cardiovascular risk, thus attributing a 
certain cardiovascular and offspring risk to the pregnancy. Additional predictors were identi-
fied by Khairy et al.5 The European Society of Cardiology guidelines for the management of 
heart disease in pregnancy advise to estimate maternal risk according to the modified World 
Health Organization (WHO) classification.9,11 This classification integrates knowledge from 
the total body of literature and takes into account the underlying heart disease, ventricular 
and valvular function, as well as predictors identified by several studies. Patients are classified 
as low, moderate or high risk, or contraindication for pregnancy.9,11 Because risk of pregnancy 
is associated with disease complexity, risk assessment may also be performed using a gener-
ally accepted disease complexity (DC) classification.1,10,12 A prospective external validation 
and comparison of the abovementioned risk scores and risk assessment models has not been 
performed. 
We therefore aimed in this prospective multicenter study to provide external validation of 
the CARPREG and ZAHARA I risk scores and to compare the different risk assessment models 
in order to identify the optimal assessment strategy for estimating the risk of cardiovascular 
and offspring events of pregnancy in women with CHD.
PATiEnTs And mEThods
design and setting
The ZAHARA II project is an ongoing prospective observational multi-centre cohort study. 
The study design of the ZAHARA II study is published elsewhere; therefore we provide a 
comprehensive summary here.13
C
ha
pt
er
 7
116
Inclusion and exclusion criteria
Pregnant women with structural CHD (≥18 years) followed in any of 8 participating tertiary 
centers who provided written informed consent were included in the study at 20 weeks 
gestation. Miscarriage or pregnancy termination prior to 20 weeks gestation was reason for 
exclusion, as were drugs and alcohol abuse. 
Baseline characteristics
Baseline data recorded at the first prenatal visit at the cardiology outpatient clinic (at 20 
weeks gestation) included: maternal age, obstetric history (including parity), underlying heart 
disease, prior interventions, cardiac sequelae, prior cardiovascular events, co-morbidity, prior 
and present cardiac status including ventricular and valvular function assessed according to 
the recommendations and guidelines of the EAE/ASE, use of medication, alcohol and smok-
ing history.14-17
Risk assessment
Maternal cardiovascular and offspring risk of pregnancy was scored by 2 investigators who 
were ignorant of pregnancy outcome according to the foregoing risk assessment models 
using the baseline characteristics. Based on the presence of independent predictors, the 
ZAHARA I and CARPREG cardiovascular risk scores were calculated.2,7 The ZAHARA I and 
CARPREG studies published predictors of offspring risk, but did not develop a risk score. Since 
we had full access tot the ZAHARA I data, we were able to calculate a ZAHARA I offspring 
risk score using identical methodology as previously described for the maternal risk score.2 
(Figure 1) We also developed an offspring risk score based on the predictors identified in 
the CARPREG study by using the exponent value of the OR from the independent predictors 
for offspring events published by the CARPREG investigators to weigh the risk factors and 
attribute points per risk factor.7 No risk percentages per offspring risk point were available 
for this CARPREG offspring risk score. Additionally, the total number of (non-overlapping) 
predictors (TPo) (ZAHARA I, CARPREG and Khairy combined) of cardiovascular and offspring 
events were assessed. Patients were also classified according to the modified WHO classifica-
tion of pregnancy risk and according to disease complexity (DC).9,10 
Endpoints
We scored maternal cardiovascular and offspring events for each pregnancy according to 
the definitions used in the CARPREG and ZAHARA I studies. Primary cardiovascular events 
were: cardiovascular mortality, clinically significant (needing treatment) arrhythmia, clinically 
significant (needing treatment) heart failure, thrombo-embolic events (e.g. pulmonary em-
bolism, valve thrombosis or deep venous thrombosis), vascular events (e.g. cerebrovascular 
accidents, myocardial infarction and dissection), need for urgent or invasive cardiovascular 
intervention up to 6 months post partum and endocarditis.2,7 Secondary cardiac events were: 
NYHA class deterioration ≥2 points compared to baseline. Offspring events were: premature 
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delivery (delivery <37 weeks gestation), small for gestational age birth weight (<10th percen-
tile), respiratory distress syndrome and/or sepsis; intracerebral (intraventricular) hemorrhage; 
recurrence of congenital heart disease and offspring mortality (demise in utero (>20 weeks 
gestation) till the first year postpartum). 
statistical analysis
We used SPSS (version 16.0, SPSS Inc., Chicago, Illinois, USA) and STATA (version 11.0, StatCorp 
LP, College Station, Texas, USA) for statistical analysis. Descriptive statistics for nominal data 
were expressed in absolute numbers and percentages. Mean values and standard deviations 
were presented for normally distributed continuous variables. For non-normal distributed 
continuous variables median and ranges were computed. All P-values are two-sided. Exter-
nal validation of the CARPREG cardiovascular risk score and ZAHARA I cardiovascular and 
offspring risk scores were performed by plotting the expected versus observed event rates. 
We also calculated the area under the receiver-operating characteristic (ROC) curve (AUC) to 
compare the discriminative capacity of the different cardiovascular and offspring models. 
The best combination of risk assessment models was assessed by calculating the AUC follow-
ing logistic models for the different test combinations. The p-value for the AUC results from 
the Chi2 testing for random guess (AUC 0.5)). The goodness of fit of the model was assessed 
using the Hosmer-Lemeshow test. 
Figure 1. The newly developed ZAHARA I risk score for offspring events during 1302 completed (>20 
weeks gestation) pregnancies in women with congenital heart disease. Details on the ZAHARA I study can 
be found in reference 2.
C
ha
pt
er
 7
118
Ethical considerations
The study was conducted according to the principles of the Declaration of Helsinki and in 
accordance with the Medical Research Involving Human Subjects Act (WMO). The Medical 
Ethical Committee of all participating hospitals has approved the study. The Dutch Heart 
Foundation had no role in the design, data collection, analysis, interpretation, writing of the 
manuscript or the decision to submit for publication of this manuscript. The corresponding 
author has full access to all data and the responsibility for the submission of this manuscript 
for publication.
REsuLTs
Overall, 201 women with structural CHD were asked to participate and 198 women gave 
informed consent (98.5%). Fifteen women were excluded: 9 women (4.5%) because of late 
(>12 weeks) spontaneous miscarriage and 6 women (3.0%) because of protocol violations 
(non-compliance (n=4) and moving abroad (n=2)). The remaining 183 women had 191 
complete pregnancies (≥20 weeks of gestation). No women with cyanosis (oxygen satura-
tion <90%), severe pulmonary hypertension or Eisenmenger syndrome were included. The 
baseline characteristics per pregnancy (n=191) are shown in Table 1. 
maternal cardiovascular events
The distribution of CHD and the primary and secondary cardiovascular events per CHD 
subtype are shown in Table 2. No maternal death occurred. Primary cardiovascular events 
were observed in 19 pregnancies (9.9%). Most frequent events were clinically significant ar-
rhythmias (n=11), followed by heart failure (n=4) and thrombo-embolic events (n=4). Women 
with a history of arrhythmia (n=14) had 6 cardiovascular events, including 3 arrhythmias. One 
woman underwent pacemaker implantation because of atrioventricular block. Women with a 
mechanical valve prosthesis (n=11) had 6 cardiovascular events. Deterioration of NYHA func-
tional class ≥2 points (secondary cardiovascular event) occurred in 38 pregnancies (19.9%).
offspring events
Offspring events occurred in 66 children, corresponding to 63 pregnancies (33.0%). The 
distribution of offspring events per CHD subtype is shown in Table 2. Twenty-eight children 
(14.4%) were born prematurely (43% due to preterm labor), 29 children (14.9%) were born 
small for gestational age, 17 children (8.8%) had respiratory distress syndrome (59% were 
born premature) and 3 children (1.5%) had a cerebral (intraventricular) hemorrhage. Recur-
rence of CHD occurred in 10 children (5.2%). Offspring death occurred in 6 children (3.1%). 
Four children died in utero (>20 weeks gestation). Two children died within 28 days after 
birth. 
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Table 1. Maternal baseline characteristics (prior to pregnancy) at inclusion. N = 191 pregnancies.
AV, atrioventricular; AVA, aortic valve area; CHD, congenital heart disease; ICD, intra cardiac defibrillator; 
LHO, left heart obstruction; NYHA, New York Heart Association functional class; PG, peak gradient; 
PR, Pulmonary regurgitation.*Mean (± Standard Deviation); †With the exception of oral anti-
coagulation.#Moderate/ severe.
**Corrected and uncorrected.
n (%)
Demographics
Maternal age at conception (years ± SD)* 29.3 (±4.4)
Parity status
0 124 (64.9)
1 50 (26.2)
≥ 2 17 (8.9)
Clinical situation
NYHA class I 189 (99.0)
Past medical history
History of arrhythmias 14 (7.3)
Left heart obstruction (PG > 30 mmHg or AVA < 1.5cm2 or MVA < 2 cm2) 14 (7.3)
Left heart obstruction (PG > 50 mmHg or AVA < 1.0 cm2) 2 (1.0)
Systemic ventricular ejection fraction < 40% 2 (1.0)
Cardiac medication before pregnancy† 27 (14.1)
Systemic AV valve regurgitation# 6 (3.1)
Pulmonary AV valve regurgitation# 9 (4.7)
Mechanical valve prosthesis 11 (5.8)
Cyanotic heart disease** 50 (26.2)
Severe PR and/or depressed subpulmonary ventricular ejection fraction 22 (11.5)
Smoking history 34 (17.8)
Pacemaker / ICD 5 (2.6)
Congestive heart failure 2 (1.0)
Cerebrovascular accident 3 (1.6)
Medication use preconception
None 164 (85.9)
Diuretics 0 (0.0)
Antiplatelet drugs 0 (0.0)
Vitamin K antagonists/Heparin 14 (7.3)
Digoxin 2 (1.0)
Beta-adrenoreceptor blocker 23 (12)
Calcium channel blocker 5 (2.6)
Angiotensin-converting enzyme inhibitor 1 (0.5)
Antiarrhythmic drugs 2 (1.0)
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Table 2. Distribution of cardiovascular and offspring events by primary type of congenital heart disease in 
191 completed pregnancies.
Values are number of pregnancies. AoS/BiAoV, congenital aortic valve stenosis or bicuspid aortic valve; 
APVR, Anomalous pulmonary venous return; PCE, primary cardiovascular events; SCE, secondary 
cardiovascular events; TGA, Transposition of the great arteries. 
*1 Loeys Dietz, all others Marfan.
†All corrected; 2 double-outlet right ventricle (Fallot type). 
‡Pulmonary atresia with combined atrial and ventricular septal defects; truncus arteriosus. 
§Isolated cleft mitral valve, corrected with mechanical valve (St Jude 25mm).
**1 twin pregnancy
††66 offspring events in 191 pregnancies; including three twin pregnancies.
Cardiovascular events
n (%)
Offspring events 
n (%)
Maternal congenital lesion N % PCE SCE
Atrial septal defects 19 9.9 2 (10.5) 5 (26.3) 8** (42.1)
Ventricular septal defects 25 13.1 - - 2 (8.0) 7 (28.0)
Atrioventricular septal defects 9 4.7 1 (11.1) 1 (11.1) 3 (33.3)
APVR 4 2.1 - - - - 1 (25.0)
Pulmonary stenosis 19 9.9 - - 1 (5.3) 7** (36.8)
AoS/BiAoV 28 14.7 4 (14.3) 11 (39.3) 12 (42.9)
Aortic coarctation 22 11.5 1 (4.5) 3 (13.6) 3 (13.6)
Connective tissue disorders* 9 4.7 1 (11.1) # 2 (22.2) 3 (33.3)
Ebstein’s anomaly 3 1.6 - - - - 1 (33.3)
Tetralogy of Fallot† 34 17.8 3 (8.8) 6 (17.6) 13 (38.2)
TGA 13 6.8 3 (23.1) 3 (23.1) 3** (23.1)
Fontan circulation 3 1.6 2 (66.7) 2 (66.7) 3 (100.0)
Other corrected complex cyanotic heart defects‡ 2 1.0 1 (50.0) || 2 (100.0) 1 (50.0)
Other§ 1 0.5 1 (100.0) - - 1 (100.0)
Total 191 100 19 (9.9) 38 (19.9) 66†† (34.6)
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Validation of risk scores and comparison of different risk assessment 
techniques
Figure 3a shows the ROC for cardiovascular events for the different risk assessment and 
estimation models. All ROC curves of cardiovascular events deviate significantly from the 
diagonal line (no discrimination), with exception of the CARPREG risk score (AUC 0.62; 95% 
CI 0.47-0.77; P=0.081). The AUC for the ZAHARA I cardiovascular risk score was 0.73 (95% CI 
0.59-0.87; P=0.010). Of the 5 cardiovascular risk assessment models, WHO classification had 
the highest AUC for prediction of maternal cardiovascular events (AUC 0.79; 95% CI 0.69-0.89; 
P<0.0001). A combination of WHO classification, TPc and DC had a slightly higher AUC: 0.82; 
95% CI 0.72-0.92; P<0.0001). 
A B
Figures 2a and 2b show the risk of primary cardiac events during pregnancy per risk assessment 
technique. Overestimation of cardiovascular risk (expected events > observed events) was observed in 
both the ZAHARA I and CARPREG cardiovascular risk scores mainly in the mid- and/or high-risk segments, 
where relatively low number of patients could be included. 
Figure 2a. Expected and Observed cardiovascular events for the ZAHARA I and CARPREG risk scores 
Figure 2b. Observed cardiovascular event percentages for Total number of Predictors, WHO Classification 
and for Disease Complexity. 
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Figure 3a. Receiver Operating Characteristic 
Curves of cardiovascular events for the different 
cardiovascular risk assessment and estimation 
models.
*Composite ROC: optimal combination of risk 
assessment models (WHO class, total no. cardiac 
predictors and DC). The AUC differs significantly 
between WHO class and 1) CARPREG (p=0.0065) 
and 2) disease complexity (p=0.0093); as well 
as between CARPREG and total number of 
cardiovascular predictors (p=0.035). 
Figure 3b. Receiver Operating Characteristic Curves 
of offspring events for the different offspring risk 
assessment and estimation models.
*Composite ROC: optimal combination of risk 
assessment models (ZAHARA I offspring risk score 
and CARPREG offspring risk points). The AUC differs 
significantly between disease complexity and 1) total 
no. of offspring predictors (p=0.0008), 2) ZAHARA 
I (p=0.0013), and3) CARPREG (p=0.012); as well as 
between total no. of offspring predictors and WHO 
class (p=0.025).
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discussion
This study is the first to validate, compare and integrate the different risk assessment models 
that are used to predict cardiovascular and offspring risk during pregnancy and puerperium 
in women with CHD. All risk assessment models are able to some extent to identify women 
with CHD at risk of primary cardiovascular and offspring events. When comparing the 5 indi-
vidual risk assessment models, the modified WHO classification provides the most adequate 
individual assessment of cardiovascular risk in our cohort. For the assessment of offspring 
events, the difference in AUC is very small between the total number of offspring predictors, 
the ZAHARA risk score and the CARPREG risk points. A combination of the risk factors from 
ZAHARA I and CARPREG provides the highest AUC.
maternal cardiovascular events
Our study indicates that pregnancy in women with CHD is relatively safe. The cardiac event 
rate in our cohort is low compared to some other studies.5,18-20 The difference in observed 
cardiovascular events is mainly due to differences in study population and in definition of 
primary and secondary cardiovascular events. Several other studies found comparable car-
diovascular event rates. 1,2,4,7,21,22 Our cohort is a relative low risk cohort, with 99% of women in 
a b
Figures 4a and 4b show the risk of offspring events in women with CHD per risk assessment technique. 
All risk assessment techniques, with the exception of disease complexity, show an increase in offspring 
risk with increasing risk points, number of predictors or class. Figure 3b shows the ROC for offspring 
events for the different risk assessment and estimation models. All models deviate significantly from the 
reference line, with the exception of disease complexity. A combination of the ZAHARA I offspring risk 
score and CARPREG offspring risk points provided the highest AUC. The addition of other risk assessment 
techniques did not improve the AUC significantly. 
Figure 4a. Expected and Observed offspring events for the ZAHARA I risk score and Observed 
cardiovascular event percentage for CARPREG risk points.
Figure 4b. Observed offspring events percentages for Total number of offspring predictors, WHO 
Classification and for Disease Complexity. 
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NYHA class I prepregnancy and no women with cyanosis or pulmonary arterial hypertension. 
Well organized prepregnancy counseling in the tertiary centers in the Netherlands prevents 
most high risk women from becoming pregnant, which can explain the relatively low event 
rate in our cohort. 
Validation of cardiovascular risk assessment models
The ZAHARA I risk score discriminates the cardiovascular events in pregnancy better in this 
cohort of women with CHD than the more widely used CARPREG risk score. The AUC for 
ZAHARA I is higher and it deviates significantly from random guess (AUC =0.5), unlike the 
CARPREG risk score. The low prevalence of systemic ventricular dysfunction and high NYHA 
class as well as the absence of mitral valve stenosis in our cohort is the most likely explana-
tion. The CARPREG risk score overestimates maternal cardiovascular risk in our cohort, in line 
with other studies.4,5,21,22 
Overall, in our cohort of women with CHD, the WHO classification discriminates best 
for cardiovascular events. This is not surprising since the WHO classification integrates all 
knowledge about maternal risk, including known contraindications for pregnancy which are 
ignored in the CARPREG and ZAHARA I risk scores, as well as known predictors found by 
CARPREG and other studies, underlying heart disease and other morphological and clinical 
variables. A disadvantage of the WHO class may be that expert knowledge is sometimes 
required, especially when choosing between WHO class II and class III. Whether physicians 
with less expertise might make a different choice than a more experienced physician was 
not assessed in our study. Finally, it is important that WHO class I has a negative predictive 
value of 100% for maternal cardiovascular events, indicating that pregnancy is relatively safe 
in these women.
A combination of the risk classification systems from the WHO class with total number of 
cardiovascular predictors and disease complexity provides the most adequate assessment of 
cardiovascular risk in pregnancy. This illustrates that integration of clinical information and 
predictors or population-based information has additional value on top of individual risk 
assessment models.
offspring events
The offspring event rate observed in our cohort is comparable to most other studies in 
women with CHD.1,2,4-7,18-20,23,24 Offspring death occurred in 3.1% of pregnancies. Although 
offspring mortality in our cohort is in accordance with previous studies in women with CHD, 
it is much higher than in general Dutch population.2,4-7,20,25 Also premature births, small for 
gestational age and recurrence of CHD occurred more often than would be expected in the 
general Dutch population.
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Validation of offspring risk assessment models
The estimation of offspring risk by the ZAHARA I offspring risk score proved to be fairly ac-
curate. The CARPREG risk score also identified pregnancies with a higher risk of offspring 
events, however since no risk percentage could be attributed to the CARPREG risk points a 
comparison with the ZAHARA I risk model could not be made.
The risk models predicting offspring events appear to be interchangeable, because the 
differences in AUC are very small, especially between ZAHARA I, CARPREG and TPo. This is 
explained by the huge overlap between the risk factors found by ZAHARA I and CARPREG. 
The WHO class was not designed to assess offspring events in women with CHD. Therefore it 
does not take into account factors such as maternal age, parity, smoking and twin pregnancy, 
which are known risk factors for offspring events. This is probably also the main reason why 
disease complexity alone is not an accurate predictor of offspring events. 
Limitations and strengths
The participation rate was excellent with 98% of women providing written informed consent 
and only 2 women lost to follow up. Although inclusion rate is high, some limitations need 
to be addressed. Some inclusion bias might have been introduced, since only pregnancies 
of ≥20 weeks were taken into account. Additionally no patients with a high risk of maternal 
death, such as Eisenmenger syndrome, could be included. Nevertheless, the distribution 
of the CHD subtypes adequately represents a tertiary hospital pregnant CHD cohort. Ad-
ditionally, the available risk prediction systems that we validated did not allow prediction 
of more threatening events such as heart failure separately from more innocent events such 
as supraventricular arrhythmias. Despite the limitations, our study is the first prospective 
study to validate, compare and integrate the available risk estimation models to predict the 
cardiovascular risks during pregnancy in women with CHD.
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ABsTRAcT
objectives
To describe the outcome of pregnancy in patients with structural or ischaemic heart disease.
methods 
In 2007 the European Registry on Pregnancy and Heart disease was initiated by the ESC. 
Consecutive patients with valvular, congenital, ischemic heart disease or cardiomyopathy 
presenting with pregnancy were enrolled. Data for the normal population was derived from 
the literature.
Results
Sixty hospitals in 28 countries enrolled 1321 pregnant women between 2007-2011. Median 
maternal age was 30 years (range 16-53). Most patients were in NYHA class I (72%). Congeni-
tal heart disease (66%) was most prevalent, followed by valvular heart disease 25%, cardio-
myopathy 7% and ischemic heart disease in 2%. Maternal death occurred in 1%, compared 
to 0.007% in the normal population. Highest maternal mortality was found in patients with 
cardiomyopathy. During pregnancy 338 patients (26%) were hospitalized, 133 for heart fail-
ure. Caesarean section was performed in 41%. Fetal mortality occurred in 1.7% and neonatal 
mortality in 0.6%, both higher than in the normal population. Median duration of pregnancy 
was 38 weeks (range 24-42) and median birth weight 3010 gram (range 300-4850). In centres 
of developing countries maternal and fetal mortality was higher than in centres of developed 
countries (3.9% versus 0.6%, p < 0.001 and 6.5% versus 0.9% p < 0.001)
conclusions
The vast majority of patients can go safely through pregnancy and delivery as long as ad-
equate pre-pregnancy evaluation and specialized high quality care during pregnancy and 
delivery are available. Pregnancy outcomes were markedly worse in patients with cardiomy-
opathy and in developing countries.
Keywords
 pregnancy, congenital heart disease, valvular heart disease, cardiomyopathy, ischemic heart 
disease
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inTRoducTion
In women with heart disease maternal mortality is reported to be much higher than aver-
age and the risk appears to be increasing such that in western countries heart disease is 
the major cause of maternal death (1,2,3). However, we do not fully understand what the 
impact of pregnancy is on the progression of heart disease or how heart disease affects the 
outcome of pregnancy. The full spectrum of structural heart disease including congenital 
heart disease (CHD), valvular heart disease (VHD) and cardiomyopathy (CMP) and also isch-
emic heart disease (IHD) may be encountered in pregnant women. In developing countries 
that still struggle with a high prevalence of rheumatic fever, acquired valvular heart disease 
dominates, whereas in developed countries congenital heart disease is the main diagnostic 
group (2,4,5,6). In addition, over the last few years the incidence of an acute coronary event 
during pregnancy has increased, due to older childbaering age changes in lifestyle with 
more hypertension, smoking, obesity in women (9,10,11,12,13,14,15). Cardiomyopathy is 
uncommon during pregnancy, but it is difficult to manage a pregnancy in the context of left 
ventricular dysfunction or peripartum cardiomyopathy (PPCM) with a high risk of an adverse 
outcome for both the mother and the baby (16,17). 
In developed countries optimal care and preconception counselling is available in all cen-
tres although quite often not accessed by the women concerned. In developing countries 
only a minority of women with heart disease are assessed and appropriately counselled 
prior to conception. Not surprisingly this may have a major adverse influence on pregnancy 
outcome. 
Our understanding of the consequences of heart disease on pregnancy outcome is limited 
and prevents us from designing relevant randomised controled trials. To improve our under-
standing of this complex subject a registry has been established with the aim of determining 
patterns of outcome and correlating these with management strategies to determine the 
areas of danger for both mother and baby and to identify the best forms of treatment. To 
have any use such a registry has to be large to include sufficient patients with a a wide range 
of diagnoses. Consequently, the European registry on pregnancy and structural heart disease 
was initiated by the European Society of Cardiology (ESC).
mEThods
study design
In 2007 the European Registry on Pregnancy and Heart Disease was initiated jointly by the 
ESC working group on grown up congenital heart disease and on valvular heart disease and 
embedded in the Euro Heart Survey Programme of the ESC. All national societies of the ESC 
were informed and invited to contact centers in their countries dealing with pregnancy and 
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heart disease and all members of the two ESC working groups were invited to participate. 
In addition other centers from around the world who were interested in the registry were 
invited to participate. Consecutive patients with structural heart disease or IHD presenting 
with pregnancy, regardless of age, any concomitant diseases and type of heart disease could 
be enrolled, including patients who already participated in trials or other registries. When 
warranted, ethical approval or Institutional Review Board (IRB approval) was obtained (e.g. 
Germany, USA, Canada, Belgium), however, in many countries the procedure to obtain ethical 
approval was waived because of the anonymised and untraceable nature of the data. 
The registry started in January 2008. Pregnant patients from 2007 were included retrospec-
tively at that time, as it was believed that the complete data of these patients were available 
and reliable. From January 2008 patients were included prospectively. Exclusion criteria were 
non-structural heart disease, for example arrhythmias occurring in the context of a normal 
heart. 
Information included in this manuscript refer to the patients enrolled up to June 2011.
data 
Baseline data from before pregnancy were recorded including cardiac diagnosis, New York 
Heart Association (NYHA) functional class, prior cardiac events, surgery or interventions, 
rhythm status, co-morbidities , obstetric history, the use of medication and smoking. Esti-
mation of maternal risk associated with pregnancy was done by classifying the patients to 
the modified World Health Organisation (WHO) categories, which integrates the available 
knowledge from literature on known risk factors. WHO I is low risk, II medium and III repre-
sents high risk. Importantly, WHO IV means a contraindication for pregnancy (18). Countries 
were divided into developed or developing according to the International Monetary Fund 
Classification (IMF) (19).
The following data relating directly to the pregnancy were collected: age at conception, 
cardiac complications, obstetric complications, perinatal complications, medication use, 
pregnancy duration and mode of delivery. Cardiac complications included hospitalisation, 
heart failure requiring treatment, symptomatic documented arrhythmia, endocarditis, car-
diac intervention during pregnancy, thrombo-embolic and haemorrhagic complications, or 
acute coronary syndrome. Obstetric complications consisted of intra-uterine growth retarda-
tion (IUGR), pregnancy-induced hypertension (PIH i.e new onset hypertension (>140/90 at 2 
occasions) after > 20 weeks of gestation), preeclampsia (PIH criteria plus >0.3 g proteinuria in 
24-hour urine sample), eclampsia (preeclampsia with grand mal seizures), premature rupture 
of membranes (membrane rupture before onset of uterine contractions), premature labour 
(spontaneous onset of labour <37 weeks gestation) postpartum haemorrhage (vaginal deliv-
ery >500 ml, caesarean delivery >1000 ml or requiring transfusion) and placental abruption. 
Perinatal complications recorded were: fetal death (>22 weeks of gestation or >500grams); 
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perinatal death (<30 days postpartum) and CHD in the baby of a mother with congenital 
heart disease. After birth, gender, birth weight and Apgar score were recorded.
Six months after pregnancy information on additional events and complications as well as 
neonatal outcome was collected.
Data for the normal popupation was obtained from current publications on maternal 
health and pregnancy. (6, 20-22) Mean birth weight for the normal population was calculated 
as the mean of the reported birth weight from the countries that included patients in the 
registry. This figure was obtained in the countries that included most patients (together 55%: 
Egypt, Netherlands, Germany, United Kingdom, Italy and Spain).(6,23-27).
data analysis
Categorical data are presented as frequencies (numbers) and percentages. One-sample 
Kolmogorov-Smirnov tests and histograms were used to check normality of continuous data. 
Normally distributed continuous data are presented as mean values ± one standard devia-
tion (SD), whereas non-normal data are presented as medians with interquartile range (IQR). 
Differences in categorical data between independent patient groups were compared by 
binomial tests or chi-square tests. If any expected cell count was less than 5 the Fisher’s exact 
tests or in case of more than 2 groups a Monte Carlo method of approximation was used-
Mantel-Haenszel linear-by-linear chi-square tests were used to compare clinical outcomes 
in the WHO categories, since linear associations were expected. Differences in continuous 
data between independent patient groups were compared by Student’s T tests, or one-way 
analyses of variance (ANOVA), as appropriate. All statistical analyses were performed using 
SPSS 17.0 (SPSS Inc., Chicago). Unless specified otherwise, p-values <0.05 (2-sided test) were 
considered statistically significant.
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REsuLTs
The registry enrolled 1321 women with structural heart disease from 60 hospitals in 28 
countries. (Figure 1)
Baseline characteristics
Median maternal age at pregnancy was 30 years (range 16-53). Fifty-six% of the women had 
one or more previous pregnancies. In Table 1 baseline characteristics are given, comparing 
patients included in the registry versus the normal population and presenting the data for 
the diff erent subgroups. Most patients were in NYHA class I (70%), while only 0.3% of the 
patients was in NYHA class IV. Medication was used during pregnancy by 28% of the patients 
(Table 1).
diagnoses
The diagnoses are shown in more detail in Figure 2. Most patients had CHD (872 patients, 
66%) and only a minority had IHD (25 patients, 2%). Of the patients with CHD, 579 (66%) 
had at least one intervention before pregnancy. Valvular interventions were reported in 291 
cases, of which 139 surgical repairs, 69 percutaneous interventions and 83 surgical valve 
replacement (55 mechanical valves were implanted in 52 patients). At baseline patients with 
IHD were older, used medication, more often suff ered from hypertension and diabetes and 
were current smokers. More patients with CMP were in NYHA class III. (Table 1)
Figure 1. Inclusion per country.
Pregnant patients with structural heart disease included between 2007-2011. 
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Table 1 
Baseline characteristics for women with structural heart disease, compared to the normal pregnant 
population and per subgroup.
Norm data was use from: *EURO-PERISTAT † Cutler, ‡Lawrence, §Hameed, ¶ Drenthen 
CHD=congenital heart disease, VHD=valvular heart disease, CMP=cardiomyopathy, IHD=ischemic heart 
disease, NYHA=New York Heart Association, WHO=World Health Organisation categories.
P value comparison between CHD VHD CMP or IHD, if significant one of the groups is different compared 
to at least one other group. 
Normal Reg 
(n=1321)
p value CHD 
(n=872)
VHD 
(n=334)
CMP
(n=88)
IHD
(n=25)
p value
Mean age in years 
(range)*
30 (12-62) 30 (16-53) 0,93
29,6 (16-
45)
30,3 (18-53)
30,7 (18-
43)
37,3 (24-
47)
<0,001
Prior cardiac 
intervention ¶ (%)
<0,5 54 <0,001 66 34 6,8 44 <0,001
Nulliparous (%) * 44 50 <0,001 55 38 46 28 <0,001
NYHA class <0,001
NYHA class 1 70 76 58 56 64
NYHA class 2 25 21 33 32 28
NYHA class 3 3,1 1,3 6,8 8,0 0,0
NYHA class 4 0,3 1,5 7,4 8,0 0,0
WHO categories <0,001
WHO 1 18 26 3,9 0,0 0,0
WHO 2 39 38 47 26 0,0
WHO 3 38 33 42 56 96
WHO 4 4,0 2,1 7,4 10,2 4,0
Hypertension (%)† 7 6,7 0,75 6,2 4,5 12,5 36 <0,001
Current smoker (%) * 10 3,3 <0,001 3,3 1,8 5,7 12 0,022
Diabetes (%) ‡ 1,8 1,6 <0,001 1,1 2,4 2,3 8,0 0,034
Complaints of heart 
failure (%)
0 11 <0,001 6,7 20 15 0,0 <0,001
Any medication (%) § 2 28 <0,001 20 39 55 72 <0,001
Beta blocker ¶ (%) <0,5 15 <0,001 10 15 44 48 <0,001
ACE inhibitor ¶ (%) <0,5 3,7 <0,001 1,4 4,5 17 28 <0,001
Anticoagulation ¶ (%) <0,5 10 <0,001 5,7 21 13 28 <0,001
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outcome
Maternal mortality
Maternal death occurred in 13 patients (1%), of which 7 were due to cardiac reasons, 3 throm-
boembolic events and 3 suffered from sepsis. (Table 2) 
Maternal morbidity
Outcomes are described for the total population included in the registry, compared to the 
normal population and for the different subgroups in Table 3.
During pregnancy 338 patients (26% of all pregnancies) were hospitalized, most of these 
patients only once (257 patients). In 203 cases this was for cardiac reasons, of which 133 
(10% of all pregnancies) were for heart failure. There were 6 patients with acute coronary 
syndrome(ACS) during pregnancy; only one of these patients had a history of previous ACS. 
In 6 patients thrombo-embolic events were reported, consisting of one thromboembolic 
occlusion of the anterior tibial artery, 1 deep venous thrombosis, 1 ischemic cerebrovascular 
accident and 3 mechanical valve thromboses. So 3 of the 52 patients (6%) with at least one 
mechanical valve suffered from valve thrombosis. Three patients had endocarditis, two of the 
mitral valve (both patients had a history of endocarditis).
Figure 2. Cardiovascular diagnosis per sub-group
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Obstetric events during pregnancy
Hospital admission for obstetric reasons was necessary in 105 patients. Pregnancy induced 
hypertension occurred most often (table 3). Other reasons for obstetric admission reported 
were vaginal bleeding (30 patients), pregnancy induced diabetes (18 patients) and abortion/
missed abortion (27 patients).
Delivery
Forty-one percent of the patients (n=533) underwent caesarean section (CS), compared to 
23% in the general population. This was planned in 393 patients (of which 53 ended up with 
an emergency CS) and was an emergency in 141 patients who had planned vaginal delivery. 
Assisted vaginal delivery (forceps, vacuum) was performed in 32% of the vaginal deliveries. 
Table 2
Maternal mortality in women with structural heart disease.
LMWH = low molecular weight heparin, Vit K = Vitamine K antagonist, pp=postpartum, + = fetal survival, 
++= twin survival, - = fetal death 
Diagnosis NYHA 
class
Medication used 
before pregnancy
Developing/ 
Developed
Age
(years)
When Reason Fetal 
outcome
Mitral stenosis 2 None Developing 23 35 weeks Cardiogenic shock -
Mitral stenosis and 
regurgitation
1 Antiplatelets Developed 42 Delivery (CS) Heart failure and 
sudden cardiac 
death
+
Mitral regurgitation 1 None Developing 21 2 wks pp Heart failure -
Mechanical mitral 
valve
1 Antiplatelet, Vit K Developing 29 12 weeks Severe 
bronchopneumonia 
-
Dilated 
Cardiomyopathy
1 None Developed 32 5 wks pp Cardiogenic shock ++
Cardiomyopathy 
after antracycline
2 LMWH Developed 27 22 wks pp Arterial thrombus of 
solo kidney, 
+
Tricuspid 
regurgitation
1 UFH Developing 19 1 wk pp Right sided heart 
failure
_
Eisenmenger 
syndrome (ASD, 
VSD)
2 None Developed 29 1 wk pp Acute hypoxia 
after CS
+
Atrial septal defect 1 Vit K Developing 30 1 wk pp Septic shock +
Mitral stenosis and 
regurgitation
1 None Developing 25 6 wks pp Sepsis -
Pulmonary atresia 2 Diuretics, LMWH,
antiplatelets
Developed 36 1 wk pp Anoxic cerebral 
event, brain death 
+
Mitral stenosis and 
regurgitation
2 Digoxin, Vit K Developing 29 1 wk pp Brain stem 
embolization
+
Pulmonary stenosis 1 Atenolol, 
antiplatelets
Developed 21 Delivery (CS) Sudden cardiac 
death during CS
+
C
ha
pt
er
 8
138
The postpartum period
In the first week after pregnancy, 64 patients suffered a complication, consisting of heart 
failure in 31 and postpartum hemorrhage in 32. In the six months after pregnancy 38 ad-
ditional complications occurred (25 patients had heart failure). Of the total study population 
162 patients (12%) had at least one period of heart failure during or after pregnancy, while 
this is rarely if ever seen in the general population.
Table 3. Outcome and complications per diagnosis for women with structural heart disease, compared to 
the normal pregnant population and per subgroup.
Normal data was use from: *EURO-PERISTAT † Hutcheon, §Hameed, ¶ Drenthen, # Oyelese, **Ferrazzani, 
†† Jaddoe, ‡‡Ahrari
P value comparison between CHD VHD CMP or IHD, if significant one of the groups is different compared 
to at least one other group. 
Normal Reg 
(n=1321)
p value CHD 
(n=872)
VHD 
(n=334)
CMP
(n=88)
IHD
(n=25)
p value
Maternal mortality (%) * 0,007 1,0 <0,001 0,5 2,1 2,4 0,0 0,031
Maternal hospital 
admission (%) §
2 26 <0,001 20 38 33 28 <0,001
cardiac 
Heart failure(%) § 0 12 <0,001 8,0 18 24 8,0 <0,001
Supraventricular 
arrhythmias (%)¶
<0,5 0,9 <0,001 0,7 3,0 1,1 0,0 0,025
Ventricular arrhythmias 
(%)¶
<0,5 2,0 <0,001 1,6 0,6 11 0,0 <0,001
obstetrics 
complications
Pregnancy induced 
hypertension (%)†
2,5 2,4 0,93 2,3 2,4 3,4 4,0 0,61
Pre (Eclampsia)(%)† 4 3,3 0,23 2,2 3,9 11 4,0 0,001
Caesarean section (%) * 23 41 <0,001 38 42 58 60 0,001
Postpartum 
haemorrhage(%) #
5 2,9 <0,001 2,4 5,1 0,0 0,0 0,021
Fetal 
Apgar score < 7(%)* 1 10 <0,001 6,5 15 18 24 <0,001
Preterm birth <37 
weeks(%)*
8 15 <0,001 13 16 30 36 <0,001
Fetal death (%)* 0,35 1,7 <0,001 0,5 3,9 4,5 4,0 <0,001
Neonatal death(%)* 0,4 0,6 0,27 0,6 0,3 1,1 4,0 0,13
Mean birth weight 
(grams) **, ††, ‡‡
3190 3010 <0,001 3056 2959 2878 2662 0,001
Pregnancy duration 
(weeks)*
40 38 <0,001 38 38 37 36 <0,001
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Fetal outcome
Of the 1321 pregnancies fetal outcome was unknown in 43 pregnancies; Twenty-three twins 
were born and therefore outcome data were available for 1301 babies. Fetal mortality (>22 
weeks or 500grams) was observed in 1,7% of pregnancies, of which 62 % were intrauterine 
fetal death without further information, 21% were clearly due to the maternal condition and 
17 % were because of structural fetal abnormalities. The cause of neonatal mortality was se-
vere neonatal abnormalities (4), premature birth (2), bronchopneumonia (1) and one sudden 
death Congenital heart disease was reported in 29 of the 829 (3,5%) children born to women 
with CHD. Six of had the same congenital defect as their mother (2 ASD, 2 VSD, 2 Marfan) in 
addition two patient with coarctation had a child with a hypoplastic left heart syndrome.. 
Type of heart disease
Clear differences were found in maternal and fetal outcome by type of heart disease (Table 
3). Maternal mortality was highest in patients with CMP(2,4%) and also heart failure and 
ventricular arrhythmias were seen more often in these patients. Caesarean section rate was 
highest in patients with IHD or CMP, while postpartum haemorrhage occurred more often in 
patients with VHD. Of the women who had postpartum haemorrhage 58% were receiving 
oral anticoagulants compared to 9% in the patients without postpartum haemorrhage. Preg-
nancy duration was shorter and neonatal death rate higher in patients with IHD compared 
to the other groups.
WHO categories
A strong correlation with cardiac, obstetric and fetal outcome was found. In particular, mater-
nal hospital admission, heart failure, caesarean section and postpartum haemorrhage were 
clearly different between the different WHO categories and also birth weight and pregnancy 
duration showed clear differences. (Table 4)
Developed versus developing countries
Though any between group comparison is very fragile since the size of the populations were 
grossly unbalanced, significant differences were found: maternal mortality was 3,9% versus 
0,6% (p<0.001) respectively and fetal death 6,5% versus 0,9% (p<0.001). (Table 5)
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Table 4. Outcome and complications per WHO categories for severity of heart disease. 
P value comparison between WHO1, WHO 2, WHO 3 or WHO 4 if significant one of the groups is different 
compared to at least one other group. 
 
WHO 1
(n = 241)
WHO 2
(n = 514)
WHO 3
(n = 504)
WHO 4
(n = 53)
p value
Maternal mortality (%) 0,4 0,6 1,5 4,0 0,035
Maternal hospital admission (%) 13 18 36 66 <0,001
cardiac 
Heart failure (%) 1,2 5,6 19 57 <0,001
Supraventricular arrhythmias (%) 0,4 1,4 1,4 3,8 0,13
Ventricular arrhythmias (%) 1,7 0,8 3,4 1,9 0,068
obstetrics complications
Pregnancy induced hypertension (%) 1,7 3,1 2,4 0,0 0,91
Pre (eclampsia) (%) 2,1 2,9 3,4 3,8 0,32
Caesarean section (%) 27 37 49 60 <0,001
Post partum haemorrhage (%) 0,0 1,2 5,2 11 <0,001
Fetal 
Apgar score < 7 (%) 4,1 10 11 17 0,001
Preterm birth <37 weeks (%) 8,7 15 17 30 <0,001
Fetal death (%) 0,4 0,6 2,8 5,7 0,001
Neonatal death (%) 1,2 0,4 0,4 0,0 0,24
Birth weight (grams) 3109 3074 2925 2735 <0,001
Pregnancy duration (weeks) 39 38 38 37 <0,001
Table 5. Outcome and complications in pregnant patients with heart disease, per IMF Classification of 
developed versus developing countries. 
P value comparison between Developed and Developing. 
 
Total
Developed (n = 
1136)
Developing ( n 
= 185)
p value
Baseline
Mean age (range) 30 (12-62) 30 (16-53) 27 (18-45) <0,001
NYHA class I (%) 70 74 47 <0,001
Type of heart disease <0,001
 Congenital (%) 66 74 18
 Valvular (%) 25 18 72
 Other (%) 9 8 10
Prior cardiac surgery (%) 54 59 22 <0,001
Medication use before pregnancy (%) 28 26 37 0,002
Nulliparous (%) 50 52 34 <0,001
outcome
Maternal mortality (%) 1,0 0,6 3,9 <0,001
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discussion
In this large contemporary international prospective registry of 1321 patients with struc-
tural or ischemic heart disease the incidence of cardiac and neonatal complications was, as 
expected found to be much higher than in the normal pregnant population and maternal 
mortality was more than 100 times higher than in the background population. However, 
clear disticintions could be made between the different types of heart disease and between 
the outcomes in developed versus developing countries. The use of caesarean delivery was 
higher than in the normal population (41% versus 23%) with a large variation between 
countries. 
congenital heart disease
This was the largest subgroup in the registry and it’s outcomes were relatively good com-
pared to other subgroups. Most of these patients were diagnosed and treated long before 
pregnancy and nowadays have prepregnancy counseling; as a consequence they are bet-
ter prepared for pregnancy.. The high rate of successful prior cardiac corrective surgery, 
Table 5. Outcome and complications in pregnant patients with heart disease, per IMF Classification of 
developed versus developing countries. (continued)
P value comparison between Developed and Developing. 
 
Total
Developed (n = 
1136)
Developing ( n 
= 185)
p value
Baseline
Maternal hospital admission (%) 26 23 41 <0,001
Cardiac 
Heart failure (%) 12 11 23 <0,001
Supraventricular arrhythmias (%) 0,9 1,1 2,7 0,07
Ventricular arrhythmias (%) 2,0 2,2 0,5 0,16
obstetrics complications
Pregnancy induced hypertension (%) 2,4 2,5 2,2 0,80
Pre (eclampsia) (%) 3,3 3,0 4,9 0,18
Caesarean section (%) 41 40 44 0,34
Post partum haemorrhage (%) 2,9 2,9 2,7 0,88
Fetal 
Apgar score < 7 (%) 10 8,7 17 0,001
Preterm birth <37 weeks (%) 15 16 11 0,12
Fetal death (%) 1,7 0,9 6,5 <0,001
Neonatal death (%) 0,6 0,6 0,5 0,90
Birth weight (grams) 3010 3027 2899 0,004
Pregnancy duration (weeks) 38 38 38 0,93
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favourable baseline NYHA class, and low use of medication are all factors which are likely to 
have contributed to the relatively favourable outcomes. However, even in this group with 
relatively good outcome CS rates were higher and mean birth weight was lower than in the 
background population. The recent ESC guidelines advocate spontaneous onset of labour 
with vaginal delivery for most CHD patients. However, this is not based on hard data and 
clearly needs further investigations. It is possible that doctor’s decision was the main reason 
for the high number of CS. Premature birth was reported in 13% of our CHD patients, which is 
slightly lower than the 16% reported in the a previous literature review, but higher than the 
8% found in the normal population. (6) The prematurity in this group is likely to have been 
influenced in part by the decision to perform elective CS but nevertheless prematurity in any 
context must taken seriously as it has the potential to influence neonatal outcome adversely. 
Valvular heart disease
Patients with VHD were often not known to have heart disease before pregnancy and many 
patients were in NYHA class II and III before pregnancy. As expected mitral stenosis and/
or regurgitation were the commonest lesions (63%), while aortic valve disease occurred in 
23%. Patients with VHD had a higher maternal mortality rate than patients with CHD. Heart 
failure was the most frequently observed maternal complication as was also found earlier by 
Hameed et al and was recorded in 18% of cases (7). In 38% hospital admission was necessary 
and supraventricular arrhythmias were more common than in other patient subgroups. Fur-
thermore postpartum haemorrhage was encountered more often, probably associated with 
the higher use of anticoagulation. The way that this high incidence of complications relates 
to the diagnosis of valvular heart disease, the country of residence, and the time they present 
for the first time (before or during pregnancy) will be investigated in more depth when more 
patients have been included in the registry. 
cardiomyopathy
In the 88 patients with CMP the pre-pregnancy NYHA class was even worse than in the pa-
tients with VHD. Furthermore, maternal mortality, heart failure and ventricular arrhythmias 
occurred more often than in any other group. Currently, the numbers are limited making it 
impossible to correct for ejection fraction and type of CMP. As the registry is still ongoing 
we expect this analysis will be possible.in the future Until now, no European studies have 
reported on the prognosis for women with PPCM. In South Africa, case series have dem-
onstrated that mortality rates have slowly improved over time but rates of mortality within 
6 months of delivery remain as high as 10%. Our study shows that more attention needs 
to be paid to this group. A dedicated registry for patients with PPCM will start within the 
ESC-EURObservational Research Programme.
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ischemic heart disease
Ischemic heart disease is seldomly encountered during pregnancy, although the incidence 
is increasing and it was found to be an important contributor to maternal mortality in the 
British Enquiry “Saving Mothers Lives” (9,11,12). In this registry to date only 25 patients with 
IHD have been included. Not surprisingly, this patient group was older at baseline with more 
risk factors for coronary artery disease. Of the 20 patients who suffered from myocardial 
infarction prior to pregnancy, only one experienced a new ACS during the current pregnancy. 
Although these numbers are small they are encouraging and may positively influence the 
current practice of cardiologists in counselling these patients. Until now, only case reports 
on patients becoming pregnant after ACS have been described in literature In the 5 other 
patients a “new” ACS occurred during the current pregnancy, all mothers survived. How-
ever, fetal outcome was poor with babies from this group having the greatest proportion 
of low Apgar scores, preterm deliveries, the lowest birth weight and the highest mortality. 
Whether medication use, smoking, older age or other factors were the contributors to this 
unfavourable outcome has to be determined in larger series. Indeed in some women the 
high incidence of preterm deliveries and low birth weight may be the expression of a diffuse 
vasculopathy causing chronisc placental insufficiency. 
developed versus developing countries
Cultural and social pressures may have a greater influence on the decision to become preg-
nant in developing countries, meaning that pregnancies occur in a higher-risk population 
than in developed countries. In this study, we found higher maternal mortality and morbid-
ity in developing countries. This is a very complex issue but if achievable, pre-conception 
counselling focusing on the severity of the heart disease with a clear statement of the conse-
quences of pregnancy may save lives. 
Future directions
The pregnancy registry will continue to enrol patients over the next few years. This should al-
low a very large database to accumulate so that with more detailed analysis in larger disease 
specific groups firmer conclusons can be raised on the available data. These conclusions can 
then be used as the evidence base for improved management plans. Hopefully these will 
make pregnancy safer for both mother and baby in this challenging situation.
study limitations
Although this study describes a large population of patients, subgroup analysis was not 
performed in detail due to small numbers per group. Differences by diagnosis will exist, 
therefore, pooling patients is an over-simplification. In addition the input and quality of data 
was checked in only 5-10% of cases. In 5% of patients, the data was incomplete. In addition 
some centers had much higher volumes than others. Therefore, there may be bias of data. 
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Although most data were collected prospectively (2008-2011), pregnancies of 2007 (14% of 
patients) retrospectively. As participation to the registry was voluntary and there may be 
differences between sites that agreed to participate and those that did not, the registry may 
not be representative and therefore all conclusions must drawn with caution. Finally, it was 
difficult to find a good control population. By including large prospective series from the 
countries that included most patients we hope to have provided the best possible informa-
tion for comparison.
concLusions
Pregnancy in patients with heart disease results in a maternal mortality of 1% which is a hun-
dred times higher than in normal pregnant patients. However, clear differences were found 
in pregnancy outcomes with respect to the underlying diagnosis and between patients in 
developed and developing countries. Most patients with adequate counseling and optimal 
care should not be discouraged and can go safely through pregnancy. The caesarean sec-
tion rate is high and more research should focus on the optimal mode of delivery for these 
patients.
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ABsTRAcT
objectives
Only limited data exist on the optimal mode of delivery in women with heart disease. The 
reported use of caesarean section (CS) varies widely. A large study assessing the use and 
impact of CS is mandatory.
Purpose
To examine the use and impact of the mode of delivery on pregnancy outcome in women 
with heart disease.
methods
The Registry on Pregnancy and Cardiac Disease is a prospective observational registry, which 
enrolled 1321 (information about mode of delivery was available in 1262) pregnant women 
with structural heart disease between January 2007 and June 2011 from 60 hospitals in 28 
countries. 
Results
Vaginal delivery (VD) was planned in 869 women (69%), of whom 728 (84%) actually de-
livered vaginally and 143 (16%) had an emergency CS. CS was planned in 393 women: 172 
(44%) for cardiac and 221 (56%) for obstetric reasons. Post partum heart failure was highest 
in the patients who had a planned CS for cardiac reasons (9.9%). There was no difference in 
pregnancy outcome (post partum heart failure or haemorrhage) in those delivered by elec-
tive or emergency CS for obstetric reasons. 
conclusion 
The high rate of post partum heart failure in women delivered by CS for cardiac reasons was 
most probably due to the severity of the underlying heart disease. Complications were simi-
lar in elective and emergency CS and therefore attempting VD may have neonatal benefits 
in terms of later delivery and greater birth weight and are not necessarily associated with a 
greater risk of adverse maternal outcome. 
Keywords
Heart disease, pregnancy, delivery, maternal outcome, foetal outcome
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ABBREViATions
CS = Caesarean Section
OAC = Oral Anticoagulation 
PET = Pre-eclamptic toxaemia 
VD = Vaginal delivery
WHO = World Health Organization
inTRoducTion
Only limited data exist on the optimal mode of delivery in women with heart disease. The 
reported use of caesarean section (CS) in patients with heart disease varies from 21% to 52% 
in different registries and studies.(1-7) Clinical (practice) guidelines in this field are largely 
based on expert opinion(8). Evidence from large-scale prospective series is scarce if not 
absent. Generally, vaginal delivery (VD) is preferred in women with an adequate cardiac 
output, but CS may be the best option in selected high-risk patients.(8) European guidelines 
on pregnancy and heart disease recommend CS in women on oral anticoagulants (OAC) in 
preterm labour, patients with Marfan syndrome and an aortic diameter >45 mm, patients with 
acute or chronic aortic dissection and in those with acute intractable heart failure. Caesarean 
delivery may also be considered in Marfan patients with an aortic diameter larger than 40 
mm.(8) For all other patients VD is the preferred method, since VD, if necessary with an effec-
tive epidural is held to cause fewer and less dramatic changes in hemodynamic parameters. 
Furthermore, VD is known to be associated with lower risks of maternal complications such 
as haemorrhage, infection and thrombosis.(9) Set against this, clinicians have to consider the 
risk of an emergency CS, which probably carries a greater risk of an adverse outcome for both 
mother and child. 
The CS rate in pregnancies uncomplicated by heart disease varies widely between different 
countries. For example the CS rate in the Netherlands is 14%, while it is as high as 40% in Italy.
(10) Although the populations are not exactly the same, the marked differences in CS rates 
between countries suggest that the attitude towards mode of delivery varies widely. 
Our aim is to describe the current mode of delivery in a large population of women with 
congenital or acquired heart disease from various parts of the world. The relationship be-
tween pregnancy outcome and the mode of delivery is studied and determinants of the wide 
variations in the mode of delivery observed between countries are explored.
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mEThods
study design
In 2007 the European Registry on Pregnancy and Heart Disease was established as a part of 
the Euro Heart Survey Program of the ESC. All patients with structural (valvular, congenital, 
or cardiomyopathy) or ischemic heart disease were eligible for enrolment. The prospective 
registry started in January 2008. However, patients who where pregnant in 2007 could be 
included retrospectively, when the complete data of these patients were available. A total 
of 60 hospitals in 28 countries enrolled 1321 pregnant women with structural heart disease. 
Data on the mode of delivery were available in 1262 (96%) patients.
When warranted, ethical approval or Institutional Review Board (IRB approval) was ob-
tained (e.g. Germany, USA, Canada, Belgium), however, in many countries the procedure to 
obtain ethical approval was waived because of the anonymised and untraceable nature of 
the data. 
data 
On June 1st 2011 the analysis performed from this on-going registry, served as the basis for 
this manuscript. The study protocol and first results of this registry were published previously.
(11) Information on delivery included place of delivery, intended mode of delivery (planned 
mode of delivery), performed mode of delivery, reason for CS, start of labour, rupture of 
membranes and complications during delivery. 
We stratified the patients into 4 risk groups using a modified World Health Organization 
(WHO) risk classification for pregnancy in women in cardiac disease. In this risk stratification 
model the patients are allocated to a score according to diagnosis and severity of disease. 
A WHO category 1 indicates low risk, WHO 2 indicates intermediate risk, WHO category 3 
indicates high risk and WHO category 4 indicates a contraindication for pregnancy.(8, 12) 
Endpoints for this study were maternal and fetal mortality, heart failure (requiring treatment), 
postpartum haemorrhage (VD>500 ml, CS >1000 ml or requiring transfusion), gestation 
length, the occurrence of premature labour (spontaneous onset of labour <37 weeks gesta-
tion) and birth weight.
statistical methods
Categorical data are presented as frequencies (numbers) and percentages. One-sample 
Kolmogorov-Smirnov tests and histograms were used to check normality of continuous data. 
Normally distributed continuous data are presented as mean values ± one standard deviation 
(SD), whereas data which were not normally distributed were presented as medians with in-
terquartile range (IQR). Differences in categorical data between independent patient groups 
were compared by chi-square tests. Fisher’s exact tests were applied if any expected cell count 
was less than 5 (a Monte Carlo approximation was used in case more than 2 independent 
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groups were involved). Differences in continuous data between independent patient groups 
were compared by Student’s T tests. Odds ratios were calculated using logistic regression. 
All statistical analyses were performed using SPSS 17.0 (SPSS Inc., Chicago). Unless specified 
otherwise, p-values <0.05 (2-sided test) were considered statistically significant.
REsuLTs
Baseline characteristics
Median maternal age was 30 years (SD 5.6 range 16-53). Half of the women had had one or 
more previous pregnancies. The baseline characteristics are shown in table 1. 
Table 1. Baseline characteristics and outcome in patients with planned CS versus patient who where 
planned to have VD.
Total group Planned VD Planned CS p value
Age (range, SD) 30 (5,6) 30 (6,0) 30 (5,5) 0.105
Prior cardiac intervention (%) 54 48 56 0.029
Nulliparous (%) 50 44 52 0.012
Type of heart disease 0.028
Congenital heart disease (%) 67 58 69
Valvular heart disease (%) 24 30 25
Cardiomyopathy (%) 6 10 4.4
Ischemic heart disease (%) 2 3.1 1.2
NYHA class 1 (%) <0,001
NYHA class 1 (%) 70 61 76
NYHA class 2 (%) 25 31 21
NYHA class 3 (%) 3 6.1 1.4
NYHA class 4 (%) 0 0.5 0.5
Pre eclampsia 3.3 2.3 5.9 0.001
Anticoagulation 10.4 9.1 14.5 0.004
outcome
Maternal mortality (%) 1 0.6 2 0.018
Postpartum HF (%) 3.6 2.4 6.9 <0,001
Postpartum haemorrhagic event (%) 2.9 2.5 4.1 0.138
Late fetal death (%) 1.7 1.6 1.5 0.912
Neonatal death (%) 0.6 0.5 0.8 0.684
Pregnancy duration (weeks) 38 38 37 <0,001
Birth weight (grams) 3010 3106 2809 <0,001
APGAR score at 1 min < 7 (%) 9.8 9.4 12 0.133
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Location of delivery 
Two third (864) of the patients delivered in a tertiary centre, 27% (361 patients) delivered in 
regional centres and 0.5% (7 patients) delivered at home. We had no information on the place 
of delivery in 7.5% (99 patients). 
mode of delivery
Information on the mode of delivery was available in 1262 women. Vaginal delivery was 
planned in 69% (869) and CS was planned in 31% (393) as shown in Figure 1. Of patients 
planned for CS 14 % (53) delivered by emergency CS of which 47% (25) were for cardiac 
reasons (heart failure n=13, acute coronary syndrome n=1, arrhythmia n=5 and ischemic ce-
rebral event n=1, specific indication not stated n=5) and 53% (28) were for obstetric reasons. 
who risk categories
The distribution of WHO categories varied widely between the modes of delivery as is shown 
in Figure 2. A larger number of high-risk patients had a CS for cardiac reasons (p<0.001, Fig. 
2b). Other groups (VD, elective CS for obstetrics reasons and emergency CS for obstetrics 
reasons) had a comparable WHO category distribution (Fig. 2c). 
Figure 1. Flowchart: Mode of delivery
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Figure 2. Distribution of WHO category 
Planned CS for obstetric reasons, planned CS for cardiac reasons and planned VD
Performed VD, elective CS for obstetric reason and emergency CS for obstetric reason
Table 2. Baseline characteristics and outcome in patients planned CS for obstetric reasons versus for 
cardiac reason.
   
Planned obstetric CS 
(n=221)
Cardiac reason for CS 
(n=172)
p value Cardiac CS versus 
obstetric CS
Baseline
Age ( SD) 31 (6.1) 30 (5.8) 0.17
Prior cardiac intervention (%) 52 44 0.11
Nulliparous (%) 43 45 0.61
Type of heart disease 0.028
 Congenital heart disease (%) 64 49
 Valvular heart disease (%) 25 35
 Cardiomyopathy (%) 8.6 13
 Ischemic heart disease (%) 2.7 3.5
NYHA class <0.001
 NYHA class 1 (%) 73 45
 NYHA class 2 (%) 22 43
 NYHA class 3 (%) 2.3 11
 NYHA class 4 (%) 0 1.2
Pre-eclampsia (%) 7.7 4.1 0.14
Anticoagulantia use 6.5 25 <0.001
outcome
Maternal mortality (%) 0 4.7 0.001
Postpartum HF (%) 7.2 9.9 0.35
Postpartum haemorrhagic event (%) 4.5 7.6 0.200
Fetal death (%) 0.9 2.3 0.25
Neonatal death (%) 1.4 0 0.26
Pregnancy duration (weeks) 38 37 <0.001
Birth weight (grams) 2890 2827 <0.001
APGAR score at 1 min < 7 (%) 10 15 0.12
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outcome related to planned mode of delivery 
The outcome in relation to planned mode of delivery is shown in table 1 and 2. Maternal 
death was higher in patients with planned CS 2% versus planned VD 0.6% (p=0.018). Post 
partum heart failure was higher in patients planned for CS (p<0.001). Women with planned 
CS had higher rates of pre-eclamptic toxaemia (PET). Postpartum heart failure was higher 
(6.9% versus 2.4%) in patients with a planned versus planned VD (p=0.035). The odds ratio of 
PET for post-partum heart failure was 10 (CI 95% 5-20) in the total registry. Fetal outcome was 
better in the patients planned for VD with longer pregnancy duration (p<0.001) and higher 
birth weight (p<0.001) as shown in table 1. Compared to VD, fetal mortality and birth weight 
were similar within the planned CS groups. When looking further in to detail in the patients 
planned for CS, patients with CS for cardiac reasons had a high rate of maternal mortality 
4.7% versus 0% in patients with CS for obstetric reasons 0% (p<0.001). Post partum heart 
failure and haemorrhage was comparable between the two reasons for CS. 
outcome related to performed mode of delivery 
In this analysis patients with cardiac reasons for CS were excluded so that we could examine 
the impact of mode of delivery in a group of women deemed suitable for VD. Maternal mor-
tality and postpartum haemorrhage did not differ between patients delivered by emergency 
CS, elective CS or VD (table 3). Postpartum heart failure was highest in patients with an elec-
tive CS 7.6% versus 5.2% after emergency CS (p=0.37). Heart failure was different between 
elective CS 7.6% and after VD 2,9% (p=0.002). This may be influenced by the co-existence of 
PET. Pre-eclampsia had an odds ratio for heart failure of 13 (CI 95% 6-29) in the patients in 
this analysis. 
Table 3. Outcome in patients delivered vaginally, elective CS or emergency CS.
 
Performed VD 
(n=726)
Elective CS 
(n=197)
Emergency CS 
(n=154)
p value VD 
vs elective
p value elective 
vs emergency
Pre-eclampsia (%) 1.9 8.1 5.2 <0.001 0.29
Anticoagulantia use 8.9 7.1 5.9 0.42 0.64
Postpartum HF (%) 2.9 7.6 5.2 0.002 0.37
Postpartum haemorrhagic event (%) 4.7 5.1 4.5 0.82 0.83
Fetal death (%) 1.8 1.0 0.6 0.52 0.72
Neonatal death (%) 0.4 1.5 0.6 0.12 0.45
Pregnancy duration (weeks) 38 37 38 <0.001 0.09
Birth weight (grams) 3145 2835 2920 <0.001 0.25
Apgar score at 1 min < 7 (%) 7.9 10 17 0.30 0.06
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Variation in mode of delivery in different populations
There were large differences in mode of delivery for patients with heart disease between 
countries. For example the rate for CS was 56% for patients in Italy, whereas this was 20% 
in the Netherlands. The results are displayed in figure 3. Overall the CS rate was 160% of 
the expected CS rate. In a univariable analysis the CS rate in the women with heart disease 
appeared to be independent of the normal population CS rate (R2 = 0.13 p =0.12, figure 4a) 
but depended of the proportion of patients with WHO category > 2 (figure 4 b). Using a 
multivariate analysis, we found that both the normal CS rate for the general population (p= 
0.015) and the proportion of patients with high WHO category (p=0.003) were predictors for 
CS rate (with a combined R2 = 0.501 with p = 0.004).
Figure 3. Percentage caesarean section per country in the normal population and the ROPAC.
Figure 4. CS rate per country
Distribution of expected (normal) CS rate against CS rate in the registry
Distribution of CS rate (CS rate in registry divided by the CS rate in the background population) compared 
with percentage of patient with WHO category 3 or WHO category 4.
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discussion
In this large cohort of patients with heart disease almost half of the patients were delivered 
by CS, which is more than one and a half times higher than the rate in normal pregnant 
women. Large differences between countries were found. 
study design
This study is primarily hypothesis generating, but equally, performing a randomised trial in 
this heterogeneous population seems very difficult and ethically challenging. Performing a 
prospective observational registries with matched patients is the only practical way to draw 
conclusions about which mode of delivery is preferable. To date, the published observational 
studies have been relatively small and retrospective. Stangl et al. showed a higher rate of 
CS in high-risk patients in a single-centre study of 93 pregnancies. Other studies, published 
by Khairy (90 pregnancies), Siu (599 pregnancies), Jastrow (312 pregnancies) and Drenthen 
(1301 pregnancies but mode of delivery was not reported), focused on risk stratification 
mainly.(2-4,13) Jastrow and Khairy reported a CS rate of around 23%. In the study of Siu et 
al, the CS rate was higher in women with heart disease compared with normal patients (29% 
versus 23%).(2) In a study by Robinson et al. including 559 patients, rates of caesarean section 
was comparable with controls. In this study caesarean section was related with adverse neo-
natal outcome.(21) Certainly, these studies did not focus on the association between mode 
of delivery and fetal or maternal morbidity and mortality.(1-4,13-15) In the current study, we 
gathered information on both the planned and performed mode of delivery, the underlying 
reason for the decision (obstetric or cardiac) and outcome related to the mode of delivery. 
However, since CS is chosen as the mode of delivery in selected severely ill patients, major 
bias is present with respect to baseline characteristics of the patients. 
maternal complications
The greater proportion of women with poor NYHA status having a cardiac CS may explain 
the higher maternal mortality rate and occurrence of post-partum heart failure. However, 
the rate of post-partum heart failure was higher in the CS for obstetric reasons too, suggest-
ing that delivery by CS may increase the risk of heart failure. This group had higher rates of 
pre-eclampsia, which would increase the risk of developing pulmonary oedema. Therefore 
the risk for heart failure seems to have been mediated primarily through the occurrence of 
PET and not through the occurrence of CS itself. Further, a greater proportion of women 
with planned CS were delivered preterm, consequently the mothers would have been given 
antenatal steroids to help to mature the fetal lungs and this too may have increased the 
tendency for fluid retention and consequently for developing pulmonary oedema. Further 
investigation of the occurrence of maternal death and heart failure, by excluding women 
with a cardiac indication for CS showed that the high rates of maternal mortality were no 
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longer apparent.(Table 2) This confirmed our suspicion that this risk was predominantly in 
women with severe heart disease (with cardiac CS). Post partum haemorrhage was similar 
across all 3 groups in our initial analysis. This was counter to our expectations as CS is associ-
ated with an increased risk of post partum haemorrhage (22-23). First we thought that the 
data may have been skewed by OAC use, but usage was similar across all groups, suggesting 
that this is not the case. In addition the definition of significant blood loss differs between CS 
(>1000ml) and VD (>500 ml) and haemorrhage is assessed visually, which can be inaccurate. 
Therefore it is still hard to draw firm conclusions.
Fetal complications
In terms of fetal complications, fetal and neonatal death rates were not different, but preg-
nancy duration was shorter and birth weight lower in CS deliveries (Table 1). This difference 
persisted after cardiac CS cases were excluded (Table 2). It was particularly marked in the 
elective CS group, even when corrected for the presence of pre-eclampsia, which is associ-
ated with reduced fetal growth. These data suggest that those women who were delivered 
by CS actually had impaired fetal growth, which may have resulted in fetal distress in labour 
and the need for delivery by emergency CS. Indication for delivery by CS may have been fetal 
growth restriction and this may be another reason for the co-existence of early delivery and 
low birth weight. Apgar scores tended to be lower in the CS group (Table 1), but these dif-
ferences did not reach significance even after exclusion of cardiac cases (Table 3). Pregnancy 
duration was consistently shorter in the planned CS groups (Tables 1 and 2). 
Elective vs. Emergency
CS is associated with an increased risk of complications, such as venous thrombo-embolism, 
infection, peripartum haemorrhage and the risk of general anaesthesia.(16-19) and these 
risks are held to be greater in emergency as compared to elective CS.(25) Indeed, the greater 
risk with emergency CS is often the stated rationale for choosing an elective CS over attempt-
ing a VD in women at high-risk of an emergency CS. However, we found that maternal com-
plications were similar in both CS groups. This is important as it means that we can reassure 
women who are advised to have VD that if they need an emergency CS during labour that the 
risks are no greater than with an elective CS. Clearly, this is not a randomised controlled trial, 
consequently, conclusions should be drawn with caution. The only consistent finding was the 
shorter pregnancy duration, which, can be associated with increased neonatal morbidity.(24)
distribution around the world
We observed marked differences between different countries in this cohort of women with 
heart disease. Large differences between countries exist in CS rates in healthy women.(10) 
We thought that the variation in the CS rates between countries could explain the differences 
we observed, but in our initial analysis there was no relationship between the background 
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CS rate of each country and the observed rate in our study. However, when we corrected for 
the background CS rate, we found a relationship between the CS rate and the proportion of 
women with more severe heart disease, supporting the idea that the severity of the heart 
disease also influenced the CS rate. A further variation is likely to be introduced by the experi-
ence of the attending specialist (either cardiologist or gynaecologist).
Limitations
Given the heterogeneity of the population studied with a multitude of different underlying 
cardiac diagnoses, collected from 60 different hospitals, conclusions should be drawn with 
caution. As in every registry, some data (in 5% of patients) are missing, especially on obstetric 
complications. For instance the type of anaesthesia used during CS was not collected in the 
case report form of this registry and this could have influenced our results. As participation to 
the registry was voluntary, there may be differences between sites that agreed to participate 
and those that did not. 
concLusion
Higher rates of maternal mortality were found in women having a CS for cardiac indications, 
probably due to the severity of their underlying heart disease. The greater rates of post-
partum heart failure in both CS groups seemed to be related primarily to the higher rates 
of pre-eclampsia. Complications were similar in elective and emergency CS and therefore 
attempting VD may have neonatal benefits in terms of later delivery and greater birth weight 
and are not necessarily associated with a greater risk of an adverse maternal outcome. 
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ABsTRAcT 
Aim
Data on pharmacological management of pregnant women with heart disease is scarce. The 
aim was to describe type and frequency of cardiac medication used in pregnancy in patients 
with cardiovascular disease and to monitor impact on fetal outcome.
methods and results
Between 2007 and 2011 sixty hospitals in 28 countries enrolled 1321 pregnant women. All 
had structural heart disease (congenital 66%, valvular 25% or cardiomyopathy 7%) or isch-
emic heart disease (2%). Medication was used by 424 patients (32%) at some time during 
pregnancy, some patients had more then one type of medicine, 22% used beta blockers, 12% 
antiplatelets, 7.1% diuretics, 2.8% ACE inhibitors and 0.5% statins. Compared to those who did 
not take medication patients taking medication were older, multiparous, had valvular heart 
disease and were less often in sinus rhythm. The odds ratio of a fetal adverse event in users 
versus non-users of medication was 2.6 (95% CI 2.0-3.5) and after adjustment for cardiac and 
obstetric parameter 2.4 (95% CI 1.8-3.2). The babies of patients treated with beta blockers 
had a significantly lower adjusted birth weight of 3140 gram versus 3240 gram, p=0.002. The 
highest rate of fetal abnormalities was found in patients treated with ACE-inhibitors (7.9%). 
conclusion
One third of pregnant women with heart disease used cardiac medication during their preg-
nancies. During their pregnancies, these women had more cardiac and obstetric complica-
tions than those women who had heart disease, but were not taking any medication. Birth 
weight was significantly lower in children of patients taking beta blockers. 
Keyword 
Medication, pregnancy, heart disease, fetal outcome, birth weight
ABBREViATions
ACE = angiotensin-converting-enzyme
NYHA= New York Heart Association
ROPAC = Registry on pregnancy and cardiac disease
SGA = small for gestational age
WHO = World Health Organisation 
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inTRoducTion
The number of women with heart disease becoming pregnant is growing and some of 
these women will need cardiac medication for the management of their heart condition.
(1) Heart failure, arrhythmias and/or hypertensive disorders may complicate pregnancy in 
patients with heart disease.(2) These complications compromise not only the mother but 
also the baby and adequate treatment is of vital importance for both. With the increasing 
use of cardiac medication,(3) it is crucial to have information on the adverse fetal effects of 
cardiac medication so that the advantages of treating the mother can be weighted against 
the possible negative effects on the baby. 
Most experience is present with cardiac medication used in the treatment of hypertension 
and pre-eclampsia,(4) where some mediations have been shown to be fetotoxic and others 
to be teratogenic.(5) Some drugs are considered safe and are commonly used in pregnancy, 
for other drugs there is a lack of clear information.(6) 
One of the main reasons for starting the Registry On Pregnancy And Cardiac disease 
(ROPAC), which is supported by the European Society of Cardiology, was to study the use 
of cardiac medication in pregnant women with cardiac disease. The first aim of the current 
study was to assess the percentage of patients with heart disease actually using cardiac 
medication during pregnancy and to define which cardiac medication was being used most 
often. The second aim was to investigate the effect of cardiac medication on pregnancy and 
fetal outcome. Our overall aim is to optimise the care of women with heart disease during 
pregnancy.(7)
mEThods
Patients
ROPAC started in January 2008, pregnant patients from 2007 could be included retrospec-
tively and from January 2008 all patients with structural heart disease (valvular, congenital, 
or cardiomyopathy) or ischemic heart disease were enrolled prospectively. The full protocol 
has been described previously.(7)
data and definitions
This registry is on-going and an interim analysis, which was performed on June 1st 2011, 
served as the basis of this manuscript. Recorded data included cardiac medications used 
before pregnancy and continued during pregnancy and also cardiac medication started 
during the index pregnancy. Outcome parameters included: birth weight, all fetal abnormali-
ties (either cardiovascular or any other) and fetal adverse events. A fetal adverse event was 
defined as: fetal death (defined as fetal death after 22 weeks of pregnancy or birth weight 500 
C
ha
pt
er
 1
0
168
gram), neonatal death, low birth weight (< 2500 grams) or premature birth (< 37 weeks of 
gestation). In this manuscript we did not focus on anticoagulation in detail, since more data 
is necessary to draw conclusions in this topic. However, anticoagulation was included in the 
calculations of “any cardiac medication”. 
We used the modified World Health Organisation (WHO) categories to stratify patients 
into different risk categories. The categories are: WHO category 1: low risk, WHO category 
2: intermediate risk, WHO category 3: high risk and WHO category 4: contraindication for 
pregnancy.(8)
statistical methods
Continuous data are presented as mean with standard deviation and were compared us-
ing the Student-T or Mann-Whitney test as appropriate. Discrete variables are presented in 
absolute numbers and percentages and were analysed using the chi-square or Fischer’s exact 
test and Mann-Whitney test for ranked discrete data. Odds ratios for fetal adverse events 
(both univariable as multivariable) were calculated using binomial logistic regression. Odds 
ratio was first adjusted for parameters described to have influence on fetal outcome, such as 
maternal diabetes, smoking, age, hypertension and preeclampsia and secondly also for the 
occurrence of heart failure during pregnancy, WHO class and main diagnosis. To calculate 
corrected birth weight and the association with the use of beta-blockers a linear regression 
was used. This analysis was adjusted for gestational age, smoking, fetal sex, maternal age, 
diabetes and pre-eclampsia. The level of significance was p < 0.05 (2-sided). The data were 
analysed with the SPSS version 20.0 software (SPSS Inc, Somers, NY).
REsuLTs
Cardiac medication was used by 32% of the 1321 female patients at some time during their 
pregnancy. In table 1 the baseline characteristics of these women are compared to the 
patients without cardiac medication. Patients taking cardiac medication were older, multipa-
rous and typically had an underlying diagnosis of valvular heart disease. Their pregnancies 
were more often complicated by heart failure. 
Beta blockers were used by 291 patients. As shown in figure1, in women taking beta-
blockers the birth weight was on average 100 grams lower (p=0.002) than those not taking 
beta blockers. When considering the women in the different WHO categories, this difference 
was most significant in WHO category 2 (p=0.04). The indication for the use of beta block-
ers (before and/or during pregnancy) is shown in table 2. The group of patients with “other” 
indications for the use of beta blockers included diagnosis such as transposition of the great 
arteries with atrial switch (n=7), Tetralogy of Fallot (n=5) and double outlet right ventricle 
(n=2).
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The crude odds ratio of a fetal adverse event (fetal death, neonatal death, low birth weight, 
premature birth) was 2.6 (95%CI: 2.0-3.5) in patients who used any cardiac medication dur-
ing pregnancy versus patients without medication. The odds ratio was 2.5 (95%CI: 1.9-3.3). 
After correction for obstetric confounders: maternal age, smoking, diabetes, hypertension 
and preeclampsia). The odds ratio was 2.4 (95%CI: 1.8-3.2) after correction for cardiologic 
confounders: heart failure during pregnancy, WHO class and main diagnosis.
Table 1. Baseline characteristics.
SD= standard deviation. NYHA = New York Heart Association 
Total No cardiac medication Any cardiac medication P value
897 424
Mean age (SD) 30 (5.6) 29.7 (5.4) 30.6 (6.1) 0.005
Sinus rhythm (%) 93 94 87 <0.001
Type of heart disease <0.001
 Congenital (%) 66 75.8 45.3
 Valvular (%) 25 20.7 35.4
 Cardiomyopathy (%) 7 3 14.4
 Ischemic (%) 2 0.4 5
Current smoking (%) 3 3.1 3.5 0.69
Diabetes (%) 1.6 1.1 2.8 0.023
NYHA class 1 (%) 70 77.9 54.1 <0.001
Nullipara (%) 50 53 42.7 <0.001
Heart failure during pregnancy (%) 10 4.7 21.5 <0.001
Figure 1. Birth weight in patient with and without beta blockers per WHO class adjusted for gestational 
age, smoking, fetal sex, maternal age, diabetes and pre-eclampsia.
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The effects of different drugs on fetal mortality and rates of abnormality are shown in table 
3. The highest rate of fetal abnormalities was found in patients treated with angiotensin-
converting-enzyme (ACE)-inhibitors (n=3; 7.9%) of which 1 dandy walker 1 delay in arterial 
duct restriction and 1 non-cardiac abnormality. Fetal abnormalities included a wide spectrum 
of different cardiac (e.g. univentricular hearts and persistent arterial ducts) and non-cardiac 
abnormalities (e.g. syndactyly, trisomy 18 and encephalocele). 
Table 2. Indications for use of beta blockers.
* Adjusted for gestational age, smoking, fetal sex, maternal age, diabetes and pre-eclampsia.
Beta blockers 
continued during 
pregnancy (n=164)
Beta blockers 
started during 
pregnancy 
(n=127)
Total 
(n=291)
Reduction in birth 
weight (grams)
p value
Valvular disease 42 19 61 -169 0.007
Arrhythmias 14 40 54 -119 0.07
LV dysfunction 38 10 48 -72 0.30
Hypertension 34 11 45 1 0.99
Aortic disease 29 6 35 -21 0.81
Other 7 25 32 -268 0.002
Heart failure 0 16 16 -9 0.94
Table 3. Outcome per cardiac medication group.
AT II = Angiotensin II receptor antagonist
ACEi = angiotensin-converting-enzyme (ACE)-inhibitors
Total 
group
No 
medication Any med p value
Beta 
blocker
Anti 
platelet Diuretic
Anti 
arrhythmic ACEi Statin AT II
Number 1321 897 424 291 155 94 55 38 6 7
Fetal mortality 
(%)
1.7 1.1 2.8 0.023 2.1 3.2 4.3 7.3 2.6 16.7 0
Fetal 
abnormalities (%)
4.7 5 4 0.42 4.1 5.2 2.1 1.8 7.9 0 0
Pregnancy 
duration (weeks)
38 38 37 0.004 37 36.7 37 36.3 38 38 37.5
Mean birth 
weigth (grams)
3010 3100 2835 0.019 2830 2789 2720 2774 2921 2770 2652
Small birth 
weight (<2500 
gram) %
14 9.7 23.3 <0.0001 23 27.1 23.4 23.6 13.2 16.7 42.9
Pregnancy 
duration (< 37 
weeks) %
15 11 23.6 <0.0001 23 33.5 31 36.4 15.8 16.7 14.3
Apgar (< 7) % 10 8.1 13.6 0.003 13 13.5 12.8 20 15.8 16.7 0
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discussion
This study shows for the first time very clearly that cardiac patients receiving cardiac medica-
tion during pregnancy had more fetal adverse events than patients without cardiac medica-
tion. Up until now it has been generally thought that although cardiac medication taken 
during pregnancy may have disadvantages, not treating the mother hampered fetal outcome 
even more. In our analysis we corrected for potential obstetric and cardiological confounders 
and still the odds ratio of having a fetal adverse event was 2.38 for mothers taking cardiac 
medication. Khairy et al. showed that both anti-platelet therapy and anti-arrhythmic cardiac 
medication were univariable predictors for spontaneous abortion.(9) Drenthen et al. showed 
that cardiac medication was a predictor for neonatal complications in multivariable analysis.
(10) We showed that mothers taking cardiac medication had more adverse fetal events, 
despite correcting for many obstetric and cardiovascular parameters. The question remains 
whether the patients needing cardiac medication during pregnancy had worse cardiac func-
tion, or had other parameters for which we did not correct or that the effect found is indeed 
valid. Although we corrected for WHO categories and diagnosis, the patients needing cardiac 
medication probably are the more symptomatic patients within their patient group. On the 
other hand, medication was also prescribed as prophylactic therapy, for instance in patients 
with Marfan syndrome, as advised by the guidelines, and no clear impact of more severe 
disease can be expected here. We have not studied the effect of intentional omission of 
treatment. Therefore we cannot give the advice that all cardiac medication is contraindicated 
during pregnancy. However, a high degree of reluctance to medicate, which is a sentiment 
often expressed by pregnant women, seems to be an appropriate position. 
The rate of fetal abnormalities was comparable in patients with and without cardiac 
medication. Although rates of 4-5% for fetal abnormalities seem quite high, this should not 
be compared with the rate of fetal abnormalities in normal healthy women as women with 
CHD are more likely to have children with a cardiac anomaly. Indeed the recurrence risk of 
fetal cardiac disease was been reported to be 3-5% in most studies focussing on congenital 
patients (forming two thirds of our study population), therefore these figures were expected.
(11,12) Fetal abnormalities were especially high in patients taking ACE-inhibitors. In most 
patients taking ACE inhibitors, the drugs were stopped during the first trimester and cardiac 
medication was only taken for a short period of time, this may explain why the 8% rate of fetal 
abnormalities was lower than previously described.(13-15) In the 6 patients taking statins 
there was one fetal death and no fetal abnormalities. No conclusions can be drawn from such 
a small patient group, more data is clearly needed. Statins have been reported to cause fetal 
abnormalities in animal studies when given in excessively high dosages, but consistent with 
our observation of no malformations, a recent meta-analysis showed only isolated congenital 
anomalies without a consistent pattern in human studies.(16) 
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The birth weight of the whole group was lower than expected (partly because of prema-
ture birth and partly probably due to maternal cardiac dysfunction).(7,17) In this study beta 
blockers showed an additional significant overall reduction in birth weight of 100 grams. 
In our study we also found differences in the effect on birth weight when considering the 
indication for beta blockade; this reduction was most marked in the patients with valvular 
heart disease (of whom most had mitral valve disease) and in the arrhythmia group. In pa-
tients with aortic disease the effect on birth weight was intriguingly small. Also in patients 
taking beta blockade for hypertension this weight reduction was not found, which confirms 
the results of a randomised study by Movi et al. In this study mildly pre-eclamptic patients 
were treated with labetolol, methyldopa or standard care and they showed no influence of 
cardiac medication on birth weight.(18) On the other hand Meidahl et al and Nakhai-Pour et 
al showed an increase in the number of babies who were small for gestational age (SGA) after 
use of beta blockers, in these studies most patients received beta blockers for hypertension 
or pre-eclampsia.(19,20) This study can be seen as hypothesis-generating. Hereby urging 
either a case-control study or randomised trial to confirm the impact of beta blockers on 
fetal outcome, though designing such a trial will present ethical obstacles, which might be 
difficult to overcome.
An important question is whether these children show catch-up growth as has been 
described in most SGA children and preterm children of healthy mothers.(21,22) A low birth 
weight could lead to long term effects such as short stature and intellectual impairment. 
(21,23,24) The effects of beta blockers must be studied in further detail in the future.
clinical implications
During pre-pregnancy counselling the use of cardiac medication should be discussed with 
both parents commenting on the available findings and explaining the persistent uncertain-
ties. Patients needing cardiac medication should be considered as having a higher risk for 
adverse fetal outcome. Doctors and pregnant women should maintain the current state of 
caution to medicate unless absolutely necessary, and especially beta blockers should be 
titrated to keep the dose as low as possible. Depending on the indication, stopping the drug 
should be contemplated with restarting them after pregnancy as appropriate. This especially 
holds for cardiac medication only given to improve long-term prognosis. Equally, although 
this study supports the idea of using the minimum dose of a given drug, it clearly does not 
lend any support to the notion that all drugs should be stopped with the diagnosis of preg-
nancy. Such an approach could be catastrophic for both mother and child in some condition, 
such as peripartum cardiomyopathy with a subsequent pregnancy in women remaining with 
poor left ventricular systolic function.(25)
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Limitations
Although this is a large registry, some subgroups are small. As in most registries some data 
(5%) were missing. We did not collect the exact dosage of cardiac medication, therefore we 
could not correct for this. In addition the use of hard and soft drugs of addiction and caffeine 
have been described to have influence on birth weight and these data were not collected. As 
participation to the registry was voluntary and there may be differences between sites that 
agreed to participate and those that did not, the registry may not be completely representa-
tive. Finally the observational methodology is not appropriate to test efficiency of cardiac 
medication therefore all data and comments on this matter must be seen in this light.
concLusion
Pregnant women with heart disease receiving cardiac medication had more fetal adverse 
events than comparable patients who did not receive medication. Fetal abnormalities were 
found most often in patients taking ACE inhibitors. The birth weight in women taking beta 
blockers was 100 grams lower compared to women without beta blockers.
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ABsTRAcT
Aim 
Heart failure is one of the most important complications in pregnancy, causing maternal 
mortality and morbidity. The aim of this study is to describe the incidence, onset, outcome 
and predictors of heart failure (HF) in patients with structural or ischemic heart disease dur-
ing pregnancy. 
methods and results
Sixty hospitals in 28 countries enrolled 1321 pregnant women with valvular heart disease, 
congenital heart disease, ischaemic heart disease, or cardiomyopathy presenting with 
pregnancy between 2007-2011. In total 173 (13.1%) of the 1321 patients developed HF, 
making HF the most common major cardiovascular complication during pregnancy. Baseline 
parameters associated with HF in multivariable analysis were NYHA class>2, signs of HF, WHO 
category>2, cardiomyopathy or pulmonary hypertension. HF occurred at a median time of 
31 weeks gestation (IQR 23-40) with the highest incidence in the second trimester (34%) or 
peripartum (31%). Maternal mortality was higher in patients with HF (4.8% in patients with 
HF and 0.5% in those without HF p<0.001). Pre-eclampsia was strongly related to HF (odds 
ratio 7.1, 95% CI 3.9-13.2, p<0.001). Fetal death and the incidence of preterm birth rate were 
higher in women with HF compared to women without HF (4.6% versus 1.2%, p=0.001; and 
30% versus 13%, p=0.001).
conclusion 
HF was the most common complication during pregnancy and occurred typically in the sec-
ond and third trimester or after birth. It was most common in women with cardiomyopathy 
or pulmonary hypertension and was strongly associated with pre-eclampsia and an adverse 
perinatal outcome. 
Keywords
pregnancy, heart failure, maternal outcome, neonatal outcome
Heart failure in pregnant patients with cardiac disease 179
ABBREViATions
CHD = Congenital Heart Disease 
HF = Heart failure
IHD = Ischemic Heart Disease 
IQR = Inter Quartile Range 
NYHA class = New York Heart Association
ROPAC = Registry on Pregnancy and Cardiac disease
SD = Standard Deviation
VHD = Valvular Heart Disease 
WHO = World Health Organization 
inTRoducTion
Pregnancy may be considered as a physiological stress test, revealing latent medical condi-
tions such as hypertension and diabetes.(1) This is particularly true for women with underly-
ing heart disease, where pregnancy may cause a deterioration of a known heart condition 
or precipitate the presentation of an undiagnosed heart problem.(1) During pregnancy 
cardiac output increases by 30%–50%.(2) The increase in cardiac workload may precipitate 
heart failure (HF)(3-5), which is associated with significant maternal and fetal morbidity and 
mortality.(6) 
Despite the poor prognosis associated with the diagnosis of HF, there is very little informa-
tion in the literature on the subject. With a first manifestation of peripartum cardiomyopathy 
HF by definition occurs towards the end of pregnancy or in the months following delivery.
(7) In women with Valvular Heart Disease (VHD), Elkayam et al observed that HF occurs most 
commonly on the day after delivery.(8) Data are lacking on the onset of HF in patients with 
underlying Congenital Heart Disease (CHD). Labour and delivery are considered a particularly 
high-risk period due to the rapid fluid shifts occurring at this time. (9)
In pregnant women with underlying heart disease, the risk of developing complications 
depends on the type and severity of cardiac disease.(2,5,10-14) Large cohort studies have 
focused on prediction of a composite endpoint of cardiac events (arrhythmia, HF and other 
cardiovascular complications).(2-4) This approach fails to distinguish between the relatively 
easily managed complications, such as most supraventricular arrhythmias, and the more 
severe complications, such as HF. Therefore, in this study, we have investigated the timing 
of the diagnosis of HF, its associations and the factors which predict its occurrence in a large 
cohort of pregnant women with structural or Ischemic Heart Disease (IHD). 
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mEThods
study design
The Registry On Pregnancy And Cardiac disease (ROPAC) was established in 2007. Sixty hos-
pitals in 28 countries enrolled 1321 pregnant women with structural or IHD. Enrolled patients 
were pregnant between 2007 and June 2011. 
data 
The study protocol with definitions and the first results of this registry were published previ-
ously.(14) Heart failure was defined as signs or symptoms of HF requiring new treatment or 
change of treatment or hospital admission. Pulmonary hypertension was judged as such by 
the including cardiologist. Onset of HF in terms of gestational age was calculated using the 
expected term date. When a patient developed HF after delivery, we described the timing 
as the number of weeks after delivery. In patients with both HF during and post pregnancy, 
only the first manifestation of HF was used to compute the time of HF. For the calculation of 
median time of HF per diagnosis, we added the number of weeks after delivery to 40 weeks 
when HF occurred after delivery. For example, HF occurring 6 weeks after delivery in a woman 
delivered at 38 weeks is calculated as HF at 46 weeks.
We stratified the patients into 4 risk groups using a modified World Health Organization (WHO) 
risk classification for pregnant women with cardiac disease. Dependent on diagnosis and 
severity of disease, risk classification ranges from class I (low risk), to class IV (contraindication 
for pregnancy).(5,15) CHD patients were further classified by complexity of heart disease, 
according to a generally accepted classification.(16) Diseases that were not accounted for in 
this classification were scored by 2 authors (TR and PP). In addition the type of heart lesion 
was classified into left-sided lesions (such as aortic valve disease, mitral valve disease and 
most cardiomyopathies), right-sided lesions (such as Ebstein’s anomaly, tetralogy of Fallot, 
pulmonary stenosis) and shunt lesions (such as atrial or ventricular septal defects). 
statistical methods
Categorical data are presented as frequencies (numbers) and percentages. One-sample 
Kolmogorov-Smirnov tests and histograms were used to check normality of continuous 
data. Normally distributed continuous data are presented as mean values ± one standard 
deviation (SD), whereas data which were not normally distributed were presented as me-
dians with interquartile range (IQR). Differences in categorical data between independent 
patient groups were compared by chi-square tests. Fisher’s exact tests were applied if any 
expected cell count was less than 5. Differences in continuous data between independent 
patient groups were compared by Student’s T tests. Adjusted birth weight was calculated 
using a linear regression, and was adjusted for gestational age, smoking, fetal sex, maternal 
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age, diabetes and pre-eclampsia. Univariable logistic regression analysis was performed to 
identify baseline patient characteristics (before pregnancy) associated with HF. The follow-
ing baseline variables were assessed: CHD, VHD, cardiomyopathy, IHD, right-sided lesion, 
left-sided lesion, shunt lesion, NYHA (New York Heart Association) class > 2, modified WHO 
class > 2, atrial fibrillation, nulliparity, hypertension, smoking, developing versus developed 
countries (according to international monetary fund classification), signs of HF, pulmonary 
hypertension, mechanical valves and the use of any medication before pregnancy. Echocar-
diographic data (fractional shortening<30 or ventricular function (qualitatively scored) mod-
erate/severely impaired: systemic or pulmonary) were used only in the univariable regres-
sion, since adequate data were only available in 259 patients. We excluded patients with first 
manifestation of peripartum cardiomyopathy in current pregnancy for the univariable and 
multivariable analysis only. Variables that were associated with an increased incidence of the 
studied endpoints (p<0.15) entered the multivariable analysis. Unless specified otherwise, 
p-values <0.05 (2-sided test) were considered statistically significant. All statistical analyses 
were performed using SPSS 20.0 (SPSS Inc., Chicago).
REsuLTs
Baseline characteristics
Of the 1321 enrolled patients 173 (13.1%) developed HF during pregnancy or after delivery. 
Baseline characteristics of patients with and without HF are shown in Table 1. There was a 
significant difference in type of lesion (p<0.001), with fewer women with HF having a right-
sided lesion (12% vs. 27%) or a shunt lesion (20% vs. 27%). In contrast, more women with HF 
had left-sided lesions (68% vs. 45%).
Predictors of hF
The results of the univariable and multivariable logistic regression are shown in Table 2. 
Independent baseline parameters associated with HF were NYHA class>2 and signs of HF 
prior to pregnancy in agreement with previous studies. New independent baseline factors 
associated with HF were WHO category>2, cardiomyopathy or pulmonary hypertension. 
During pregnancy, a diagnosis of pre-eclampsia was related to the occurrence of HF with 
an odds ratio of 7.1 (95% CI 3.9-13.2 p<0.001). Of all patients in the registry who developed 
pre-eclampsia, 30% developed heart failure as well. Of patients with both pre-eclampsia and 
HF 29% had peripartum cardiomyopathy. In the univariable analysis CHD was associated with 
a lower risk of HF than other diagnoses with an odds ratio of 0.3 (95% CI 0.2-0.4). When cor-
rected for other univariable predictors of HF in a multivariable model, this was still significant 
with an odds ratio of 0.40 (95% CI 0.23-0.62 p<0.001). 
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Table 1. Baseline characteristics of patient with and without heart failure. 
Total group
n=1321
Patient with HF 
n=173
Patient without HF 
n=1148 p value
Mean age in years (SD)* 30 (5.6) 29 (6,2) 30 (5,6) 0,18
Nulliparity (%) 50 42 51 0,021
Atrial fibrillation (%) 2 6,4 1,3 <0,001
Hypertension 6,7 8,1 6,5 0,45
Smoking (%) 3,3 4 3,1 0,53
Any medication before pregnancy (%) 28 36 27 0,01
NYHA class <0,001
NYHA class 1 (%) 70 36 76
NYHA class 2 (%) 25 48 21
NYHA class 3 (%) 3,1 15 1,3
NYHA class 4 (%) 0,3 1,2 0,2
WHO category <0,001
WHO 1 (%) 18 1,8 21
WHO 2 (%) 39 19 42
WHO 3 (%) 38 60 35
WHO 4 (%) 4 19 1,9
Type of heart disease <0,001
Valvular heart disease (%) 25 37 24
Cardiomyopathy (%) 6,7 21 4,5
Ischemic heart disease (%) 1,9 1,2 2
Congenital heart disease (%)  66 41 70
Complexity of CHD 0,24
Simple heart disease 35 35 26
Moderate complex disease 52 52 57
Complex heart disease 13 13 17
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Table 2. Predictors for heart failure.
univariable odds ratio 95% ci p value
Congenital heart disease 0,3 (0,2-0,4) <0,001
Valvular heart disease 1,9 (1,4-2,7) <0,001
Cardiomyopathy 4,8 (3,0-7,88) <0,001
Ischemic heart disease 0,6 (0,1-2,4) 0,45
Right sided lesion 0,4 (0,2-0,6) <0,001
Left sided lesion 2,7 (1,9-3,8) <0,001
Shunt lesion 0,7 (0,5-1,0) 0,08
NYHA class > 2 6,2 (3,7-10,5) <0,001
WHO > 2 5,3 (3,7-7,6) <0,001
Nulliparity 0,7 (0,5-0,9) 0,02
Hypertension 1,3 (0,7-2,3) 0,45
Smoking 1,3 (0,6-3,0) 0,53
Developing countries 3,2 (2,2-4,6) <0,001
Signs of HF prior to pregnancy 17,3 (11,6-25,7) <0,001
Rhythm: Atrial fibrillation before pregnancy 5,1 (2,3-11,4) <0,001
Pulmonary hypertension 4,5 (3,1-6,6) <0,001
Mechanical valves 0,5 (0,2-1,5) 0,25
Any medication before pregnancy 1,6 (1,1-2,2) 0,011
Echo prior to pregnancy:
Systemic ventricular function moderate/ severely impaired 4,2 (1,7-10,3) 0,002
FS < 30 3,4 (1,3-8,9) 0,02
Pulmonary ventricular function moderate/ severely impaired 3,1 (0,9-10,5) 0,07
multivariable
Valvular heart disease 1,0 (0,5-1,7) 0,88
Cardiomyopathy 4,6 (2,3-9,1) <0,001
Developing countries 0,9 (0,5-1,6) 0,77
NYHA class > 2 2,3 (1,2-4,4) 0,01
WHO > 2 2,3 (1,5-3,6) <0,001
Any medication before pregnancy 0,8 (0,4-1,0) 0,08
Rhythm: Atrial fibrillation before pregnancy 2,4 (0,8-6,9) 0,11
Signs of HF prior to pregnancy 9,6 (5,9-15,5) <0,001
Pulmonary hypertension 1,8 (1,0-3,0) 0,04
Left sided lesion 1,6 (1,0-2,7) 0,07
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onset of hF
Median onset of HF was at 31 weeks of gestation (IQR 23-40). Of all patients with HF, 106 
(61%) had HF only during pregnancy, 40 (23%) only after delivery and 27 (16%) patients both 
during pregnancy and after delivery. HF occurred in 7% in the first trimester, 34% occurred in 
the second trimester, 28% in the third trimester, 10% at delivery and 21% postpartum. More 
detailed timing of HF is displayed in Figure 1. There is a peak in week 23-30 of gestation and 
in the first weeks after delivery. Heart failure after delivery mainly occurred in the first week 
(20 patients, 61%). In 11 of these patients (55%) HF occurred in the first 24 hours after deliv-
ery. There were large differences in frequency and timing of HF in different patient groups 
(Figure 2). HF was common in patients with a cardiomyopathy and occurred mainly in the 
weeks around delivery. In VHD patients HF occurred throughout pregnancy. In patients with 
shunt lesions HF typically occurred around 25 weeks of gestation and was more common in 
patients with uncorrected shunts and/or pulmonary arterial hypertension. 
Figure 1. Occurrence of heart failure in patients with structural heart or ischemic heart disease during and 
after pregnancy
Percentage of patients with heart failure and distribution over time. In between brackets numbers of 
patients still pregnant at the beginning of the period. In dark blue heart failure at the first day after 
delivery. In light blue heart failure in the weeks post partum (PP). 
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maternal and fetal outcome
The diagnosis of HF was associated with a significantly higher maternal mortality (p<0.001). 
Obstetric complications were also more common in these patients, as shown in Table 3. Mode 
of delivery in patients with HF, was by emergency caesarean section in 22%, by elective cae-
sarean section in 36% and vaginally in 40%; in 3% mode of delivery was not recorded. Overall, 
58% of patients with HF were delivered by caesarean section compared to 38% in patients 
without HF (p<0.001). Caesarean section was for cardiac reasons in 57% of all HF patients 
with a caesarean section, versus 29% in patients without HF (p<0.001). 
Fetal death occurred more often in patients with HF (p=0.001). Birth weight was lower than 
2500 grams in 13% in patients without HF and in 24% of patients with HF (p<0.001). Of these 
children 33(80%) were born prematurely. Median time of delivery was 38 weeks (IQR 36-39) 
for patients with HF and 39 weeks (IQR 37-40) in patients without HF (p<0.001). There was no 
correlation between onset of HF and timing of delivery (R2=0.003) nor was there a correlation 
(R2=0.023) between onset of HF and birth weight (corrected for time of delivery). 
Figure 2. Onset of heart failure in patients per different diagnostic group.
On the left Y-axis the timing of HF in weeks of gestation in different diagnosis is showed (IQR), with a 
reference of time at the right Y-axis. The X-axis displays the frequency of heart failure for each diagnosis.
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discussion
In this large worldwide registry of patients with underlying cardiac disease, HF was the most 
common complication, occurring in 13% of the patients. We showed that the onset of HF 
depended on the underlying cardiac diagnosis, with HF most frequently diagnosed in the 
second or third trimester or shortly after delivery. Heart failure was found most often in 
women with poor pre-pregnancy cardiac function with a diagnosis of cardiomyopathy or 
pulmonary hypertension. Patient with HF had a higher rate of adverse maternal and fetal 
outcomes. Furthermore this is the first study to identify specific predictors for the occurrence 
of heart failure.
Rate of hF in relation to different underlying cardiac diagnoses
In this registry the rates of HF in various diagnoses slightly differ from reported rates in the 
literature. For simple diagnosis such as mitral regurgitation, aortic coarctation, aortic abnor-
malities and shunt lesions rates of HF are high in this registry when compared to the literature.
(17,18) This may be partially explained by the high percentage of unrepaired shunt defects, 
Table 3. Pregnancy outcome in patients with and without heart failure.
*Birthweight corrected for: Gestational age, smoking, preeclampsia, fetal sex and nulliparity.
 
Total Group
n = 1321
Patients with HF
(n=173)
Patients without 
HF
(n=1148) p value
Maternal mortality (%) 1 4,8 0,5 <0,001
Cardiac
Atrial fibrillation (%) 0,9 1,2 0,9 0,71
Ventricular arrhythmias (%) 2 2,9 1,8 0,35
Thrombo-embolic events (%) 0,5 1,2 0,3 0,14
Endocarditis (%) 0,2 1,2 0,1 0,006
Bleeding complications during pregnancy (%) 1,6 2,9 1,4 0,14
Bleeding complications post partum (%) 4,9 4,6 5 0,85
Obstetric
Intra uterine growth retardation (%) 5,8 13 4,6 <0,001
Pregnancy induced hypertension (%) 2,4 2,9 2,4 0,67
(Pre-)eclampsia (%) 3,3 12 1,9 <0,001
Fetal outcome
Fetal death (%) 1,7 4,6 1,2 0,001
Neonatal death (%) 0,6 0,7 0,6 0,92
Premature birth < 37 weeks (%) 15 30- 13 <0,001
Birth weight < 2500 gram (%) 14 24 13 <0,001
Apgar score < 7 (%) 10 13 9,3 0,10
Adjusted mean birth weight (grams) * 3328 3358 0,46
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mainly in developing countries, leading to a relatively high rate of pulmonary hypertension 
associated with these lesions. Yap et al. described a higher rate of complications in patients 
with uncorrected shunts, in patients with atrial septal defects and ventricular septal defect, 
but none of the women developed HF.(19,20) We reported a HF rate of 3.8% in patients with 
atrial correction for transposition of the great arteries which is relatively low compared to 
previously reported rates of 2,7%, 4.1% and 7.1%.(21-23) 
Predictors
In our univariable analysis several factors were associated with an increased or low risk of 
HF. (Table 2) The factors cardiomyopathy, NYHA class>2, WHO>2, pre-pregnancy HF and 
pulmonary hypertension remained significantly associated in the multivariate analysis (Table 
3). The presence of a left sided lesion and medication use prior to pregnancy showed a weak 
association. The loss of several of the factors of the univariate analysis suggests that their risk 
was indirectly mediated through a second factor. For example the relationship of HF with 
developing countries was probably due to the severity of heart disease. Of those factors that 
remained significant the strongest were pre-pregnancy HF and poor functional class and in 
addition high risk of pregnancy as represented by high WHO class. These are useful param-
eters in counselling of women with heart disease considering pregnancy. In the prospective 
study of Siu et al., EF<40% predicted complications. We found that EF and fractional shorten-
ing were univariable predictors of heart failure in the subgroup of patients in which these 
data were available, however, these variables could not be tested in the multivariable model 
due to missing data. Pulmonary hypertension has also been identified as a high risk condition 
in previous studies,(24). However, because of low prevalence pulmonary hypertension did 
not predict complications in the studies of Drenthen et al. and Siu et al.(2,3) We could identify 
pulmonary hypertension as a predictor of HF because we included patients from developing 
countries where the prevalence is relatively high.
In our series, the presence of a mechanical valve was not a predictor of HF, but these pa-
tients are mainly at risk for other complications such as haemorrhage and valve thrombosis. 
Similarly, IHD was not a predictor of HF, possibly because left ventricular function was almost 
normal in most of these patients. Patients with CHD had a lower risk than patients with VHD, 
IHD or cardiomyopathy, but compared to the rate of HF in the normal healthy population this 
risk is still increased. 
Timing
To date, data on the timing of HF in pregnant women with heart disease are scarce. The 
peripartum period has been regarded as high risk period because of the rapid fluid shifts.
(9) While peripartum cardiomyopathy by definition occurs in the months around delivery, 
also patients with VHD are reported to present with HF mainly in the peripartum period (7,8) 
In our study, there appeared to be two peaks, one at the end of the second and beginning 
C
ha
pt
er
 1
1
188
of the third trimester and the other around delivery. Within this pattern, there were distinct 
clusters of diagnostic groups. Women with pulmonary hypertension typically went into HF 
before 30 weeks gestation, for those with VHD HF tended to occur in mid to late pregnancy. In 
those with cardiomyopathy HF was diagnosed peripartum. The first peak, corresponding to 
23-30 weeks occurred when most of the important haemodynamic changes had taken place. 
Stroke volume then has reached its maximum (up to 130% of normal) for a number of weeks, 
but heart rate is just starting to increase. Firm conclusions for all diagnostic groups can’t be 
made, some of the diagnostic groups were small. 
Pregnancy outcome in patients with hF
Pre-eclampsia during pregnancy was associated with HF with an odds ratio of 7.1. In previ-
ously healthy women who develop pre-eclampsia, diastolic and systolic left ventricular func-
tion abnormalities have been demonstrated, but these rarely develop into HF.(25) However, 
in women with pre-existing heart disease, the added strain of pre-eclampsia precipitates HF 
resulting in a rate as high as 30% of the patients. This is an important novel finding of our 
study, which indicates that patients with heart disease who develop pre-eclampsia should 
be monitored carefully for the development of HF. One third of the heart failure associated 
with pre-eclampsia was in patients with peripartum cardiomyopathy, which is a known as-
sociation (26). However, two-third of the heart failure occurring in patients with pre-clampsia 
occurred in patients with other underlying diseases. .(26) Caesarean section rates were high 
in patients with HF, with the majority having a CS for cardiac reasons. Women with HF were 
often delivered preterm probably to shorten the period of volume load and to be able to 
institute more aggressive therapy for the treatment of HF, however the decision for early 
delivery may have a negative impact on the offspring in the longer term.(27) On the other 
hand, fetal death and intra-uterine growth retardation were higher in patients with HF, which 
may keenly illustrate the difficult balance between early delivery and prolonging pregnancy 
in this high risk situation. Reassuringly, neonatal death rates were not different.
Limitations
Some of the parameters previously described in the literature were not collected in this da-
tabase, such as the severity of left ventricular outflow tract obstruction (peak aortic gradient 
>50 mmHg or aortic valve area <1.0 cm2). Therefore we could not confirm nor contradict the 
value of these previously identified predictors. Important measures of ventricular function 
and HF, such as LV EF and natriuretic peptides, were not known in most patients and could 
not be involved in the multivariable analysis. Although we showed that timing of HF was 
dependent of underlying heart disease, some of the subgroups were small. Consequently, 
our findings need to be confirmed in future large studies. As with all registries there was 
some missing information, this was about 4%. 
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concLusion
HF was the most common complication in this pregnancy registry. Timing of HF was depen-
dant on the underlying cardiac diagnosis, with HF in the second trimester occurring mainly 
in patients with shunt lesions or VHD. In contrast, patients with cardiomyopathy and IHD 
developed HF shortly after delivery. In addition to the previously recognised risk factors 
such as pre-pregnancy signs of HF, high NYHA class or WHO category>2, we discovered new 
predictors for HF: cardiomyopathy or pulmonary hypertension. Furthermore pre-eclampsia 
during pregnancy was associated with HF and patients with HF were delivered preterm more 
frequently. 
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Coronary Artery Disease and Pregnancy.
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ABsTRAcT 
The occurrence of an acute coronary syndrome in women of childbearing age is rare, but 
when it happens it can have devastating effects on the mother and the child. Pregnancy has 
shown to increase the risk of ACS 3- to 4-fold. With an overall reported incidence of pregnancy 
related acute coronary syndrome of 6 per 100,000 deliveries. One of the most important risk 
factor for ACS during pregnancy is maternal age.
Pregnancy is a hypercoagulable state and has a major impact on hemodynamics. The increase 
in blood volume, stroke volume and heart rate and the decrease of vascular resistance results 
in 30-50% increase of cardiac output. The presence of reduced left ventricular function in-
creases the chance of an adverse maternal and fetal outcome. 
Evaluating chest pain in pregnant women can be challenging, since chest pain in pregnancy 
is common and may be caused by benign as well as life threatening diseases. In addition 
physical examination and diagnostic tests can be misleading during pregnancy. The underly-
ing cause of an acute coronary syndrome may be different from outside pregnancy and espe-
cially dissection and coronary spasm are more often encountered then in the non-pregnant 
population. With the introduction of PCI as the preferred treatment modality, mortality due 
to ACS during pregnancy has decreased. 
The mode of delivery should be planned in a multidisciplinary team consisting of at least 
an obstetrician, anaesthesiologist and cardiologist. In women with adequate cardiac output 
vaginal delivery is preferred but caesarean section may be the best option in high risk pa-
tients. 
Keywords 
Pregnancy, acute coronary syndrome, outcome.
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inTRoducTion 
Although an acute coronary syndrome (ACS) in women of childbearing age is rare, conse-
quences are considerable, especially in pregnant women. In this chapter we will give an 
overview of the current literature regarding pregnancy and ACS. Acute coronary syndrome 
prior to pregnancy, acute coronary syndrome in the antepartum, peripartum and post 
partum period and heart failure during pregnancy will be described using patient cases, fol-
lowed by an overview of literature and recommendations. Epidemiology, pathophysiology, 
counselling, use of medication, treatment possibilities, delivery, maternal and fetal outcome 
will be discussed.
EPidEmioLogy
Acute coronary syndrome (ACS) is rare in women of childbearing age (16 to 45 years of age). 
During these years pregnancy has shown to increase the risk of ACS three- to fourfold. (James 
et al., 2006) Between 1991-2000 the overall incidence of pregnancy related acute coronary 
syndrome was reported 2,7 per 100.000 deliveries (Ladner et al., 2005). A decade later James 
published on risk factors of ACS during pregnancy in a population based study in the United 
States. He reported an incidence of 6,2 per 100.000 deliveries between 2000-2002. (James et 
al., 2006) The higher incidence can be explained by three causes: First of all with the improved 
diagnostic tests, especially troponine assessment, more women with acute chest pain have 
been diagnosed with ACS; secondly, an increase of known cardiovascular risk factors is seen 
in the pregnant population; and finally, maternal age increased in the western world (Ventura 
et al., 2004). 
Cardiovascular risk factors specific for ACS during pregnancy are very similar to the risk fac-
tors of non-pregnant patients. The main risk factors for ACS in women are smoking, lipid me-
tabolism disorders, hypertension and diabetes. But in pregnant patients also thrombophilia 
and anaemia are risk factors for ACS. In the last decades lifestyle has changed in the western 
world. (Ogden et al., 2006) As a consequence of high calorie intake and little exercise the 
incidence of obesity and diabetes has increased drastically. (Cecchine et al., 2010) 
In addition to cardiovascular risk factors, a few obstetric risk factors have been discovered. 
The most important being multiparity, but also a history of preeclampsia, post-partum haem-
orrhage, transfusions and post-partum infections are risk factors for ACS during pregnancy. 
(Ladner et al., 2005). In addition, obstetric complications may elevate the risk of delevoloping 
ACS later in life. Still birth, preeclampsia and recurrent miscarriage are a risk factor for ACS 
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later in life in the general population. Endothelial dysfunction is hypothesised to be the link 
between hypertension in the pregnancy and cardiovascular disease later in life. (Pina, 2011).
Maternal age is one of the most important risk factor for ACS during pregnancy. Over the age 
of 30 women have an odds ratio of 9.5. This is even higher in women over 40, with an odds 
ratio of 31.6. (James et al., 2006) There is a continuing trend of childbearing at older ages, 
caused by carrier choices of highly educated women. The advances in reproductive technol-
ogy enable many older women to conceive, leading to more women with a high risk for ACS 
during pregnancy. Therefore it may be expected that the incidence of ACS during pregnancy 
will increase further in the coming years. 
chAngEs duRing PREgnAncy 
Knowledge of the normal physiological changes during pregnancy, labour and the postpar-
tum period is essential for doctors looking after pregnant women with heart disease. In the 
following section we will give an overview of the most important physiological changes in 
pregnancy.
The majority of the cardiovascular changes occur in the first twenty weeks of gestation. 
The first hemodynamic change is a decline in total peripheral vascular resistance (TPVR) of 
40-70%. The decline in TPVR is a response to circulating gestational hormones. The drop in 
TPVR results in a relatively underfilled vascular state reflected by a fall in blood pressure. The 
blood volume increases with 1-1,5 litre (30-50%) as a response to the low blood pressure. The 
increase in plasma volume is relatively higher than the increase in red blood cells resulting 
in a physiological haemodilution. The combined changes result in a fifty percent increase in 
circulating blood volume during pregnancy. (Robson et al., 1989)
Cardiac afterload decreases with the fall in TPVR and cardiac preload increases with the rise 
of blood volume. These changes result in an increase in cardiac output of 30-50% from the 
20th week of gestation as shown in figure 1. During pregnancy heart rate increases by 10-20 
beats per minute, this mainly happens in the third trimester. Pregnancy is associated with 
changes in cardiac structure secondary to the increase in cardiac output, with left ventricular 
dimensions increasing from between 10-30%, ejection fraction and fractional shortening 
also increase. (Hunter & Robson, 1992)
The vascular system changes with the increase in stroke volume. Arterial stiffness decreases 
during the first trimester, but slightly rises from the second trimester and vascular distensi-
bility is increased (Ulusoy et al., 2006). These changes are partially mediated by gestational 
hormones, for example estrogen has favourable effects on the endothelium and vascular 
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smooth muscle cells and increases vasodilatation (Mendelsohn & Karas, 1999), but progestins 
reduce estradiol-induced endothelium-mediated vascular relaxation. (Skafar et al., 1997).
Delivery increases the stroke volume by 20%, which contributes to the 25% increase in 
cardiac output. This is initiated by the greater maternal oxygen consumption caused by the 
increase in uterine contractions in combination with maternal stress and pain, which in turn 
stimulates higher epinephrine levels. 
Major hemodynamic changes also occur during the puerperium, (from birth until 6 to 8 
weeks after delivery). Decompression of the inferior cava and the return of uterine blood 
to the circulation (auto-transfusion) cause a period of overfilling. In women with impaired 
cardiac function this may result in cardiac decompensation. All gestational hemodynamic 
changes return to prepregnancy levels 3-12 months after pregnancy. 
Pregnancy is a hypercoagulable state, probably an evolutionary adaptation to reduce the 
risk of severe haemorrhage after labour. There is a decrease in releasable tissue plasminogen 
activator (tPA), an increase in fast-acting tPA inhibitor and an increase in factors V, VII, VIII, 
IX, X, XII and von Willebrand factor (Fletcher et al, 1979). Protein S is increased through out 
pregnancy, while increased resistance to activated protein C is only seen during the second 
Figure 1. Hemodynamic changes in the normal pregnancy: CO cadiac output, SV stroke volume, HR heart 
rate, Hb haemoglobin concentration and TPVR total peripheral vascular resistance. Reproduced from: 
“Karamermer Y, Roos-Hesselink JW. Pregnancy and adult congenital heart disease. Expert Rev Cardiovasc 
Ther 2007; 5: 859-869” with permission of Expert Reviews Ltd .
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and third trimesters (Coolman et al., 2006). The hypercoagulable state is partially reversed by 
haemodilution and the activation of the fibrinolytic system. During delivery the placenta and 
myometrium release tPA inhibitors further increasing the hypercoagulable state (Yoshima et 
al., 1992); but by around 6 weeks after pregnancy the coagulation and fibrinolytic systems 
return to normal.
In summary pregnancy is a hypercoagulable state and an increase of 30-50% in cardiac output 
is seen as a result of decrease of vascular resistance and increased blood volume, stroke volume 
and heart rate. 
mEdicATion duRing PREgnAncy 
The food and drug administration (FDA) made a classification system for the use of drugs in 
pregnant women: 
category A: Adequate and well-controlled studies have failed to demonstrate a risk to the 
fetus in the first trimester of pregnancy (and there is no evidence of risk in later trimesters). 
Category B: Animal reproduction studies have failed to demonstrate a risk to the fetus and 
there are no adequate and well-controlled studies in pregnant women. 
category c: Animal reproduction studies have shown an adverse effect on the fetus and 
there are no adequate and well-controlled studies in humans, but potential benefits may 
warrant use of the drug in pregnant women despite potential risks. 
category d: There is positive evidence of human fetal risk based on adverse reaction data 
from investigational or marketing experience or studies in humans, but potential benefits 
may warrant use of the drug in pregnant women despite potential risks. 
category X: Studies in animals or humans have demonstrated fetal abnormalities and/or 
there is positive evidence of human fetal risk based on adverse reaction data from investiga-
tional or marketing experience, and the risks involved in use of the drug in pregnant women 
clearly outweigh potential benefits.
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Table 1. Medication during pregnancy
ACE: Angiotensin-converting enzyme inhibitors. ARB: Angiotentin receptor antagonists.
Medication Indication FDA Safe 
during 
pregnancy
Extra information Safe 
during 
breast 
feeding
Extra information
Atenolol Hypertension, 
Arrhythmias,
D Yes IUGR and premature 
birth
No A case report of adverse 
effects
Other beta 
blockers
Hypertension, 
Arrhythmias, 
Marfan disease 
ACS
C Yes Low birth weight, 
hypoglycemia and 
bradycardia in the 
fetus
Yes Careful monitoring of the 
neonatal heart rate.
ACE inhibitors Hypertension, 
Heart failure
D No High incidence fetal 
death and fetotoxic 
effect: renal failure, 
renal dysplasia
Yes Traces are detected 
in breast milk, fetal 
monitoring is advisable
ARB Hypertension, 
Heart failure
D No High incidence fetal 
death and fetal anuria
No data
Spironolactone Hypertension, 
Heart failure
D No Potential anti-
androgenic effects on 
the developing male 
fetus
Yes
Thiazide diuretics Hypertension, 
Heart failure
C No Hypovolemia can lead 
to reduced uterine 
perfusion
Yes May suppress lactation.
Loop
diuretics
Hypertension, 
Heart failure
C Yes Hypovolemia can lead 
to reduced uterine 
perfusion
Yes
Digoxin Arrhythmias C Yes No reports of 
congenital defects
Yes Neonatal heart rate 
should be monitored after 
delivery.
Nitrates Hypertension, 
Angina 
B Yes Careful titration is 
advised to avoid 
maternal hypotension.
No data 
Calcium channel 
antagonists
Hypertension,
Preeclampsia
C Yes Diltiazem: an increase 
in major birth defects 
have been reported
Yes Excreted in breast milk. 
Statins  Lipid disorders X No Animal studies 
demonstrated 
increased skeletal 
abnormalities, 
fetal and neonatal 
mortality.
No Probably appears in breast 
milk, there are some 
concerns with disruption 
of infant lipid metabolism
Aspirin ACS,
Arrhythmias
C Yes Low dose aspirin 
is safe
Yes No adverse effects have 
been reported in low dose.
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PRE-EXisTing coRonARy disEAsE
A 39 year old woman was seen at the out patient clinic of a referral hospital for counselling. 
Three month earlier she had suffered a non ST elevation myocardial infarction (NSTEMI). On 
coronary angiogram (CAG) a thrombotic occlusion of an atherosclerotic lesion of the left 
coronary artery was seen and treated with a drug eluting stent. She had never been preg-
nant, had recently stopped smoking, was a non diabetic and normotensiv. Her family history 
did not reveal any cardiovascular disease. Her left ventricular function was assessed with 
echocardiography and the estimated ejection fraction was 48%. She was prescribed aspirin, 
clopidogrel, simvastatine, perindopril and nifedipine. 
counselling prior to pregnancy 
Ideally all women of reproductive age with cardiac disease should undergo thorough evalua-
tion before becoming pregnant. This evaluation should focus on identifying and quantifying 
risk to the mother and the unborn child. During pre pregnancy counselling life expectancy 
and ethical aspects of parenthood should also be discussed. An exercise test, and echocar-
diogram should be performed. Risk stratification is made to inform the patient of possible 
complications during pregnancy. The influence of pregnancy on the cardiac condition has to 
be considered, but also the cardiac condition may influence pregnancy outcome, especially 
the incidence of hypertension, preeclampsia, arrhythmias and thrombotic complications 
may be higher.
Low dose aspirin, beta blockade and nitrates should be continued during pregnancy. The 
safety of clopidogrel is unknown. In individual cases with recent drug eluting stent place-
ment, continuation should be considered. ACE inhibitors and ARBs should be stopped in all 
patients or in the pre-conception clinic or immediately when pregnancy is diagnosed. Gener-
ally, statins should be stopped, however, in an individual patient with very high cholesterol, 
continuation may be considered.
Recurrence rate
Only limited data on recurrence risks have been published. Badui et al described 18 women 
in the literature with previous ACS, the mothers were 1 or 2 years after ACS and none of these 
patients had a recurrent ACS. (Badui & Enciso, 1996) One of the reasons for this lack of data is 
the fact that many women are advised against pregnancy after ACS. Doctors advise against 
pregnancy for a number of reasons, first it is suggested that the hypercoagulable state of 
pregnancy raises the chance of recurrence of thrombotic obstruction of the coronary arter-
ies. Second the increase in left ventricular mass and heart rate lead to a high cardiac oxygen 
demand. The increased cardiac oxygen demand can lead to relative coronary flow mismatch 
Coronary Artery Disease and Pregnancy 201
in patients with pre-existing coronary artery disease. Finally, fear of complications may make 
them conservative. 
The first patient was advised to wait for at least 3 more months before trying to become 
pregnant to make sure that she was cardiovascularly stable. Before conception perindopril, 
statin and clopidogrel are advised to be discontinued until after delivery. If pregnancy oc-
curred, then the plan was made for outpatient review at 6, 12, 20 and 32 weeks of gestation.
Impaired left ventricular function
A 41 year old patient presented to the out patient department of a referral hospital with a 
desire for pregnancy. She had not been pregnant before. One year earlier she had suffered 
from a STEMI, CAG at that time revealed atherosclerosis and thrombosis of the LAD and she 
was treated with thrombosuction and a drug-eluting stent. Six month after the ACS her left 
ventricular function was measured with echocardiography, ejection fraction was 35 %. 
In 2000 Siu published predictors of cardiac events, mainly heart failure and arrhythmias. Prior 
cardiac events, left ventricular outflow obstruction, NYHA class > II, cyanosis and systemic 
ventricular dysfunction (ejection fraction >40%) were predictor for adverse maternal out-
come. If one predictor was present, cardiac event rate was 27%. (Siu et al., 2001) However, the 
patient population consisted of patients with congenital or valvular disease and a diminished 
systemic ventricular function was mainly found in patients with transposition of the great 
arteries after atrial repair. To use these results to predict cardiac events in ischemic cardiomy-
opathy patients is at least questionable. 
Generally women are advised against pregnancy if they have a left ventricular dysfunction 
with an ejection fraction under 40% and have a dilated left ventricle (Prebitero et al., 2009). 
In a study on pregnancy in patients with dilated cardiomyopathy, an OR of 43 was found for 
moderate or severe left ventricular dysfunction and 39% of the pregnancies where compli-
cated (Grewal et al., 2009). Risk factors for adverse events were moderate (EF 30%-44%) or 
severe (EF<30%) ventricular dysfunction and NYHA class III or IV at baseline or prior cardiac 
event. Compared with non-pregnant patients with dilated cardiomyopathy, pregnant pa-
tients needed more medication and adverse cardiac events were more common. Pregnancy 
seemed to have a negative impact on the short-term clinical course for women with dilated 
cardiomyopathy (Grewal et al., 2010). We need similar data for women with ischemic left 
ventricular dysfunction. 
In case of heart failure during pregnancy diuretics are considered to be first choice, but 
diuretics could result in hypovolemia, leading to reduced uterine perfusion and so should 
be used with caution. Nitrates can be used safely and digoxin can be considered, especially 
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if the patients has atrial fibrillation. Such patients should be treated in hospital and bed rest 
is advisable. 
In the study of Grewal et al, the neonatal complication rate was high, especially in women 
with severe dilated cardiomyopathy, suggesting that in the context of severe left ventricular 
dysfunction, the heart may not be able perfuse the utero-placental circulation sufficiently. 
Therefore, regular growth scans to indentify fetal growth restriction and frequent review in a 
combined clinic with an obstetrician and cardiologist is advised. (Signore et al., 2010) 
The second patient was informed about the high maternal and fetal risks associated with 
pregnancy in women with impaired left ventricular function as well as the lack of information 
on the recurrence rates of ACS during pregnancy. She decided not to take the risk.
Delivery
Planning delivery should be done in a multidisciplinary team consisting of an obstetrician, 
anaesthesiologist and cardiologist. The patient should be informed about the considerations 
prior to delivery, since patients preference has to be taken into account. Timing of delivery 
is individualized, according to the cardiac and obstetric status of the mother and fetal well 
being. In patients with heart failure delivery at 34 weeks can be considered to allow early 
optimisation of treatment modalities for the mother.
The mode of delivery depends on the maternal hemodynamic situation and obstetric factors. 
Women with adequate cardiac output may tolerate induction of labour and vaginal delivery. 
Vaginal delivery can lead to fluctuations in blood pressure, especially in prolonged labour. 
Assisted vaginal delivery (by vacuum or forceps extraction) is recommended in some women 
to avoid excessive maternal efforts and prolonged labour (Roth & Elkayam, 2008). Adequate 
pain relief is very important, but epidural anaesthesia is contraindicated when the patient is 
on antithrombotic or anticoagulant treatment.
During caesarean section blood pressure can be controlled, stress and pain can be relieved 
and a stable environment can be created. However, caesarean section has been associated 
with a higher risk of venous thrombo-embolism, infection and peripartum haemorrhage. In 
some cases general anaesthesia will be necessary with some risk of complication (Deneux-
Tharax et al., 2006). In addition, blood loss during caesarean section has been shown to be 
greater than during vaginal delivery. 
Post partum period 
The volume shifts caused by auto-transfusion can be dangerous in patients with diminished 
left ventricular function. Close monitoring on a medium care unit may be advisable for the 
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first 3 days after delivery. Early recognition of heart failure and immediate treatment with 
diuretics can be achieved by close monitoring of the patients and measurement of the cen-
tral venous pressure. Some cardiologists advise prophylaxic diuretics in patients with severe 
systemic ventricular dysfunction. Ideally monitoring should be done in a unit with neonatal 
care, since early bonding of mother and child is very important. In patients with normal ven-
tricular function after ACS prior to pregnancy close monitoring in-hospital for at least three 
days after delivery is advisable. The main risk during this period consists of thrombo-embolic 
events cause by the hypercoagulable state of pregnancy exacerbated by even higher tPA 
inhibitor levels immediately after delivery. 
Breast feeding 
The effects of breast feeding on maternal cardiovascular function are caused by circulating 
hormones. High levels of oxytocin circulate through the body. In the study of Mezzacappa 
cardiac output during breastfeeding was found to be higher than in bottle feeding mothers. 
They describe a decrease in heart rate and a slight increase in systolic blood pressure during 
the first minutes of breast feeding (Mezzacappa et al., 2001). Light et al described a lower 
blood pressure in breast feeding mothers one hour after breast feeding (Light et al., 2000). 
In the first weeks of breast feeding, women produce around 800 millilitres of milk daily. With 
the production of breast milk large volume shifts take place, these may cause a problem in 
patients with reduced left ventricular function. 
The fluctuations in blood pressure may be harmful in severely symptomatic patients and 
bottle feeding should be considered. Lactation is also associated with a risk of bacteraemia 
secondary to mastitis. (Guideline pregnancy and heart disease
AnginA in ThE PREgnAnT PATiEnT.
A 41 year old patient presented to the emergency department with acute chest pain. There 
was a myocardial infarction at young age in her family history. She was 18 weeks pregnant 
with her first child. She did not, take any alcohol or medication during pregnancy. But she was 
continuing smoking during pregnancy. She had a blood pressure of 135/85mmHg, a pulse 
of 95 beats per minute and auscultation of the chest revealed normal breath sounds without 
rales. The ECG was normal. Transthoracic echocardiography revealed no wall abnormalities. 
Troponine levels were normal. During exercise testing she performed 92% of expected and 
during testing a down sloping ST depression of 2-3 mm was found in lead II, III and aVf.
signs and symptoms 
Evaluating chest pain in pregnant women can be challenging, since chest pain in pregnancy 
is common and can be caused by various conditions. Most often chest pain is caused by 
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gastro-oesophageal reflux which is benign in most cases. Chest pain should never be ignored 
as it may also represent possible life threatening disease such as pericarditis, myocarditis, 
aortic dissection, hypertensive crisis, pulmonary thrombo-embolism or acute coronary 
syndrome. Urgent complete cardiac review is always appropriate if a pregnant woman who 
presents with chest pain.
Physical examination can be misleading, hypotension and tachycardia are physiological 
responses to normal pregnancy (as describe in sub-chapter 3). In this case normal lung 
examination and oxygen saturation made pneumonic disease less likely, but pulmonary 
thrombo-embolism remained a possibility. Measuring blood pressure in both arms is impor-
tant since aortic dissection is a part of the differential diagnosis.
diagnostic testing 
Criteria for ACS in pregnancy are the same as in non pregnant women, consisting of a combi-
nation of symptoms, ECG changes and positive cardiac markers. Normal diagnostic tests can 
be used in pregnancy, but outcome has to be evaluated against normal pregnancy values, 
since abnormal values can be normal in pregnancy. Table (2) gives a brief summary of the 
changes most often seen in diagnostic tests.
The electrocardiogram (ECG) changes as a result of the upward shift of the diaphragm with 
the growing uterus. A left axis deviation with Q waves in lead III and aVF is seen in the third 
trimester. T waves can be inverted in lead III, V1 and V2. In case of a caesarean section with 
general anaesthesia ST depression is seen often (Prebitero et al., 2009).
The use of echocardiography is safe in pregnancy because echocardiography does not 
involve radiation. Detection of wall motion abnormalities can be used as a sign of possible 
acute coronary syndrome. In normal patients exercise tests are used to confirm the diagnosis 
of coronary artery disease or after ACS to establish exercise capacity and exclude residual 
ischemia. In pregnancy it is advisable to use submaximal exercise (<70% of the maximum 
predicted heart rate) testing, since fetal bradycardia and absence of body movement have 
been described after heavy maternal exercise (Elkayam et al., 1998). There is no evidence of 
increased risk of spontaneous abortion after exercise testing. 
Biomarkers are used in the cardiological practice to confirm the diagnosis of acute coronary 
syndrome. During labour elevated creatinine kinase (CK) and CK MB are found due to uterine 
contractions. These levels normalize during the second day after labour. (Poh & Lee, 2010) 
Troponine I is not elevated in normal pregnancy, as a result troponin I is the recommended 
biomarker in pregnancy. However, troponin I serum levels can be elevated in patients with 
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pre-eclampsia and hypertensive crisis. It is not totally clear whether this is a sign of cardiac 
ischemia in these partients.
Chest radiography is only used in pregnancy during emergency medical conditions. If proper 
shielding of the abdomen is used radiation of chest radiography is considered relatively safe 
(especially in the third trimester). (Hirshfeld et al., 2005) 
Treatment choices in patients with chest pain 
The choice of treatment is dependent on the diagnosis and the presence of ECG changes. In 
patients without any ECG changes, other causes of chest pain should be considered; troponin 
should be measured in all patients. In women with ACS, conservative treatment (bed)rest, 
nitrates and beta blockers is advised. In NONSTEMI patients a careful assessment should be 
made. Troponin levels, hemodynamic state and relief of pain determine whether the patient 
should have a coronary angiogram. A coronary angiogram will reveal the origin of the prob-
lem, eg dissection, thrombus. But a conservative treatment may be best in the majority of 
patients. STEMI patients need immediate treatment and PCI as first choice treatment should 
be performed as soon as possible. 
In patients with angina catherization should be considered. If proper shielding of the abdo-
men is used, radiation dose is low. An interventional procedure may result in a fetal exposure 
of <1 rad. Termination of pregnancy is generally not recommended, although it may be 
considered when the fetal radiation dose exceeds 10 rad. (Roth & Elkayam, 2008)
The patient became pain free after the use of nitroglycerine and was treated with beta block-
ade. Further pregnancy was uneventful and she delivered a healthy baby boy at 39 weeks 
after spontaneous vaginal delivery. 
Acute coronary syndrome during the first or second trimester of pregnancy.
A 38 year old patient came to the emergency department with acute chest pain. She was 25 
weeks pregnant with her second child. The first pregnancy was complicated by preeclampsia. 
Table 2. Changes in diagnostic tests in normal pregnancy.
Diagnostic test Effect of normal pregnancy
Electrocardiogram Left axis deviation and Q waves in lead III and aVF, inverted T waves in lead III 
Exercise test Decreased exercise tolerance
Echocardiogram Increase in left ventricular mass, mild mitral regurgitation
Serum creatinin kinase Elevated during labour 
Troponin Not affected during normal pregnancy
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She has no dyspnoea, syncope, cough or fever. She did not smoke nor use any alcohol or 
medication during pregnancy. She had a blood pressure of 100/60mmHg, a pulse of 105 
beats per minute and was tachypnoeic at 24 breath per minute. Oxygen saturation by pulse 
oximetry was 99%. Auscultation of the chest revealed normal breath sounds without rales. 
The heart sounds were normal, no murmur or gallop was heard. Abdominal examination did 
not reveal any abnormalities and there was no oedema. The results of the ECG were con-
sistent with STEMI of the anterior wall with ST elevation in V1-V3 and ST depression in lead 
II, III and aVF. Transthoracic echocardiography revealed a dyskenetic left anterior wall. The 
patient underwent coronary angiography three hours after onset of complaints and revealed 
a thrombotic obstruction of the left main artery with TIMI flow grade 1. 
cause of Acs
ACS in pregnancy has other causes than in the non-pregnant state. In the review of Roth 
and Elkayam only 40% (41 of the 103 patients) was caused by coronary artery stenosis. (Roth 
& Elkayam, 2008) Other causes were thrombus in 8%, coronary artery dissection in 27%, 
vascular spasm in 2% and normal coronary arteries were found in 13% of the patients. (Roth 
& Elkayam, 2008) ACS has been noted to occur more often in the anterior wall (Iadanzo et al., 
2007).
Coronary dissection is very rare in the non-pregnant population, but more frequently seen 
in pregnancy (27%) especially in patients with ACS in the peripartum period (50%). Excess 
of progesterone is thought to be one of the causes of coronary dissection, since it causes 
biochemical changes of collagen in the coronary vessel wall and weakens the media. The 
impact of increased blood volume and cardiac output may cause extra wall stress which is 
hypothesised to be an additional factor (Roth & Elkayam, 2008) also autoimmune conditions, 
such as systemic lupus erythromatosis and anti-phospolipid-antibody syndrome, have also 
been linked to coronary artery dissection. (Nallamonthu et al., 2005)
Normal coronary artery morphology is found in 13% of patients, perhaps caused by transient 
coronary spasm or thrombus. Vascular spasm was found in 2 % of the case reports described 
by Roth. (Roth & Elkayam, 2008) Spasm might be caused by enhanced vascular reactivity 
to angiotensin II, norepinephrine and endothelial dysfunction (Nisell et al., 1985). Vascular 
spasm in combination with the hypercoagulable state of pregnancy may cause coronary 
thrombus leading to acute coronary syndrome. Patients who continue to smoke during 
pregnancy have an increased risk of coronary artery thrombosis due to enhanced platelet 
aggregability in smokers. 
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Treatment 
When tests have confirmed the diagnosis of acute coronary syndrome, it is important to 
make a treatment plan and inform the patient about maternal and fetal risks of all possible 
treatment options. 
There is only limited information available on PCI during pregnancy. Nowadays pregnancy 
is not a contraindication for PCI and since PCI is the primary treatment for non-pregnant 
STEMI patients, more and more cases of stenting during pregnancy are published. With PCI 
as a treatment modality during pregnancy mortality of ACS has dropped. James described 
PCI in 135 patients (of which 127 were with stenting), but no information on outcome was 
published. In the first review of Roth and Elkayam in 1996 only 3 of the 125 patients had 
PCI (Roth & Elkayam, 1996). Whereas in their second review 38 patients had a PCI, all with 
bare metal stenting. In this review 92 patients had a coronary angiogram (of which 43 were 
postpartum). After PCI one patient needed CABG because of extensive coronary dissection 
(Roth & Elkayam, 2008).
The preference for bare metal stenting is caused by the requirement of dual anti-platelet 
treatment around the delivery and the lack of experience. The use of drug eluting stents has 
been described in 2 case reports. One patient with STEMI at 27 weeks of gestation received 
a drug eluting stent, she delivered a healthy child by elective caesarean section at 35 weeks. 
Antiplatelet therapy was continued during delivery. However, post partum she had a haemo-
globin drop of 5 g/dL and needed a blood transfusion (Al-Aqeedi & Al-Nabti, 2008).
Since pregnant women are excluded from most clinical trials no randomised controlled 
trials have been preformed on thrombolytic therapy, PCI or CABG in the pregnancy. How-
ever, thrombotic therapy is considered to be relatively contraindicated in patient with acute 
coronary syndrome because of bleeding complications. In stroke, pulmonary embolism and 
mechanical heart valve thrombosis there is some clinical experience with several strategies 
such as tPA, urokinase and streptokinase. This medication does not cross the utero-placental 
barrier (Leonhardt et al,. 2006). Maternal and fetal outcomes were favourable, but compli-
cations, as maternal haemorrhage, fetal loss, abruption placenta, preterm delivery and 
post partum haemorrhage have been reported in up to 10% and maternal mortality was 
1.2 % (Turrentine et al,. 1995). The risk of haemorrhage is highest in the peripartum period 
(Murugappan et al,. 2006) and given the high incidence of coronary dissection in pregnancy, 
the use of thrombolytic therapy could lead to haemorrhage and further progression of the 
dissection. Thrombolytic therapy should be considered in case of thrombosis and possibly 
when primary PCI is not available. ( Roth & Elkayam, 2008)
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Very limited data is available on coronary artery bypass grafting (CABG) during pregnancy, 
no conclusion on safety for the mother or the unborn child can be made. In normal non-
pregnant patients with ACS CABG is used when multiple vessels or the left main coronary 
artery are involved (Nallamonthu et al., 2005). In the data by James 61 women underwent 
CABG, but there was no specific data on outcome in these patients. In the case study of 
Roth and Elkayam 10 patients were described who underwent CABG, of which were 7 due 
to coronary artery dissection (Roth & Elkayam, 2008), in these cases one fetal death and one 
late maternal death were reported (Garvey, 1998). Large differences in maternal mortality 
rates were found for ACS in pregnant women in the last decades, ranging from 5,1%(James 
et al., 2006) to 38%(Koul et al., 2001). The decline in mortality rate could be explained by the 
detection of ACS in less severely ill patients as well as improvement in treatment options in 
the last decades (Roth & Elkayam, 2008). 
delivery
Delivery should be postponed if possible for at least 2 or 3 weeks after the ACS to allow 
adequate healing. (Prebitero et al., 2009) Anti-platelet therapy should be continued in case 
of recent stent implantation, low dose aspirin is also advisable in patient with other forms 
of coronary artery disease, but doctors should be aware of a higher risk of post partum 
haemorrhage. Vaginal delivery with shortened second stage of labour and adequate pain 
relief can be safe. Caesarean section is the preferred mode of delivery in patients with cardiac 
instability.
Post partum period 
Close monitoring on a medium care unit may be advisable for the first 3 days after delivery. 
With anticoagulant and anti-platelet therapy given during pregnancy, special attention 
should be paid to major haemorrhage. Ideally monitoring should be done in a unit with 
neonatal monitoring.
In our patient thrombosuction was performed and a bare metal stent was inserted. She was 
treated with heparin for 24 hours and received aspirin beta blockade and nitrates during the 
remainder of the pregnancy. Clopidogrel was not given during pregnancy. She delivered 12 weeks 
later at 37 weeks by the assisted vaginal route. Epidural pain medication was given to limit pain 
and stress. A healthy girl (3045 gram) was born. After delivery she was treated with a statin and 
an ACE inhibitor. 
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AcuTE coRonARy syndRomE in ThE ThiRd TRimEsTER 
A 34 year old patient presented to the emergency department with acute chest pain. She was 
36 weeks pregnant. The results of the ECG were consistent with acute myocardial infarction 
of the anterior wall. The patient underwent cardiac catheterisation two hours after onset of 
symptoms, coronary angiogram revealed a coronary artery dissection of the left anterior 
descending artery. 
Acs in the third trimester
Coronary artery disease in the peripartum period differs from ACS in the antepartum period 
in terms of coronary abnormality, cause, treatment options and mortality rate. Coronary 
dissection was the primary cause of coronary artery disease in the peripartum period (50%) 
and more commonly in post-partum period (34%) compared to antepartum period (11%). 
This is probably the result of hormonal changes and the stress on the walls of the coronary 
arteries during labour. In some cases an association with the administration of the medicine 
terbutaline (a medicine used to stop early uterine contractions) was found. 
The mortality rate in patients with ACS in the peripartum period is 18% versus 9% in the 
antepartum and postpartum period (Roth & Elkayam, 2008). This was also shown in the study 
of Ladner, who reprted a mortality rate of 19% in the peripartum period. No specific cause 
for the high maternal mortality in the peripartum period was given. Different causes for 
high mortality rates could be hypothesized. The symptoms could be misinterpreted during 
delivery and both patient delay as well as doctor delay could lead to late recognition of ACS. 
A second reason could be the complication and mortality rate is relatively higher in patients 
with coronary artery dissection compared to coronary arthrosclerosis (Basso et al., 1996). A 
third reason is that major haemorrhage may result from anti-thrombotic therapy. And finally, 
cardiac failure after delivery caused by autotransfusion with stressing the injured myocytes 
could lead to maternal death. Moran et al described myocardial ischemia in normal patients 
during elective caesarean section. By using Holter monitoring and analysis of troponin I he 
showed ischemic changes in 8% of the patients and 81% had ST segment changes. None of 
these patients needed any form of treatment. This study showed that even normal healthy 
women experience ECG changes which may reflect some myocardial ischemia during caesar-
ean section. (Moran et al., 2001) 
Treatment in peripartum period 
Treatment options are limited in the peripartum period, since anticoagulation and anti-
thrombotic therapy should be discontinued 24 hours prior to delivery to avoid major bleed-
ing complications. PCI is the treatment of choice in patients with STEMI. As pregnant patients 
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have a substantial higher chance of coronary dissection and a high maternal mortality, PCI 
should be preformed in a larger referral centre with cardiothoracic surgery standby. 
delivery and postpartum period
Caesarean section prior to CAG is a possible strategy in patients with ACS diagnosed after 
32 to 34 weeks of gestation (Hameed & Sklansky, 2007). At this point fetal outcome is gener-
ally good and maternal benefit is high because of reduced stress during the last weeks of 
pregnancy and the use of antithrombotic therapy after PCI. Close monitoring on a medium 
care unit may be advisable for the first 3 days after delivery. 
It is very important to consider ACS in peripartum patients with acute chest pain. Early recogni-
tion and diagnosis can save lives. A healthy baby girl was born at 39 weeks. The patient stayed in 
the hospital until 3 days after delivery.
AcuTE coRonARy syndRomE in ThE PosTPARTum PERiod
After delivery of a healthy girl, a 31 year old patient was treated with bromocriptine to sup-
press lactation. Four days after delivery she presented to the emergency department with 
acute severe chest pain. The ECG showed an acute anterior myocardial infarction with ST 
elevation in V1-V3. Coronary angiography revealed a dissection of the left anterior descend-
ing artery and she was treated with bare metal stenting. She remained in the hospital for 3 
more days and was treated with betacblockade, aspirin and clopidogrel. 
Post partum Acs 
Coronary dissection was found in 34% of the coronary angiograms and this was the most 
frequent cause of ACS in the postpartum period as it was in the peripartum period. Post-
partum, some cases of ACS are associated with the administration of medicine. There are 
nineteen cases reported of ACS after the administration of bromocriptine, which is used 
to suppress lactation. Bromocriptine has dopaminergic agonist properties and may have 
vasopastic effects which can lead to thrombus formation (Hopp et al., 1996). This medication 
has been taken off the market as a lactation suppressant because of these reports. The sec-
ond medicine associated with ACS is ergotamine, which is commonly used to prevent post 
partum haemorrhage by stimulating uterine contractions. Ergot derivatives are known to 
reduce the capacity of the intravascular lumen by 15-20% in normal coronary arteries. Eight 
cases of postpartum myocardial infarction have been described. (Eom, 2005) It is important 
to consider ACS as a possible complication before administration of this medicine in high risk 
patients (high age and cardiovascular risk factors). 
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Treatment post partum Acs 
After delivery the treatment options are greater. Only maternal health determines the treat-
ment, as is usual in “normal” cardiac patients PCI is the treatment of choice. Drug eluting 
stents can be used now. However, the uterine vascular bed has to be considered a large 
wound until one week after delivery. 
Bromocriptin, ergotamine and terbutaline have been associated with post partum ACS. 
nEonATAL ouTcomE 
Neonatal outcome is strongly correlated with maternal outcome. In the first report of Roth 
and Elkayam 16 fetal deaths in 125 pregnancies (13%) were reported, of which 10 (62%) as-
sociated with maternal death (Roth & Elkayam, 1996). In the second report only a 9% fetal 
death rate was reported, of which two were elective terminations because of potential drug 
teratogenicity (Roth & Elkayam, 2008). Ladner et al described low birth weight and prematu-
rity in patients with antenatal ACS and a 10% fetal death rate was reported in patients with 
intrapartum ACS (Ladner et al, 2005).
Fetal mortality is high in cardiac surgery during pregnancy with rates as high as 30% reported 
(Parry & Westaby, 1996). Factors which predicted an adverse fetal outcome were severity of 
maternal illness, total operative time, emergency surgery, reoperation, advanced maternal 
age and gestational age. (Barth, 2009) 
During cardiopulmonary bypass, continuous fetal monitoring should be performed. The fetal 
heart rate can be used as an indicator of placental perfusion to guide bypass pump flow 
(Chandrasekhar et al., 2009). Uterine monitoring is essential to allow early control of these 
contractions as they are associated with significant fetal loss. (Parry & Westaby, 1996). Del-
eterious effects on the fetus are thought to be related to hypotension, hypothermia, embolic 
complications and inadequate placental flow. Caesarean delivery prior to CABG or PCI can be 
considered from 28 weeks of gestation. (Barth, 2009) 
Fetal mortality in PCI compared to CABG is low. Proper shielding of the abdomen is essential 
in fetal protection. (Roth & Elkayam, 2008) Where chest radiography is considered relatively 
safe (especially in the third trimester). Cardiac catherization and intervention procedures may 
result higher fetal exposure with some chance of fetal abnormalities especially when used in 
the first trimester.
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concLusion
Acute coronary syndrome in women of childbearing age is rare, but pregnancy has shown to 
increase the risk of ACS 3- to 4-fold. (James et al., 2006) The overall incidence of pregnancy 
related acute coronary syndrome was reported between 2.7 and 6.2 per 100,000 deliveries 
and seems to have been increased in the last decadetime. Maternal age is one of the most 
important risk factor for ACS during pregnancy. Mortality rate has declined over the last 
decades from 19% in 1922-1994 to 5,1% in 2001-2002, probably as a result of improvement 
in treatment modalities. 
Evaluating chest pain in pregnant woman can be challenging, since chest pain in pregnancy 
is common and may be caused by benign as well as life threatening diseases. Physical exami-
nation and diagnostic tests can be misleading, since normal pregnancy changes the results 
of these tests. Coronary artery disease in pregnancy has different causes than seen in non-
pregnant women, artherosclerosis is less frequently found, whereas thrombus, dissection, 
spasm and normal coronary arteries are more often reported. 
Not all medication is safe during pregnancy, fetal and maternal risks have to be taken into 
account when medication is given. Pregnancy is not a contraindication for PCI anymore and 
this is probably the main reason maternal mortality has fallen recently. Very limited data is 
available on CABG during pregnancy, and it should only be considered when all other thera-
peutic options have failed. 
The delivery should be planned by a multidisciplinary team consisting of an obstetrician, 
anaesthesiologist and cardiologist. Women with adequate cardiac output may tolerate in-
duction of labour and vaginal delivery, but it is possible to create a potentially more stable 
environment during a caesarean section in high risk patients. Close monitoring in-hospital 
for at least one week after delivery is advised for patients with ACS in pregnancy.
Table 3. Oversight of different patient groups in ACS in pregnancy. 
Patient group Counselling First treatment 
choice
Maternal outcome Fetal outcome
Previous ACS Check medication Medication No data No data
ACS and impaired LV function Risk stratification Medication No data, high risk No data
ACS antepartum Not applicable PCI 9 % mortality 11 % mortality
ACS peripartum Not applicable PCI 18 % mortality 5 % mortality
ACS postpartum Not applicable PCI 9 % mortality No fetal mortality
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Chapter 13
A pregnant patient with native aortic coarctation 
and aneurysm, a case report.
TPE Ruys, JA Bekkers, JJ Duvekot, 
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KEywoRds
Aortic coarctation; pregnancy; thoracic aortic aneurysm
cAsEREPoRT
Aortic coarctation accounts for 6-9% of all congenital heart disease. In most cases aortic 
coarctation is discovered and treated during childhood. Uncorrected coarctation in adult 
patients is rare. In adult life uncorrected coarctation may lead to therapy resistant hyper-
tension.1 Retrospective observational studies showed hypertension and occasionally aortic 
dissection to be the principal risks during pregnancy after correction of aortic coarctation.2 
The risks of pregnancy in patients with uncorrected coarctation are largely unknown.
A 28-year-old pregnant lady presented at our outpatient clinic with severe hypertension at 32 
weeks of gestation. Two previous pregnancies had also been complicated by hypertension, 
but no diagnosis was made at that time. On physical examination we saw a healthy woman 
with blood pressure of 186/80 mmHg at the right and 126/65 mmHg at the left arm. The ECG 
showed left ventricular hypertrophy. Echocardiography showed an increased systolic veloc-
ity of up to 4 meters per second over the distal aortic arch and continuous antrograde flow 
throughout diastole. Furthermore, severe dilatation of the descending aorta, distal to the left 
subclavian artery was discovered. (Panel A and B). The X-ray showed rib notching and signs of 
an aortic aneurysm (Panel C). On MRI the diagnosis of native coarctation (minimal diameter 
of 0,8 cm) and a huge saccular aortic aneurysm of 4,5 x 8,8 cm was confirmed. An elective 
caesarean section under regional anesthesia was performed at 35 weeks of gestation and a 
healthy girl (2625 gram) was born. After delivery a CT-angiography was performed showing a 
stable situation (Panel D). Two months later successful resection of the aneurysm and aortic 
coarctation, with graft interposition was performed (Panel E and F). 
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Figure 1
Panel A Echocardiography: Descending aorta with diastolic runoff 
Panel B Echocardiography: Abdominal aorta with diastolic runoff 
Panel C Chest radiography showing rib notching and aortic aneurysm
Panel D 3D reconstruction of CT angiogram showing an aortic aneurysm of 4,5 x 8,8 cm
Panel E Photograph: The aneurysm during operation
Panel F Photograph: Graft interposition after operation
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discussion
No other pregnant patient with native coarctation and aortic aneurysm was described so far. 
Beauchesne described a series of 44 pregnancies in 16 patients with native coarctation. (3) 
Seven additional cases were published since 1990. 4-10 
Our patient was known with hypertension and the diagnosis was missed in an earlier stage. 
Diagnosis requires a high index of suspicion in young patients with hypertension. The arm-
leg blood pressure difference and a diastolic run off Doppler pattern in the abdominal aorta 
can easily unmask the diagnosis. Our case stresses the importance of thorough physical 
examination and echocardiography in young patients with hypertension. The latter should 
always include Doppler registration of the abdominal aorta. Timely diagnosis of coarctation, 
as the cause of hypertension, may prevent the occurrence of difficult late complications.
During pregnancy, due to hormonal changes, the aortic wall may become more vulnerable 
to dissection. 11 Choosing the optimal time and mode of delivery in this patient with na-
tive coarctation complicated by hugh aneurysm formation was difficult. We decided to plan 
caesarean section at 35 weeks, since this patient already had 2 successful pregnancies and an 
elective caesarean section was thought optimal with all specialists available. Although argu-
ments for immediate aneurysm resection after delivery were present, we choose to wait 2 
months to let the placenta bed recover, before performing surgery under full heparinisation. 
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Chapter 14
Growth in children of mothers with congenital heart 
disease.
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ABsTRAcT 
Aim 
To describe the growth of children born from mothers with congenital heart disease and 
to study if the children born small for gestational age remained small or showed catch-up 
growth. 
methods
Mothers participating in the ZAHARA I-study (focussing on cardiac and obstetric and neonatal 
outcome in patients with congenital heart disease) were asked to participate in this neonatal 
study. Growth data (height, weight and head circumference) of their children measured at 
standard intervals at the counselling centres were collected. These data were converted into 
a standard deviation by using Growth Analyser. 
Results 
The growth of 450 children was studied from birth to 2.5 years of age. At birth the children 
had a height and weight of 0.3 standard deviations smaller than of the normal population. 
Height, weight and head circumference showed some catch-up growth, mainly in the first 
6 month. Premature children showed slower and less catch-up growth. Of the small for 
gestational age children 87% reached normal values after 1 year. Children of mothers with 
complex heart disease had a smaller height and weight at birth. Children of mothers with 
complex heart diseas showed a similar growth pattern to premature children, their growth 
was slower and they remained smaller during follow-up. 
conclusion
Although children were born smaller than normal, most showed catch-up growth in the 
first 6 months of life, although premature children grew slower and remained smaller. Head 
circumference reached nearly normal values. Children of mothers with complex heart disease 
showed slower catch-up growth and remained smaller. 
Key words 
Pregnancy, heart disease, small for gestational age, premature, neonatal growth
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ABBREViATions
GGD = Dutch: Gemeenschappelijke GezondheidsDienst (Municipal Health service), 
SDS = Standard Deviation Score, 
SGA = Small for Gestational Age, 
ZAHARA = Dutch: Zwangerschap bij Aangeboren HARtAfwijkingen (Pregnancy and 
congenital heart abnormalities)
inTRoducTion
With the progress made in open heart surgery more and more women with congenital heart 
disease are reaching childbearing age and become pregnant. Although still rare in the ob-
stetric practice, these women now constitute the majority (>70%) of pregnant women with 
heart disease in the developed world.(1,2) These patients need careful attention as they are 
at risk of maternal mortality and morbidity.(3, 4) 
Studies on pregnancy in women with congenital heart disease have shown a high rate 
of preterm delivery and fetal mortality.(1,5,6) Fetal outcome was associated with maternal 
disease and problems during pregnancy.(6,7) More children were small for gestational age 
or had lower birth weight in babies from mothers with heart disease, especially when the 
mother had cyanotic heart disease.(5,8) How these outcomes influence the development of 
these children during their further life is important but until now not investigated.
There have been studies investigating growth patterns in preterm and small children from 
mothers with no heart disease. These studies show that most children show catch-up growth 
within the first year.(9,10) Children who do not show catch-up growth are at risk for short 
stature and neurodevelopmental disorders.(11)
The goal of this study was to describe the growth in children of mothers with congenital 
heart disease. We aimed to study if children born small for gestational age showed catch-up 
growth after birth. Furthermore, we were interested if there were predictors for neonatal 
growth, such as complexity of maternal disease and premature birth. 
mEThods
Patients
Previously we studied the outcome of women with congenital heart disease in the ZAHARA I 
study (NL26121.078.08). This is a multicenter retrospective clinical study in the Netherlands, 
collecting the data of women with congenital heart disease who became pregnant between 
1980 and 2007. The results of maternal and fetal outcome of this study have been published 
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previously.(6) In the current study we focus on the neonatal outcome of the babies born alive 
from the mothers with mild, moderate or complex congenital heart disease. In the Nether-
lands every child is prospectively followed in a nationwide standard program with check-ups 
every 4 weeks in the first four months, than every 8 weeks until the first year and every 3/6 
months thereafter until the age of 3 at special counselling centres everywhere in the country.
data
Height and weight data and head circumference values have been collected by contacting 
the mother, GGD (Dutch local authority of health care) and the counselling centres. In addi-
tion to growth parameters, we collected data on disorders and medication use of the child 
and the medical condition and medication use of the mother. All data have been collected 
with written informed consent of the parents. 
Birth weight was corrected for gestational age. Height, weight and head circumference 
were compared to the general Dutch population using the programme Growth Analyzer 
(version 35). For a precise interpretation of height, weight and head circumference standard 
deviation scores (SDS) were calculated and used for analysis. The average of the normal 
population lies on 0.0 SDS and the values for the normal limits lie between 2.0 and –2.0 SDS. 
Growth Analyser was not corrected for gestational age and starts to collect data from week 
1. Birth weight was corrected for gestational age. This creates a fictive difference between 
birth and week 1. Therefore in premature children birth weight was not used in the analysis. 
definitions
Small for gestational age: Height or weight or both height and weight at birth smaller than 
2,0 SDS of normal.(11) Catch up growth: Growth velocity (cm/y) greater than the median for 
chronologic age and gender.(12,13) Premature birth was defined as birth before 37 weeks of 
gestation. 
statistical analysis
Categorical data were presented as frequencies (numbers) and percentages. Normally distrib-
uted continuous data were presented as mean values ± one standard deviation (SD), whereas 
data which were not normally distributed were presented as medians with interquartile range 
(IQR). Unless specified otherwise, p-values <0.05 (2-sided test) were considered statistically 
significant. 
To account for the correlation in the measurements take from the same child we performed 
a repeated measurements analysis for each parameter using linear mixed effects models.(14) 
Due to the fact that the evolution of each parameter during pregnancy may be nonlinear, we 
used in our model specifation regressions splines (in particular natural cubic splines) for both 
the fixed- and random effects parts, allowing thus for nonlinear patient-specific trajectories. 
The models assumptions were validated using residuals plots. 
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To assess the strength of the association between the maternal and fetal risk factor and 
growth we fitted for each parameter linear mixed models that allowed for different, possi-
bly nonlinear, average longitudinal evolutions per risk factor. All these analyses have been 
controlled for baseline differences in maternal and paternal weight and height. To account 
for the fact that each risk factor is tested three times (i.e., for each parameter) we adjusted 
p-values using Holm’s method. All statistical analyses were performed using SPSS 20.0 (SPSS 
Inc., Chicago) or in R version 2.15.1 (2012-06-22) using package nlme (version 3.1-105).
REsuLTs
In this study 246 women agreed to participate with a total of 450 pregnancies. The growth 
of these 450 children was studied. Mean number of measurements was 13.3 (±3.4) per child. 
Mean follow up time was 3.3 years (± 1.29).
Table 1. Type of heart disease of the mother
Number of 
patients
Percentage of total 
patients
Atrial septal defect 66 15%
Pulmonary valve stenosis 62 14%
Aortic coarctation 50 11%
Tetralogy of Fallot 42 9.3%
Ventricular septal defect 42 9.3%
Aortic stenosis* 38 8.4%
Complete transposition of the great arteries (atrial switch) 32 7.1%
Marfan syndrome 16 3.5%
Pulmonary atresia 10 2.2%
Right ventricular outflow tract obstruction 9 2%
Mitral regurgitation 8 1.8%
Congenital corrected transposition of the great arteries 6 1.3%
Morbus Ebstein 6 1.3%
Persistant ductus arteriosus 5 1.1%
Pulmonary hypertension 3 0.7%
Double outlet right ventricle 3 0.7%
Atrioventricular septal defect 2 0.4%
Congenital complete heart block 2 0.4%
Other 8 1.8%
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Baseline characteristics of the parents
Type of heart disease of the mother is described in table 1. Simple congenital heart disease 
was present in 28%, moderately complex in 59% and complex heart disease in 13%. Mean 
maternal height was 170 cm (±6.9) and weight 70 kg (±12.5). Mean paternal height was 182 
cm (±7.9) and weight 86 kg (±15). This was comparable to the normal Dutch population.(15)
Baseline characteristics of the children
Mean pregnancy duration was 38 weeks (±7.7) and 8.7% of the children (54% male) was 
born premature. In total 13.3% of the children had a disease or abnormality: 4% a cardiac 
abnormality (e.g. Marfan syndrome, atrial septal defects or aortic coarctation), 2% some kind 
of psychiatric disorder (mainly autism spectrum) and 1% had asthma. Medication was used 
by 12.4% of the children, mostly inhalation (e.g. ventolin, flixotide) or ADHD medication. 
overall growth 
At birth children of mothers with heart disease had a height and weight of 0.4 standard 
deviation smaller than expected. As can be seen in figure 1, height-, weight- and head 
circumference growth showed catch–up growth, mainly in the first 6 months. Both weight 
and height stabilised after the first year. After this period children showed a growth pattern 
similar to the normal population. 
Growth was comparable in male and female (p=0.75) children. No significant difference 
was found between children with or without a disease (weight growth p=0.24 and height 
growth p=0.25) and between children with or without medication (p=1.0). 
growth in premature children
At the first measurement. 2 weeks after birth. weight. height and head circumference were 
2.0 SDS smaller in premature children compared to children in the normal population. As 
shown in Figure 2 premature children showed fast catch-up weight growth in the first month. 
Height growth of these children took a bit longer, up to 1 year. Head circumference showed 
some catch-up growth until 1 year. The growth was different from that in children not born 
premature (p<0.001). After 2.5 years they remained 1.0 SDS smaller than expected. 
small for gestational age
In total 23 children were born small for gestational age (SGA), of which 8 had a small height, 
12 a low weight and 3 had both small height and weight. Five of the 23 children were both 
small for gestational age and born premature. Of these 23 children 87% showed catch up 
growth to > -2 SDS, of which 89% within the first 6 month and the other 11% within 2 years. 
In total 18 children (4%) had a small head circumference and of these, 16 showed catch-up 
growth, while in the two others only one measurement was available. 
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Figure 1. Overall height, weight and head circumference growth in children of mothers with congenital 
heart disease.
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Figure 2. Height, weight and head circumference growth of premature children and non premature 
children. 
Growth in children of mothers with congenital heart disease 235
Figure 3. Height, weight and head circumference growth of the children divided per maternal complexity 
of congenital heart disease. 
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growth in different complexity of maternal heart disease 
Baseline characteristics of children per complexity of maternal heart disease are shown in 
table 2. Figure 3 shows birth weight in relation to severity of maternal heart disease. All 
growth parameters (weight, height and head circumference) were statistically different 
between the groups of disease complexity in the mother (p<0.002). Children of mothers with 
simple heart disease started almost at a normal weight and height and these children grew 
within the first 6 month towards the expected values. Children of mothers with moderate 
complex heart disease started at 0.5 SDS smaller than normal. These children showed catch-
up growth within the first 6 month, but remained slightly smaller than normal after 2.5 years. 
Children of mothers with complex heart disease had a 1.5 SDS smaller weight, height and 
head circumference at birth. After birth these children showed catch-up weight growth in 
the first month of life. But height growth took longer and looked similar to the pattern of 
premature children with slower catch-up growth until 1 year. In these children there was a 
strong catch-up growth of head circumference. After the first year these children remained 
growing at 0.5 SDS under the normal growth curve. 
discussion
Children of mothers with congenital heart disease are born smaller and more often born 
small for gestational age and/or prematurely.(1,6) In this large cohort most children did 
show catch-up growth in the first 6 months of life. However. especially premature babies 
and babies from mothers with more complex heart disease showed slower growth and they 
remained smaller than expected.
overall growth 
In the first 6 months height, weight and head circumference clearly showed catch–up growth 
as shown in figure 1. After one year both height growth and weight growth stabilised and 
reaches nearly normal values. This catch-up growth is probably an indication for beneficial 
Table 2. Baseline characteristics of children divided per complexity of congenital heart disease of the 
mother
Simple Moderately complex Complex p value
Number of children (n) 126 226 58
Male (%) 49.2 54.5 65.5 0.119
Child with disease (%) 3.2 8.3 10.3 0.058
Child with medication (%) 7.9 13.2 19 0.094
Premature (%) 6.1 9.4 25 0.002
Median gestational age (IQR) 40 (38-40) 40 (38-40) 39 (36-40) 0.085
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long-term outcomes. In different populations it has been shown that low birth weight or be-
ing small for gestational age is associated with a wide range of metabolic disorders including 
hypertension, obesity and cardiovascular disease later in life.(15,16,17) It will therefore be of 
interest to study this population further. As surgical repair is only available since the 1960’s, 
most mothers and therefore especially their children are just reaching middle age. 
growth in premature children
Premature children showed catch-up height growth around half a year later than non-
premature children in this cohort and premature children remained smaller than the normal 
population. Gibson et al described impairment in growth in premature children of normal 
mothers, with children remaining having a short length after 60 months. He hypothesised 
that this impaired catch up growth was long lasting, thereby causing children to remain 
smaller than others.(9)
small for gestational age
Various factors are associated with SGA children such as fetal syndromes, fetal cardiac ab-
normalities, maternal hypertension or maternal cyanosis.(13) In our study almost all children 
born small for gestational age showed catch-up growth to normal limits for weight and 
height mainly in the first 6 months. Similar catch-up growth has been described in studies of 
children from “healthy” mothers.(10,11,13) A study by Casey et al showed that the absence 
of catch-up growth within the first 2 years was associated with short stature and a lower 
Intelligence Quotient at 8 years of age. In their study no difference was found in behavioural 
status or general health status between children with and without failure to thrive.(19) In a 26 
years follow-up study by Strauss no differences were found in employment, marital status, or 
satisfaction with life between SGA children and healthy controls.(20) To confirm his findings 
we would need a prospective follow-up study in the children of our patient with congenital 
heart disease.
growth in different complexity of maternal heart disease 
Previous studies have shown that fetal growth and birth weight are associated with the type 
of maternal cardiac disease.(7,8,9) In one study the presence of maternal cyanosis and a 
reduced cardiac output were the most significant predictors for reduction in fetal growth 
rate.(9) We showed that this influence remains visible after birth, with large differences in 
growth between different complexities of heart disease. Children of mothers with mild and 
moderate complexity showed comparable growth patterns. Although they were born slightly 
smaller than normal, both groups showed catch-up growth in the first half year until nearly 
normal values. A quarter of the children of mothers with complex heart disease were born 
premature. Children of mothers with complex heart disease showed slower catch-up height 
growth and remained smaller than the normal population. This strengthens the hypothesis 
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that maternal heart disease has a long-lasting effect on the child. Head circumference was 
also smaller, but showed remarkable catch-up growth until nearly normal values. Whether 
this results in normal intelligence development is unclear. To study this further and confirm 
our current results a prospective case-control study with longer follow-up is indicated.
study limitations
Since this study was done only in the Netherlands data may not be representative for other 
countries. The analyses have not been corrected for some factors which have been described 
to have influence on birth weight, such as smoking, caffeine intake, pre-eclampsia and diabe-
tes since information concerning these factors were not collected. Some data were missing 
(9%). By using a linear mixed model, which takes missings into account in the analysis, this 
will probably have had no major effect on the growth curves. 
concLusion
This large retrospective cohort study assessed child growth of mothers with congenital heart 
disease. Although children were born slightly smaller than normal, most showed catch-up 
in the first 6 months of life. Catch-up growth was slower in premature children and these 
children remained smaller after 2.5 years with consequently worse long term prospective. 
Almost all children small for gestational age showed catch-up growth in the first 6 months. 
Complexity of maternal heart disease had a long lasting influence on growth, as children of 
mothers with complex heart disease showed slower catch-up growth and remained smaller. 
Whether the lower birth weight and catch-up growth are predictors of metabolic disorders or 
lower intelligence later in life in this population remains to be studied. 
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sAmEnVATTing
In dit proefschrift richt ik mij op de groeiende groep van volwassenen met een aangeboren 
hartafwijking. Vaak wordt de diagnose “aangeboren hartafwijking” al op jonge leeftijd gesteld 
en zijn op de kinderleeftijd al één of meerdere operaties uitgevoerd. Sommige kinderen zijn 
na één ingreep volledig genezen, maar de meesten hebben nog restafwijkingen, variërend 
van een lekkende hartklep tot hartfalen of ritmestoornissen. Velen hebben een nieuwe 
ingreep nodig op volwassen leeftijd. Weinig is nog bekend over de uitkomsten in de verschil-
lende periodes van operatie en weinig is nog bekend over het verloop van een zwangerschap 
bij mensen die zelf een hartafwijking hebben. Zwangerschap met een hartafwijking heeft 
impact op zowel de moeder als op het kind. Deze twee thema’s vormen het onderwerp van 
mijn onderzoek waarvan ik de resultaten in dit proefschrift heb beschreven. Hieronder vat ik 
de verschillende hoofdstukken kort samen.
dEEL i VoLwAssEnEn mET EEn AAngEBoREn hARTAFwijKing
studie naar lange termijn uitkomsten 
In 1968 vond in Rotterdam de eerste open hart operatie plaats met behulp van de hartlong-
machine. Het eerste cohort patiënten, geopereerd in Rotterdam tussen 1968 en 1980, werd 
uitgebreid cardiologisch en psychologisch onderzocht in 1990 en 2001. De resultaten van dit 
onderzoek werden eerder gepubliceerd en het leidde tot vier proefschriften1,2,3,4. De patiënten 
werden bestudeerd met een elektrocardiogram (ECG), een 24-uur ECG (Holter monitoring), 
een fietstest en een echocardiogram. Tevens ondergingen de patiënten een 2.5 uur durend 
psychologisch onderzoek waarbij verschillende gestandaardiseerde vragenlijsten werden 
afgenomen. 
In 2009 hebben wij eenzelfde onderzoek uitgevoerd maar nu bij de patiënten die 
geopereerd zijn tussen 1980 en 1990: het tweede cohort. Daarbij gebruikten wij dezelfde 
onderzoekmethode, zodat we de uitkomsten van de patiënten geopereerd tussen 1968 en 
1980 konden vergelijken met patiënten geopereerd tussen 1980 en 1990. Het idee achter 
de vergelijking van deze twee cohorten was dat de overleving, de cardiale functie en het 
psychologisch welbevinden zouden zijn verbeterd, aangezien de chirurgische techniek, de 
postoperatieve zorg en de begeleiding van de ouders zijn verbeterd in de loop van de tijd. 
In dit proefschrift bespreken we de resultaten van twee groepen patiënten, namelijk die 
met een transpositie van de grote vaten en patiënten met een tetralogie van Fallot, en we 
vergelijken de uitkomsten van het eerste cohort met die van het tweede cohort. Bij beide 
cohorten vond het na-onderzoek 25 jaar na de correctieve operatie plaats.
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Transpositie van de grote vaten
Bij patiënten met een transpositie van de grote vaten zijn bij de geboorte de lichaams-
slagader (aorta) en de longslagader (arteria pulmonalis) verwisseld. In de eerste twee dagen 
na de geboorte worden deze kinderen cyanotisch (blauw). Zonder ingrijpen van de chirurg 
sterven ze meestal in het eerste levensjaar, dus vóór 1968 waren er weinig kansen voor deze 
kinderen. 
In de eerste chirurgische periode (1968-1980) kregen patiënten eerst een shunt van de 
aorta naar de arteria pulmonalis. Later in het leven kregen deze kinderen een hartoperatie, 
de Mustard of Senning procedure. Tijdens deze operatie wordt chirurgisch een verbinding 
aangelegd om het zuurstofrijke bloed naar het lichaam te laten stromen. Dit gebeurt door 
een verbinding op boezemniveau te maken. De rechterhartkamer is hierbij de systemische 
kamer, dat wil zeggen dat hij hoge druk moet opbouwen om het bloed naar de hoge druk in 
de lichaamscirculatie te pompen. De rechter hartkamer bleek hier op lange termijn niet goed 
aan te kunnen voldoen en ging uiteindelijk falen.
In de loop van de 80-er jaren worden de meeste kinderen op nog jongere leeftijd, vrij-
wel direct na de geboorte, geopereerd. Vanaf deze periode worden de arteria pulmonalis 
(longslagader) en aorta (grote lichaamsslagader) teruggedraaid in plaats van de omleiding 
op boezemniveau. Bij deze zogenaamde “Arteriële Switch Operatie” (ASO) moeten wel de 
kransslagaderen (coronairen) opnieuw geïmplanteerd worden. In onze studie (hoofdstuk 2) 
tonen we aan dat de patiënten geopereerd met een ASO een betere lange termijn overleving 
hebben. De re-operatie/re-interventie vrije overleving na 25 jaar is 77% na ASO ten opzichte 
van 44% na een Mustard operatie (p=0.04). Wel zien we dat de patiënten met een ASO soms 
een her-operatie nodig hebben voor vernauwing van de arteria pulmonalis. Ook heeft 21% 
van de ASO patiënten een licht tot matig lekkende aortaklep, terwijl dit slechts bij 16% van 
de Mustard patiënten wordt gevonden (p=0.31). Na vijfentwintig jaar blijkt de pompfunctie 
van de systeem linker kamer goed te functioneren in 93% van de ASO patiënten, terwijl na 
de Mustard operatie de functie van de systeem rechter kamer maar in 6% van de patiënten 
goed blijft (p<0.01). Dit is dus een enorme verbetering. Aangezien een aantal patiënten met 
een ASO toch restafwijkingen hebben en de toekomst nog grotendeels onbekend is, is het 
belangrijk ook deze patiënten levenslang te blijven volgen.
Tetralogie van Fallot
Patiënten met een Tetralogie van Fallot (ToF) worden geboren met een aanlegstoornis die 
leidt tot een viertal hartafwijkingen: 1) de aorta (lichaamsslagader) staat zowel boven de 
rechterkamer als boven de linkerkamer, 2) er is een gat in het tussenschot van de kamers, 3) 
er is een vernauwing van de arteria pulmonalis (longslagader) en 4) de rechterkamerwand 
is verdikt. In de zeventiger jaren werd vaak eerst een shunt geplaatst tussen de aorta en de 
arteria pulmonalis. Bij de correctieve operatie werd vervolgens het eerste deel van de arteria 
Summary/ Samenvatting 247
pulmonalis verwijd, het obstruerend myocard (spier) weefsel uit de rechterkamer uitstroom-
baan verwijderd en het gat tussen de twee kamers gesloten. 
In de jaren tachtig opereerde men de patiënten op jongere leeftijd, waardoor een shunt 
niet nodig was. Relatief werd er vaker een transannulaire patch geplaatst ter hoogte van de 
pulmonalis klep. Onze studie, waarin we opnieuw een vergelijking maken tussen het eerste 
cohort patiënten, geopereerd in de 70-er jaren (ToF70), en het tweede cohort, geopereerd 
in de 80-er jaren (ToF80), lijkt een trend te laten zien dat de sterfte in de eerste dertig dagen 
na de operatie is verminderd in het tweede chirurgische cohort (p=0.098) (hoofdstuk 3). De 
vijfentwintig jaars overleving na succesvolle operatie is 93% voor ToF70 en 98% voor ToF80 
(p=0.22). ToF80 patiënten hebben minder vaak een verwijde aortawortel en een verwijde 
linkerkamer. Verder blijkt aorta insufficiëntie aanwezig in 21.1% van de ToF70 patiënten en in 
7.5% van de ToF80 patiënten (p<0.001). Dit zijn allemaal gunstige ontwikkelingen. Wel blijkt 
dat patiënten uit ToF80 die een transannulaire patch hebben, vaker een pulmonalis klep 
vervanging nodig hebben. Ook lijkt de rechterkamer van patiënten geopereerd in de jaren 
tachtig vaker een verminderde functie te hebben. Samenvattend kunnen we vaststellen dat 
er verbeteringen en verslechteringen zijn in het tweede cohort vergeleken met het eerste 
cohort. Dit geeft aanleiding om de chirurgische techniek verder onder de loep te nemen en 
waar mogelijk aan te passen. Vooral het gebruik van de transannulaire patch lijkt nadelen te 
hebben en mogelijk geeft een kleinere patch betere lange termijn uitkomsten. Dit zal in een 
nieuwe studie moeten worden onderzocht.
Psychologische functie 
In hoofdstuk 4 laten we zien dat patiënten met een transpositie van de grote vaten geopereerd 
met de nieuwere techniek (ASO) beter scoren op psychologische functie, gemeten met de 
zogenaamde SF36, een gestandaardiseerde vragenlijst, in vergelijking met dezelfde meting 
na de Mustard operatie en zelfs beter dan gezonde “controle” proefpersonen. Arteriële switch 
(ASO) patiënten hebben een significant betere score vergeleken met Mustard patiënten in 
de subdomeinen fysiek functioneren (p<0.01), algemeen welbevinden (p=0.04) en vitaliteit 
(p=0.04). Arteriële switch patiënten hebben een significant hogere score vergeleken met 
gezonde proefpersonen in de subdomeinen fysiek functioneren, vitaliteit en beperkingen 
door emotionele problemen (p<0.01). Een mogelijke oorzaak hiervan zou overcompensatie 
kunnen zijn, dit is een beschreven coping strategie bij patiënten met een aangeboren hart-
afwijking. Daarbij is beschreven dat patiënten die lang leven met een ziekte zich gelukkiger 
voelen, omdat ze al zoveel problemen hebben doorstaan. 
Bij patiënten met Tetralogie van Fallot blijkt geen duidelijk verschil in psychologisch 
functioneren tussen patiënten in het eerste en het tweede cohort. Vergeleken met gezonde 
patiënten scoren Fallot patiënten minder goed op fysiek functioneren. Dit zou het gevolg 
kunnen zijn van ziektebesef in het dagelijks leven. Ze scoren echter beter op sociaal functi-
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oneren. Daarnaast hebben ze minder gedragsproblemen zoals angst en agressie. Ze voelen 
zich niet beperkt in sociaal en mentaal functioneren. 
dEEL ii ZwAngERschAP Bij VRouwEn mET EEn hARTAFwijKing.
Veranderingen in het hart tijdens de zwangerschap
In hoofdstuk 6 beschrijven we de veranderingen van het hart tijdens een zwangerschap 
bij vrouwen met een hartafwijking, gemeten door middel van echocardiografie. In eerdere 
echocardiografische studies worden gezonde vrouwen bestudeerd. Deze studies tonen aan 
dat er een toename optreedt van hartspierweefsel en van het volume bloed dat per minuut 
door het hart wordt uitgepompt: het hart minuut volume. Tevens wordt in deze studies 
aangetoond dat alle veranderingen ongeveer drie tot twaalf maanden na de zwangerschap 
normaliseren, afhankelijk van het wel of niet geven van borstvoeding.
In onze studie beschrijven wij de cardiale verandering van 35 vrouwen met een hartaf-
wijking. Daarbij tonen wij aan dat in sommige gevallen linker ventrikel dilatatie optreedt. 
Dit negatieve effect blijft bestaan na de zwangerschap. Verder tonen we een toename van 
hart minuut volume aan zoals ook bij gezonde zwangere vrouwen wordt gezien. Bij de 
hartpatiënten wordt deze toename echter in mindere mate veroorzaakt door een stijging 
in hartfrequentie en meer door het slagvolume. Tevens tonen we een toename aan van 
diastolische dysfunctie met een toename van E/E’ ratio.
Hieruit kunnen we concluderen dat de veranderingen van het hart tijdens de zwanger-
schap bij vrouwen met een hartafwijking anders verlopen dan bij gezonde vrouwen. Dit is 
een kleine studie. Het is van belang deze resultaten te bevestigen met een grotere studie en 
dit inzicht vervolgens te gebruiken om beter te bepalen welke vrouwen het grootste risico 
lopen tijdens de zwangerschap. 
Risico inschatting van vrouwen die zwanger willen worden
Het is van belang voor een cardioloog om tijdig te weten of een patiënt zwanger wil worden, 
zodat er tijdig verdere onderzoeken kunnen worden gedaan. Daarna kan goede informatie 
worden gegeven over de eventuele risico’s van een zwangerschap voor de individuele pa-
tiënt. Het is van belang een inschatting te kunnen maken welke patiënten een hoog risico 
hebben op complicaties tijdens de zwangerschap. Als dit risico voor moeder of kind sterk is 
verhoogd, kunnen eventueel extra maatregelen worden genomen. Ook kan doorverwezen 
worden naar een centrum met speciale expertise of kan het zelfs nodig zijn een zwanger-
schap af te raden. 
In hoofdstuk 7 vergelijken we verschillende risicomodellen die verschillende predictoren 
hebben onderzocht om te kunnen voorspellen welke patiënten een verhoogd risico hebben. 
De volgende 5 modellen zijn vergeleken: Khairy, Siu (CARPREG), de Zahara onderzoekers, 
Summary/ Samenvatting 249
ziektecomplexiteit score en de WHO risico categorieën. Daarbij maken we gebruik van de 
oppervlakte onder de curve van de “receiver-operating characteristic curve”, waarbij 1 de 
optimale waarde aangeeft. Voor ZAHARA I was de waarde 0.73, voor CARPREG 0.62, voor 
WHO 0.79 en voor ziekte complexiteit score 0.64. Van al deze modellen blijkt de WHO risico 
categorie het best te voorspellen welke patiënten een complicatie zouden kunnen krijgen. 
Een combinatie van de WHO en ziekte complexiteit score, geeft de hoogste waarde van 0.82.
uitkomst van zwangerschap bij vrouwen met een hartafwijking (resultaten van 
de RoPAc)
Professor Roos-Hesselink en Professor Hall hebben in 2007 met hulp van de Europese ver-
eniging voor Cardiology (ESC) een grote internationale zwangerschap registratie geïnitieerd. 
In deze digitale registratie, de Registry Of Pregnancy And Cardiac disease (ROPAC), worden 
vanuit de hele wereld patiënten ingevoerd. In hoofdstuk 8 beschrijven we de analyses 
uitgevoerd op 1321 patiënten die in deze registratie zijn opgenomen in 2011. De meeste 
patiënten hebben een aangeboren hartafwijking (66% van de patiënten), anderen hebben 
een klepafwijking (25% van de patiënten), cardiomyopathie (ziekte van de hartspier, 8% van 
de patiënten) of een ischemische hartziekte (hartinfarct, 1.9% patiënten). 
In totaal overleed 1 op de 100 hartpatiënten tijdens of vlak na de zwangerschap, dit is 
100 keer zo veel als in de gezonde bevolking. Ook blijkt de sterfte van het ongeboren kind 
4 keer hoger dan verwacht. Deze studie toont daarnaast aan dat de kans op complicaties bij 
patiënten die in ontwikkelingslanden wonen nog eens extra is verhoogd. Dit kan worden 
verklaard uit het feit dat in deze landen ziekere vrouwen (vaak tegen advies van de dokter in) 
zwanger worden. Dit is mede cultureel bepaald, de maatschappelijke status is afhankelijk van 
het krijgen van een kind. Uit deze studie blijkt dat patiënten met een aangeboren hartafwij-
king relatief minder complicaties hebben dan patiënten met andere typen hartafwijkingen 
zoals kleplijden of cardiomyopathie. Patiënten met cardiomyopathie ontwikkelen het meest 
hartfalen tijdens de zwangerschap. 
Bevalling bij vrouwen met een hartafwijking (RoPAc)
Relatief vaak (42%) bevallen vrouwen met een hartafwijking door middel van een keizer-
snede. In hoofdstuk 9 laten wij zien dat dit zowel om obstetrische als om cardiale redenen 
wordt gedaan. Vrouwen met een cardiale reden voor een keizersnede hebben een relatief 
hoog cardiaal risico profiel (volgens de WHO categorieën). Deze patiënten hebben tevens 
vaker hartfalen na de bevalling. Er is geen verschil in uitkomst gevonden tussen patiënten 
die een geplande en zij die een spoed keizersnede ondergaan. De kinderen geboren met een 
keizersnede worden relatief vaak vroeg geboren (vóór 37 weken) en hebben vaker een laag 
geboorte gewicht (onder 2500 gram).
Er is een groot verschil tussen de diverse landen in het toepassen van de keizersnede. Dit 
verschil zien we ook bij gezonde vrouwen. Daarnaast kan dit gebruik van de keizersnede 
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verklaard worden door het aantal vrouwen met een ernstige vorm van hartziekte. Conclusie 
is dat het aantal complicaties in de eerste dagen na de bevalling niet afhankelijk is van de 
manier van bevallen maar eerder van de ernst van de hartafwijking bij de moeder. Problemen 
bij het kind, zoals vroeggeboorte en laag geboorte gewicht, komen wel vaker voor na een 
bevalling door middel van een keizersnede. 
medicijngebruik bij vrouwen met een hartafwijking (RoPAc)
In deze sub-studie van de ROPAC tonen we aan dat ongeveer 33% van de vrouwen met een 
hartafwijking op enig moment tijdens de zwangerschap medicijnen gebruikt. Dit is hoger 
dan verwacht. In hoofdstuk 10 vergelijken we de uitkomsten van vrouwen met en zonder 
medicijngebruik tijdens de zwangerschap. 
We tonen aan dat medicijngebruik bij vrouwen met een hartafwijking tijdens de zwanger-
schap vaak ongunstige gevolgen heeft voor het kind (zoals vroeggeboorte, laag geboorte-
gewicht, foetale sterfte of kindersterfte in de eerste 30 dagen). Na correctie voor bekende 
risicofactoren (zoals roken, suikerziekte en preeclampsie) en cardiale risicofactoren (ernst 
van de hartafwijking en hartfalen tijdens de zwangerschap) concluderen we dat de kans 
op een ongunstige uitkomst voor de baby 2,4 keer zo hoog is bij vrouwen die medicijnen 
gebruiken tijdens de zwangerschap. Zo tonen we ook aan dat het gebruik van zogenaamde 
“betablokkers” (medicijnen die de hartslag en bloeddruk verlagen) gepaard gaat met een 
geboortegewicht van gemiddeld 100 gram lager. Dit is vergelijkbaar met het effect van roken 
tijdens de zwangerschap. 
De vraag blijft of het de medicatie is die deze ongunstige effecten veroorzaakt, of dat 
patiënten die medicatie gebruiken tot de ziekere groep van patiënten behoort. De toekomst 
moet uitwijzen in hoeverre een laag geboorte gewicht en vroeggeboorte daadwerkelijk 
nadelige gevolgen hebben voor het kind op de lange termijn. 
hartfalen tijdens de zwangerschap (RoPAc)
In hoofdstuk 11 beschrijven we in een substudie van de ROPAC, hoe vaak hartfalen optreedt 
tijdens de zwangerschap bij vrouwen met een hartafwijking. Hartfalen tijdens de zwanger-
schap uit zich in kortademigheid en het vasthouden van vocht. In de ROPAC is hartfalen de 
meest voorkomende complicatie, namelijk in 13% van de gevallen. In de literatuur wordt niet 
eerder beschreven op welke momenten tijdens de zwangerschap de kans op hartfalen het 
hoogst is. Meestal wordt aangenomen dat dit vooral is rond de bevalling. In onze studie laten 
we zien dat er twee pieken zijn, één rond de 25 weken (vooral bij klep- en shuntafwijkingen) 
en één rondom de bevalling (vooral bij vrouwen met cardiomyopathie en ischemische hart-
ziekte). 
Specifieke voorspellers voor hartfalen zijn: klachten van hartfalen voor de zwangerschap, 
pulmonale hypertensie, cardiomyopathie en score >2 bij WHO risico inschatting of NYHA 
klasse. Patiënten met zwangerschapsvergiftiging (pre-eclampsie) hebben een sterk verhoog-
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de kans om ook hartfalen te ontwikkelen en dienen dan ook extra in de gaten gehouden te 
worden en zo nodig opgenomen te worden in het ziekenhuis. Patiënten met hartfalen heb-
ben relatief vaak kinderen die ofwel te vroeg worden geboren of een laag geboortegewicht 
hebben. 
Acuut coronair syndroom (Acs) en zwangerschap
In hoofdstuk 12 geven wij een samenvatting van de literatuur over patiënten met een hartin-
farct voor of tijdens de zwangerschap. Allereerst beschrijven wij de literatuur over patiënten 
die voor de zwangerschap een hartinfarct hebben gehad en die zwanger willen worden. Als 
de linker ventrikel goed werkt, is het niet nodig een zwangerschap af te raden. Wel moet 
de bestaande medicatie tevoren goed in kaart worden gebracht om te beoordelen of de 
medicijnen schadelijk zijn voor het ongeboren kind. Deze medicijnen kunnen dan, wanneer 
mogelijk, gestopt worden en vervangen worden door andere medicijnen die veilig zijn. Of de 
dosis kan worden aangepast. Er is in de literatuur weinig bekend over de kans op herhaling 
van een hartinfarct tijdens een zwangerschap. Meer onderzoek is zeker nodig op dit gebied.
Daarnaast beschrijven wij de klachten, de risicofactoren en de diagnose van een hartinfarct 
tijdens de zwangerschap. Hartinfarcten tijdens de zwangerschap komen steeds vaker voor. 
Enerzijds door toename van cardiale risicofactoren zoals roken en overgewicht. Anderzijds 
doordat de gemiddelde leeftijd waarop vrouwen zwanger worden de laatste jaren is toe-
genomen. Tenslotte is de diagnostiek van het hartinfarct verder aangescherpt mede door 
de introductie van gevoelige markers zoals troponine. Als een hartinfarct optreedt tijdens 
de zwangerschap, is dat vooral in het laatste trimester van de zwangerschap. Aangezien 
klachten van kortademigheid en pijn op de borst (bij maagzuur) ook kunnen voorkomen bij 
een gezonde zwangerschap, worden hartklachten niet altijd onderkend. Er is een verhoogde 
kans op moedersterfte bij de vrouwen die tijdens de zwangerschap een hartinfarct door-
maken. Deze sterfte bij vrouwen is de laatste jaren sterk gedaald door tijdige interventie, 
vooral tijdens de bevalling. Bij tekenen van een acuut hartinfarct op het ECG bij een zwan-
gere patiënt dient men in principe hetzelfde te handelen als bij niet zwangere patiënten: een 
catheterisatie met zo nodig stenting. Bij deze patiënten heeft echter een bare metal stent 
de voorkeur boven een drug eluting stent. Een drug eluting stent wordt vaak geplaatst bij 
andere patiënten met een hartinfarct, maar daarbij moet de patient 6 tot 12 maanden spe-
ciale bloedverdunnende medicijnen (clopidogrel of prasugrel) nemen. Van clopidogrel en 
prasugrel is geen informatie bekend over de mogelijke nadelige effecten op de baby, zoals 
teratogeniteit. Daarom worden deze medicijnen bij voorkeur niet gegeven. 
Patiënt casus 
In hoofdstuk 13 presenteren we een casus van een zwangere patiënt die in het Erasmus Me-
disch Centrum werd behandeld. Ze was 32 weken zwanger van haar 3e kind en presenteerde 
zich met hoge bloeddruk en kortademigheid bij inspanning. Ze had een bloeddrukverschil 
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tussen haar rechter en linker arm en er werd een geruis gehoord. Dit is het beste te horen op 
de rug. Met echo en MRI werd een ongecorrigeerde coarctatio aorta (vernauwing van de grote 
lichaamsslagader) in beeld gebracht. Daarnaast bleek ze een groot aneurysma (verwijding 
van 8 bij 4 cm) van de aorta descendens te hebben. Dit is een levensbedreigende situatie.
Zij zou, als zij niet zwanger was geweest, meteen worden geopereerd. Echter gezien haar 
gevorderde zwangerschap, werd na uitgebreid overleg met de aanstaande ouders besloten 
te wachten tot na de geboorte. Ze werd met regelmaat gecontroleerd en er werd bij 35 we-
ken zwangerschap een keizersnede gedaan. Direct postpartum is een operatie een te groot 
risico vanwege bloedingsgevaar. Daarom werd zij pas 2 maanden later geopereerd. Deze 
casus presenteren we omdat niet eerder in de literatuur een patient is beschreven die zich 
presenteert met een natieve coarctatio en aneurysma van de aorta. Gelukkig maken moeder 
en kind het goed. 
dEEL iii KindEREn VAn moEdERs mET EEn hARTAFwijKing.
In eerder onderzoek is aangetoond dat moeders met een hartafwijking vaker kinderen met 
een laag geboortegewicht krijgen of vaker vóór 37 weken zwangerschap bevallen. De onder-
zoeksvraag van de studie, beschreven in hoofdstuk 14, is of kinderen inhaalgroei laten zien. 
Een tweede vraag is of er verschil is in de uitkomst van de gezondheid van de kinderen als de 
moeders een meer of minder ernstige en meer complexe hartafwijking hebben. 
Aangezien we in een eerdere studie de uitkomsten van moeders met een hartafwijking 
hebben onderzocht, konden we deze moeders vragen of we de groeigegevens van hun 
kinderen mochten gebruiken. De meetgegevens van het consultatiebureau werden via 
de ouders verkregen. Met een speciaal groeiprogramma, de “Growth analyser”, worden de 
gegevens vergeleken met de groei van kinderen van moeders zonder hartafwijking. 
We hebben laten zien dat kinderen van moeders met een hartafwijking in het eerste half 
jaar duidelijk inhaalgroei laten zien. Daarna zijn de kinderen bijna net zo groot als kinde-
ren van gezonde moeders. Na een jaar stabiliseert de groei en groeien ze net zoals andere 
kinderen. Kinderen van moeders met een complexe hartafwijking zijn bij de geboorte een 
stuk kleiner dan kinderen van moeders met een simpele afwijking. Deze kinderen laten meer 
inhaalgroei zien, ze blijven echter na een half jaar kleiner dan de andere kinderen. 
Of de inhaalgroei van de kinderen van moeders met een hartafwijking enkel een positief 
teken is, blijft de vraag. In studies naar inhaalgroei is aangetoond dat op lange termijn snelle 
inhaalgroei hormonale veranderingen met zich mee brengt. Als gevolg daarvan hebben deze 
kinderen op volwassen leeftijd mogelijk meer kans op hart- en vaatziekte. Hart- en vaatziek-
ten presenteren zich vaak pas later, vanaf het vijftigste levensjaar. Of kinderen van moeders 
met een hartafwijking ook vaker hart en vaatziekten krijgen blijft dan ook vooralsnog een 
vraag.
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PART i AduLT congEniTAL hEART disEAsE
study of long-term outcome
Since the introduction of cardiothoracic surgery in Rotterdam, the long-term outcome of sur-
gical procedures in children with congenital heart disease is studied in a structured manner. 
In 1990/91 and 2000/01 cardiac and psychological outcome, and survival have been studied 
in the first cohort of patients operated on between 1968 and 1980 in Rotterdam. The study 
protocol consisted of an electrocardiogram (ECG), 24 hours ECG (Holter monitoring), exercise 
test and an echocardiogram. In addition patients were assessed with various psychological 
questionnaires. 
In 2009 we performed a similar study, but now focusing on the second cohort of patients, 
operated in Rotterdam between 1980 and 1990. We used the same study protocol to enable 
a comparison of these two surgical cohorts. We expected to find an improvement in cardiac 
and psychological outcome, as surgical techniques, postoperative care and psychological 
guidance have improved over time.
Transposition of the great arteries
In the first surgical cohort the surgical procedure for transposition of the great arteries 
consisted of an atrial correction (the Mustard or Senning procedure). Studies on long-term 
outcome in this group showed that right ventricular (systemic) dysfunction and sinus node 
disease were common late complications. In the second surgical period the arterial switch 
operation was introduced and became the method of choice. In chapter 2 we showed that 
patients with an arterial switch operation (ASO) had a better (event-free) survival after 25 
years of follow-up. The event-free survival was 77% after ASO versus 44% after Mustard 
operation (p=0.04). The main indication for re-intervention in ASO patients was pulmonary 
artery stenosis. In our study nearly half of the arterial switch patients had a residual gradi-
ent across the pulmonary artery or pulmonary valve. Some of these may need additional 
re-interventions in the future, warranting further close monitoring. 
With the left ventricle as the systemic ventricle in arterial switch patients, symptomatic 
heart failure was not encountered and most patients remained in good health. Good sys-
temic ventricular function was present in 93% after ASO versus 6% after Mustard operation 
(p<0.01). Aortic regurgitation was found in 21% of the arterial switch patients versus 16% 
of the Mustard patients (p=0.31). However, aortic regurgitation was mild in most. An other 
study suggested that neo-aortic dilatation may stabilize in adulthood, but follow-up in that 
study is too short to be certain.(1)
Tetralogy of Fallot (ToF)
In chapter 3 we compare patients operated upon in the first surgical period (1968-1980: 
ToF70) with patients operated upon in the second surgical period (1980-1990: ToF80). In the 
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ToF70 patients more shunts were used prior to corrective surgery and the age of correction 
was relatively higher. With the shift towards earlier corrective surgery, more transannular 
patches were implanted in the second surgical cohort. We demonstrated that early mortality 
showed a trend to diminish when compared to the first surgical period (p=0.098). Survival at 
25 years after successful surgery was 93% for ToF70 and 98% for ToF80 (p=0.22).
The left side of the heart seemed to benefit most from earlier surgery, with positive effects 
on left venticular- and aortic dimensions. In addition aortic regurgitation was present in 21% 
for ToF70 versus only 8% for ToF80 (p<0.001). However, patients operated in the 70’s showed 
a trend towards less right ventricular dysfunction and needed less often a pulmonary valve 
replacement for pulmonary regurgitation at long-term follow-up. The use of a transannular 
patch was the only factor associated with an increase in re-operation for pulmonary valve 
dysfunction. By avoiding the extensive use of a transannular patch, which was done in the 
90’s, the need for reoperations may hopefully decrease further in future cohorts. In conclu-
sion the left side of the heart seemed to benefit at the costs of more right side problems.
Psychological findings
In chapter 4 we showed that patients with an ASO for transposition of the great arteries 
performed better on physical scales than patients after the Mustard procedure and also 
performed better than healthy controls. A significant higher score was seen in arterial switch 
patients compared to Mustard patients in the sub domains physical functioning (p<0.01), 
general health perceptions (p=0.04) and vitality (p=0.04). Arterial switch patients and the 
normal Dutch population had comparable quality of life scores and arterial switch patients 
scored even better on the scales physical functioning, vitality and role limitations due to 
emotional problems (p <0.01). A possible reason for this may be overcompensation, which 
has been described as a coping strategy in patients with Congenital Heart Disease (CHD).
Psychological or emotional functioning did not differ in patients with a tetralogy of Fallot 
operated on in the 70’s and 80’s. ToF patients of both cohorts scored lower compared to 
healthy controls with respect to general health. This could be the result of an awareness of 
disease in daily life. But patients with ToF scored higher on social functioning and experi-
enced less behavioural problems such as anxiety and aggression. Thereby indicating they did 
not feel to be hindered in social and mental functioning.
PART ii PREgnAncy in womEn wiTh hEART disEAsE
hemodynamic adaptation to pregnancy in women with structural heart 
disease.
In chapter 6 we describe the changes of the heart in pregnant women with heart disease 
measured with echocardiography. Other echocardiographic studies have described these 
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changes in healthy women and showed an increase of cardiac output, stroke volume and left 
ventricular mass. In healthy women haemodynamic changes normalised 3-12 months after 
pregnancy.(2)
In our study we showed that patients with structural heart disease show some similar 
changes as in healthy women. But in addition to the normal changes, we showed a dilata-
tion of the left ventricle, which did not return to normal after pregnancy. Heart rate did not 
increase as much as it did in healthy women during pregnancy. With an increase in E/E’ ratio, 
our findings suggest a progressive diastolic dysfunction in women with structural heart 
disease with advancing gestational age.
We concluded that the cardiac changes during pregnancy have a different pattern in pa-
tients with heart disease compared to healthy women. A large prospective trial is warranted 
to confirm our findings, considering the small number of patients in this study.
Risk predictor models in pregnant patient with cardiac disease
When patients with a CHD want to become pregnant, doctors use risk predictor models to 
stratify patients in different risk groups. These models have been used for a number of years 
to counsel patients. Over the years there have been a number of trials that created a predictor 
model for cardiovascular events during pregnancy and the first months after delivery. 
In a large cohort of congenital heart disease patients we studied the validity of the known 
risk scores: CARPREG, ZAHARA, World Health Organisation (WHO) category and the disease 
complexity score (chapter 7). A combination of WHO classification and disease complexity 
provided the highest area under the curve. The WHO classification was the most accurate 
individual risk assessment model for estimating cardiovascular risk in pregnant women with 
CHD.
outcome in pregnant patients with structural heart disease (results of the 
RoPAc)
Professor Roos-Hesselink and Professor Hall founded a registry on pregnancy and heart 
disease in 2007. The European Society of Cardiology endorsed this registry and provided ICT 
support. The registry became part of the European Observations Research Program (EORP). 
This on-going online database was named the Registry On Pregnancy And Cardiac disease 
(ROPAC). 
In chapter 8 we describe the first analysis performed in 2011 on 1321 patients. Most patients 
had congenital heart disease (66%) others had valvular heart disease (25%), cardiomyopathy 
(8%) or ischemic heart disease (2%).
The total maternal mortality was 1%. This is 100 times higher than expected in the normal 
population. Fetal mortality was 4 times higher than expected. In addition we showed that 
patients living in developing countries are more at risk of having complications, probably 
related to the impact of the culture in some countries where having children is of utmost 
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importance. First results showed that congenital patients did better than other types of heart 
disease. Heart failure was encountered in 13% of patients, most frequently in patients with 
cardiomyopathy. 
mode of delivery in patients with cardiac disease (RoPAc)
Patients with cardiac disease underwent caesarean section in 42% of cases. In chapter 9 we 
describe that caesarean section (CS) was planned for cardiac reasons in 44% and obstetrical 
reasons in 56%. Women with a cardiac reason for CS often experienced heart failure after 
delivery. Patients delivering with CS had more often adverse fetal events. However, there was 
no difference in maternal outcome after an elective or an emergency CS. Children born with 
CS were more often premature and more often had a low birth weight. 
There was a large variation in CS rate between countries. This variance was dependend on 
the use of CS in the normal population and the inclusion of women with more complex heart 
disease. 
medication in pregnant women with cardiac disease (RoPAc)
One third of women with cardiac disease becoming pregnant use cardiac medication at some 
point during their pregnancy. 
We showed that women using medication during pregnancy had more adverse fetal events 
(defined as premature birth, low birth weight, fetal death and neonatal death). The corrected 
odds ratio was 2.4 (after correction for smoking, diabetes, pre-eclampsia and severity of 
cardiac disease). The question remains whether patients needing medication have a worse 
cardiac function (and therefore more fetal events) or that the medication itself has negative 
impact on fetal outcome. In addition we showed that patients needing beta-blockers had 
children with a corrected birth weight of 100 grams lower than in other patients with heart 
disease. This may be an important difference with implications for later life in these children. 
Based on our results, we cannot give the advice that all cardiac medication is contrain-
dicated during pregnancy, since we have not studied the effect of intentional omission of 
treatment. However, a high degree of reluctance to medicate, which is a sentiment often 
expressed by pregnant women, seems to be an appropriate position. 
heart failure in pregnant patients (RoPAc)
In chapter 11 we describe risk factors, onset and outcome of heart failure during pregnancy. 
In pregnant women heart failure is difficult to diagnose. Signs and symptoms, such as short-
ness of breath and oedema can also be found in normal healthy women. 
In the ROPAC heart failure was found in 13% of patients. Heart failure occurred most often 
around 31 weeks of pregnancy (inter quartile range 23-40) with two peaks in incidence: in 
the second trimester (34%) and directly after birth (31%). Onset of heart failure was associ-
ated with the underlying diagnosis. Patients with valvular disease or shunt lesions had heart 
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failure earlier in pregnancy (around 25 weeks). Patients with cardiomyopathy and ischemic 
heart disease had heart failure most often in the first days post partum. 
Baseline parameters associated with heart failure in multivariable analysis were worse 
functional class, signs of heart failure before pregnancy, severity of heart disease, a diagnosis 
of cardiomyopathy or pulmonary hypertension. Pre-eclampsia was strongly related to heart 
failure with an odds ratio of 7.1. One third of all patients who developed pre-eclampsia also 
developed heart failure. Therefore all patients with pre-eclampsia should be carefully moni-
tored. Fetal death and preterm birth rate were higher in women with heart failure. 
Acute coronary syndrome (Acs) and pregnancy
In chapter 12 we reviewed the current literature on pregnancy and ACS. 
In the first part we described the literature on patients with a history of ACS. Only limited 
data on recurrence risk of ACS during pregnancy has been published. Badui et al described 
18 women in the literature with previous ACS. None of these patients had a recurrent ACS.(2) 
Generally women are advised not to become pregnant if they have left ventricular dysfunc-
tion with an ejection fraction under 40% or have a dilated left ventricle. ACE inhibitors and 
spironolacton should be stopped, since these medications may have fetotoxic properties. 
In the second part of this chapter we described symptoms, risk factors, diagnosis and treat-
ment of ACS during pregnancy. Acute coronary syndrome is rare in women of childbearing 
age. But the incidence has increased over the years, probably due to improved diagnostic 
tests, an older age during pregnancy and an increase of cardiovascular risk factors in young 
women, such as obesity. Evaluating chest pain in pregnant women can be challenging, since 
chest pain in pregnancy is common and can be caused by various conditions. Most often 
chest pain is caused by gastro-oesophageal reflux, which is mostly benign. Physical examina-
tion can be misleading; hypotension and tachycardia are physiological responses to normal 
pregnancy. ECG is very important in diagnosing infarction. ST elevation myocardial infarc-
tion patients need immediate treatment and PCI is the first choice treatment and should be 
performed as soon as possible. Coronary dissection was the primary cause of myocardial 
infarction in the peripartum period (50%) and more commonly in post-partum period (34%) 
compared to antepartum period (11%). The mortality rate in patients with ACS in the peripar-
tum period is 18% versus 9% in the antepartum and postpartum period.
Patient case
Chapter 13 includes images of echocardiography, X-ray, CT and the surgical procedure of a 
patient presenting with native coarctation and a huge aortic aneurysm during pregnancy. No 
other patient with native coarctation and aortic aneurysm has been described in literature. 
A 28-year-old pregnant lady presented at our outpatient clinic with severe hypertension at 
32 weeks of gestation. On MRI the diagnosis of native coarctation (minimal diameter of 0,8 
cm) and a huge saccular aortic aneurysm of 4.5 x 8.8 cm was confirmed. An elective caesarean 
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section under regional anesthesia was performed at 35 weeks of gestation and a healthy girl 
(2625 gram) was born. 
Our patient was known with hypertension and the diagnosis was missed in an earlier stage. 
Diagnosis requires a high index of suspicion in young patients with hypertension. Our case 
stresses the importance of thorough physical examination and echocardiography in young 
patients with hypertension. 
PART iii chiLdREn oF moThERs wiTh cARdiAc disEAsE
Some of our studies on pregnancy in women with CHD have shown an increased rate of 
preterm delivery, low birth weight and fetal mortality. Fetal outcome was associated with 
maternal disease and problems during pregnancy. How adverse fetal outcomes will influ-
ence the development of these children later in life is important. Until now growth in these 
children has never been investigated.
In chapter 14 post natal growth of children of mothers with congenital heart disease was 
assessed in a large retrospective cohort of 450 children. We showed that although children 
were born slightly smaller than normal, most showed catch-up growth in the first 6 months of 
life. Catch-up growth was slower in premature children and these children remained smaller 
after 2,5 years. Almost all children small for gestational age showed catch-up growth in the 
first 6 months. 
Complexity of maternal heart disease had a long lasting influence on growth, as children of 
mothers with complex heart disease showed slower catch-up growth and remained smaller. 
Low birth weight and catch-up growth have been described to cause metabolic disorders 
(such as hypertension, diabetes mellitus and cardiovascular disease).(3) Whether this is also 
an issue in this special population remains to be studied.
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Chapter 16
Future directions
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FuTuRE diREcTions
In this thesis I focussed on the importance of long-term follow up in congenital heart dis-
ease. For instance patients with an arterial switch operation showed an excellent survival, 
but there was an ongoing risk of neo-aortic regurgitation and pulmonary artery stenosis. In 
tetralogy of Fallot, the patients operated in the 80’s showed a better left ventricular function 
with less aortic root dilatation, aortic regurgitation and a smaller end diastolic left ventricle 
diameter when compared with patients operated in the 70’s. However, patients operated in 
the 80’s needed more often a pulmonary valve replacement. So some advantaged but also 
some disadvantages occurred with changes in surgical technique and timing.
By studying pregnancy and heart disease in further detail we showed that heart failure was 
the most observed complications and was found in 13% of patients with structural heart dis-
ease. Heart failure most often occurred at the end of the second trimester and near delivery. 
We showed that pregnant patients with structural heart disease often needed a caesarean 
section, the patients with caesarean section had shorter pregnancy duration and their chil-
dren had a lower birth weight. Patients with structural heart disease using medication during 
pregnancy had more fetal complications, such as preterm birth, low birth weight and fetal 
death. In children of patients with congenital heart disease neonatal growth showed some 
compensation after birth, which was correlated to complexity of maternal disease.
In this section I will try to place our most important findings in the general context and 
will try to illustrate the implications for future research. In addition I will describe some of the 
areas of interest. 
PART i congEniTAL hEART disEAsE
Cohort studies on long-term prognosis of patients with congenital heart disease have been 
published since the start in the 1950s. In most of these studies, patients were selected from 
the out-patient clinic and not as a surgical cohort. Studies from the out-patient clinic and 
from surgical cohorts are equally important. In out-patient clinic cohorts the focus is on most 
encountered complaints and complications. However, these studies present often a biased 
population, since patients will go to the outpatient-clinic when they become symptomatic. 
Surgical cohort studies focus on changes in outcome with the changes made in surgical 
techniques and these studies provide unbiased information. 
In the LUCCA (Lange termijn Uitkomsten in congenitale cardiale aandoeningen) study 
we compared the outcome in two surgical periods: 1968-1980 and 1980-1990. We aimed to 
evaluate whether both short term and long term survival have been improved with experi-
ence gained by surgeons over time. 
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Transposition of the great arteries
We showed that patients with an arterial switch operation (ASO) had better (event-free) 
survival after 25 years follow-up compared with the Mustard correction. In the future we 
will study the cohort of 1990-1995, when these patients will have reached adult age. We 
hypothesized that this second cohort of arterial switch patients will have a better survival 
and cardiac function when compared to the first cohort of arterial switch patients. De Koning 
et al. showed that patients operated between 1990-2000 showed excellent survival rate and 
low re-intervention rate (6%) 10 years after ASO. We will be interested to see if these favorable 
results remain after 25 years.(1)
As we have shown that most patients have residual lesions, they should be followed for 
the rest of their life. With the transition from pediatric care to adult clinic, some patients may 
be lost to follow up. As it is important to intervene before permanent damage will occur in 
most residual lesions, it is of great importance to find all patients who are lost to follow-up. By 
studying a specific cohort we found some of these “lost” patients. In the future extra attention 
will be paid to the transition from the pediatric to the adult clinic. 
Tetralogy of Fallot
In our cohort study comparing patient operated on in 1968-1980 and 1980-1990, we showed 
more pulmonary valve interventions after the use of a transannular patch in the right ven-
tricular outflow tract during corrective surgery for ToF. Surgery was done at an earlier age 
in the 80s, in this 80s cohort aortic regurgitation was reduced and left ventricular function 
appeared to be better. 
In patients operated on between 1990 and 2000 surgeons tried to avoid the use of a 
transannular patch and operated at an even earlier age. It would be interesting to study this 
cohort of patients and compare the results to the results from our study. Possibly both left 
and right ventricular function will be better in this cohort. Apitz et al. described in a review 
that patients were sometimes operated upon in the first days of life. Nowadays, most centres 
prefer to operate on children aged 3–6 months, reserving earlier open-heart surgery for those 
presenting with severe cyanosis or hypercyanotic spells.(2) With operations immediately 
after birth there is a frequent need for aggressive outflow tract procedures. In addition there 
are adverse effects of early bypass surgery on the neonatal brain, the often complicated and 
lengthy postoperative recovery in small infants, and implications of all these factors for late 
adverse outcomes. (3)
Elderly patients with congenital heart disease
The first corrective surgeries were performed on children and teenagers with congenital 
heart disease in the 1960s. The first results on survival in these patients were very promising. 
Therefore it was thought that most patients would be able to reach a normal lifespan. 
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As congenital heart disease patients grow older, they become more likely to develop 
coronary artery disease (CAD).(4) In the normal “healthy” population CAD becomes manifest 
in the fifth or sixth decade of life. Endothelial dysfunction is one of the main causes of CAD. 
Injury to the endothelium precipitates atherosclerosis by leading to smooth-muscle-cell 
migration and proliferation, induction of expression of growth factors and impairment in the 
plasmatic coagulation and endogenous fibrinolysis system.(5)
It has been proven by Oechslin et al that cyanotic congenital heart disease patient have 
systemic endothelial dysfunction. They showed strikingly reduced endothelial vasodilation 
to acetylcholine. They hypothesized that secondary erythrocytosis results in increased shear 
stress in cyanotic congenital heart disease, which modified the balance between vasodilators 
and vasoconstrictors and affect systemic endothelial function.(6) Also patients with an aortic 
coartation do not have normal endothelial function. Barton et al showed in an animal model 
that coarctation induced hypertension is associated with increased nitrotyrosine abundance 
in all tissues exposed to high arterial pressure, denoting enhanced reactive oxygen spe-
cies -mediated inactivation and sequestration of nitric oxide in these sites.(7) Whether the 
described endothelial dysfunction in these patients leads to coronary abnormalities and 
atherosclerosis needs to be investigated. 
A study by giannakoula et al. with 250 asymptomatic CHD patients studied the prevalence 
of CAD, in patients who had a coronary angiogram in a pre-operative screening. They showed 
that the prevalence of significant CAD in a hospital adult CHD cohort was similar to that in 
the general population. In their study predictors for coronary abnormalities were hyperten-
sion, hyperlipidemia and chest pain. However they did not study prevalence of myocardial 
infarction.(3)
With these studies showing endothelial dysfunction it will be very interesting to see if 
these patients develop coronary artery disease and myocardial infarction at an earlier age. I 
hope to see additional studies on prevalence of coronary disease in elderly congenital heart 
disease patients in the near future.
PART ii PREgnAncy And hEART disEAsE
Research in pregnancy and heart disease
Researching pregnancy and heart disease is challenging for a number of reasons. Firstly, 
cohorts are frequently heterogeneous in diagnosis. Secondly, patient numbers are rather 
small per centre. Finally, randomized controlled trials are difficult to perform in pregnancy 
and should preferably be done using an international collaboration. With the Registry On 
Pregnancy And Cardiac disease (ROPAC) a large international collaboration was established. 
At the moment this is an observational registry, but hopefully this collaboration opens the 
door to more studies. 
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The future of the Registry on Pregnancy And cardiac disease (RoPAc)
In the current analysis of the ROPAC on June 1st 2011, 1321 patients were studied. However, 
the inclusion is ongoing and by April 2013 more than 2300 patients have been included 
already.(figure 1) By advertising the registry at national society congresses efforts are made 
to involve more centres from more countries to include patients. The goal is to include over 
4000 patients in this registry, especially with a good representation of patients from all over 
the world. This will allow us to perform specific subgroup analysis, focussed on mechanical 
valve patients, patients with pulmonary hypertension patients or Marfan patients. Further-
more, with this growing number of patients in the registry the existing risk models can be 
validated. In 2011 we changed the case report form (CRF), adding information on different 
subjects, such as baseline characteristics and additional information on mode of delivery and 
medication. 
mode of delivery
Determining the best mode of delivery in patients with cardiac disease can be challenging. 
In most patients vaginal delivery is the option of choice, because of reduction of blood loss, 
infections and thrombo-embolic events. Still in some individual patients the choice remains 
difficult. Some cardiologists and obstetricians may choose a planned caesarean section 
to avoid an emergency caesarean section. With the ROPAC study on mode of delivery we 
showed that emergency caesarean section did not cause more cardiac complications than a 
planned caesarean section. The ideal way to study mode of delivery would be a randomised 
controlled trial. But some ethical issues remain. With the new CRF we are now collecting 
additional information on reasons for planned and emergency caesarean section. With this 
information we hope to do some more analysis when patient numbers are large enough. 
Figure 1. Inclusion in ROPAC per country.
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medication
The ROPAC showed that one third of pregnant women with heart disease used medication 
during their pregnancies and these women had more cardiac and obstetric complications 
than the women who had heart disease, but were not taking any medication. Birth weight 
was significantly lower in children of patients taking beta blockers. 
With these results, there is a demand for randomised controlled trials on cardiac medi-
cation in pregnancy. Studying stopping prophylactic medication would be a good start. 
Prophylactic medication is given to improve long-term outcome, not to reduce symptoms. 
Important for such a trial would be to match patients, since differences in outcome should 
not be caused by differences in baseline characteristics. The results of such a trial would be 
very important for future guidelines, to give a solid advice whether or not to stop medication 
before pregnancy. 
Another randomised trial could focus on starting medication in high-risk patient, such as 
diuretics, statins and betablockers prior to pregnancy. By starting medication before preg-
nancy maybe events such as atrial fibrillation, pre-eclampsia or heart failure may be avoided. 
By doing such randomised controlled trials, answers could be given whether medication is 
actually causing the fetal adverse events, or that the mothers needing medication have a 
worse cardiac function, which causes the adverse events. 
new diagnostics tools in pregnancy in heart disease
Biomarkers have been developed in general cardiologic practice to predict cardiac events.
(8,9) Some of these markers, such as pro-BNP, are already used in research in the congenital 
heart disease patients.(10) More biomarkers are being analysed, and evaluated to predict 
both anti-arrhythmic events and heart failure.(9) We are excited to see the influence of these 
new laboratory measurements in both research and every day practice. But so far there has 
been little information on pregnancy and biomarkers. We know that the normal values of 
biomarkers are not valid in pregnancy, since hormones and hemodynamic status alter the 
clearance and distribution of these markers. Increased B-type natriuretic peptide levels are 
found during pregnancy in many pregnant women with heart disease. In the study by Tanous 
et al. B-type natriuretic peptide levels lower than 100 picograms per milliliter had a negative 
predictive value of 100% for identifying events during pregnancy.(11) Additional studies are 
clearly warranted. 
PART iii chiLdREn oF moThERs wiTh hEART disEAsE
intelligence in children of mothers with heart disease
In the ROPAC we showed that premature birth and low birth weight were more common 
in mothers with heart disease than in the normal “healthy” population. In the Kinderen In 
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Moeders met Aangeboren Hart Afwijkingen (KIMAHA) study we showed that most children 
showed catch-up growth in the first 6 months of life. Casey et al showed that in children of 
healthy mothers the absence of catch-up growth within the first 2 years was associated with a 
lower Intelligence Quotient at 8 years of age. In this study no differences were found in behav-
ioural status or general health status between children with and without failure to thrive.(12) 
Therefore it would be very interesting to investigate intelligence and school performance of 
children of mothers with cardiac disease. 
cardiovascular disease in children of mothers with heart disease
A wide range of metabolic disorders including hypertension, obesity and cardiovascular 
disease have been associated with children born small for gestational age or with low birth 
weight in different populations. It is believed that poor nutrition in early life or even before 
birth results in permanent changes in glucose-insulin metabolism, leading to a decreased 
capacity for insulin secretion and insulin resistance.(13) This may cause a higher risk on 
developing a metabolic syndrome later in life, including diabetes, hypertension and cardio-
vascular disease.(14,15) Therefore it would be interesting to study the children of mothers 
with cardiac disease when they have reached adult or even better elderly age. The question 
is whether they have an increased rate of metabolic syndromes. But considering the fact that 
the children of the eldest congenital patients are just reaching 30 years of age, this question 
will not be answered for the next couple of decades. 
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onze avonden met discussies aan tafel in Amsterdam en Harfsen. Bij alle moeilijke en mooie 
momenten in de kliniek denk ik vaak aan hem. 
 
Professor Roos, lieve Jolien, dank voor je begeleiding en onze vriendschap. Je bent op vele 
vlakken een inspiratie. Werk bestaat niet alleen uit artikelen schrijven, maar ook uit organise-
ren, netwerken en patiënten begeleiden. Je gaf me de ruimte om me ook buiten het werk te 
ontwikkelen. We hebben een bijzondere band, die verder gaat dan werk alleen. 
 
Professor Hall, dear Roger, you have been a great coach. Over these last years I have made 
a lot of progress thanks to you. On top of that I have really enjoyed our moments talking on 
life in general and the differences between the English and the Dutch. Professor Johnson, 
dear Mark, it has been a great pleasure working with you. I’ll remember being in Paris at the 
ESC congress for my first oral presentation. You were trying to calm me down, by having me 
picture everybody around us naked. We had such a great laugh. 
 
Graag wil ik professor Takkenberg en professor Zijlstra hartelijk danken voor het plaatsne-
men in de leescommissie en voor hun snelle beoordeling van mijn proefschrift. Hanneke, 
dank voor je hulp met de statistiek in de Lucca stukken. Professor Steegers en professor 
Duncker wil ik graag bedanken voor het plaatsnemen in de grote leescommissie. Doctor Pie-
per, Els, je bent een belangrijke toevoeging van de grote commissie door je expertise op dit 
gebied. Dank voor de samenwerking op het hart falen manuscript en de kans de resultaten te 
presenteren in Utrecht. Samenwerken ging vlot en een mooi manuscript bleek het resultaat.
Publiceren doe je niet alleen. Dit proefschrift was niet tot stand gekomen zonder de hulp van 
veel anderen. Ron, dank voor de support in de statistiek en het werken met Clint. Professor 
Boersma hartelijk dank voor de samenwerking bij de statistiek voor de ROPAC. Zonder u 
hadden de artikelen nooit tot stand kunnen komen. Professor Helbing en de andere kinder-
artsen en onderzoekers (Saskia, Nienke en Sjoerd) uit het Sophia ziekenhuis, dank voor de 
samenwerking en de leerzame ochtend besprekingen. Professor Utens, Liesbeth, dank voor 
je hulp met het psychologische deel. Het afnemen van de psychologische interviews was 
belangrijk voor mijn inzicht in het leven van een patiënt met een congenitale hart afwijking. 
Dankzij jouw begeleiding kon ik dat ook vertalen naar de wetenschap. Doctor Duvekot, 
Ingrid en de andere collega’s van de gynaecologie, dank voor de fijne samenwerking. Ik hoop 
in de toekomst de kans te krijgen om nog eens met jullie samen te werken in de kliniek. 
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Graag wil ik al mijn mede auteurs bedanken voor hun kritische noten en behulpzaam com-
mentaar. Mijn artikelen zagen vele versies, maar werden met elke versie beter.
Maarten en Judith, jullie leerden me kritisch na te blijven denken over het doen van onder-
zoek. Dankzij jullie bleef ik betrokken bij de patiënten. Annemien, dank voor je vele hulp 
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Anish Kapoor “When I am Pregnant” (1992)
     De vreugde van het schrijven.
     Het vermogen te bewaren.
     De wraak van een sterfelijke hand.
     Wislawa Szymborska
